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Abstract 
 
Pancreatic cancer is the 4th leading cause of cancer related death in the United 
States with a median survival time of less than 6 months. Pancreatic ductal 
adenocarcinoma (PDAC) accounts for greater than 85% of all pancreatic cancers, and is 
marked by early and frequent mutation of the KRAS oncogene, with activating KRAS 
mutations present in over 90% of PDAC. To date, though, targeting activated KRAS for 
cancer treatment has been very difficult, and targeted therapies are currently being sought 
for the downstream effectors of activated KRAS.  Activation of KRAS stimulates 
multiple signaling pathways, including the MEK-ERK and PI3K-AKT signaling 
cascades, but the role of downstream effectors in pancreatic tumor initiation and 
progression remains unclear.  I therefore used primary pancreatic ductal epithelial cells 
(PDECs), the putative cell of origin for PDAC, to determine the role of specific 
downstream signaling pathways in KRAS activated pancreatic tumor initiation.  As one 
third of KRAS wild type PDACs harbor activating mutations in BRAF, and KRAS and 
BRAF mutations appear to be mutually exclusive, I also sought to determine the effect of 
activated BRAF (BRAFV600E) expression on PDECs and the signaling requirements 
downstream of BRAF.  
I found that both KRASG12D and BRAFV600E expressing PDECs displayed 
increased proliferation relative to GFP expressing controls, as well as increased PDEC 
survival after challenge with apoptotic stimuli.  This survival was found to depend on 
both the MEK-ERK and PI3K-AKT signaling cascades. Surprisingly, I found that this 
survival is also dependent on the IGF1R, and that activation of PI3K/AKT signaling 
  vii 
occurs downstream of MEK/ERK activation, and is dependent on signaling through the 
IGF1R.  Consistent with this, I find increased IGF2 expression in KRASG12D and 
BRAFV600E expressing PDECs, and show that ectopic expression of IGF2 rescues 
survival in PDECs with inhibited MEK, but not PI3K.  Finally, I showed that the 
expression of KRASG12D or BRAFV600E in PDECs lacking both the Ink4a/Arf and Trp53 
tumor suppressors is sufficient for tumor formation following orthotopic transplant of 
PDECs, and that IGF1R knockdown impairs KRAS and BRAF-induced tumor formation 
in this model.   
In addition to these findings within PDECs, I demonstrate that KRASG12D or 
BRAFV600E expressing tumor cell lines differ in MEK-ERK and PI3K-AKT signaling 
from PDECs.  In contrast to KRASG12D or BRAFV600E expressing PDECs, activation of 
AKT at serine 473 in the KRASG12D or BRAFV600E expressing tumor cell lines does not 
lie downstream of MEK, and only the inhibition of PI3K alone or both MEK and the 
IGF1R simultaneously results in loss of tumor cell line survival.  However, inhibition of 
MEK, PI3K, or the IGF1R in KRASG12D or BRAFV600E expressing tumor cell lines also 
resulted in decreased proliferation relative to DMSO treated cells, demonstrating that all 
three signaling cascades remain important for tumor cell growth and are therefore viable 
options for pancreatic cancer therapeutics.   
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CHAPTER I: INTRODUCTION 
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Pancreatic cancer is the 4th leading cause of cancer related death within the US 
and has shown little improvement in its death rate in decades.  In 2011 there were 
approximately 44,000 new cases of pancreatic cancer and approximately 38,00 deaths 
(Siegel, Ward et al. 2011).  The median survival time of patients diagnosed with 
pancreatic cancer is less than 6 months, and the 5-year survival rate for pancreatic cancer 
is only 6% (Siegel, Ward et al. 2011).  The bleak prognosis of pancreatic cancer is due in 
part to the late stage of the disease at the time of diagnosis, as frequently metastases are 
already present, and also to the resistance of pancreatic tumors to current 
chemotherapeutics.  Surgery offers the only chance of a cure for pancreatic cancer, but is 
only an option for those patients diagnosed with localized disease.  Of the small subset of 
patients who are able to undergo resection, the 5-year survival rate is still only 20%, 
although recent advances in adjuvant chemotherapy may improve the post-surgical 
outlook (Ahrendt and Pitt 2002).  For these reasons, there is a critical need in pancreatic 
cancer research to discover better methods the early detection of pancreatic cancer, as 
well as more effective chemotherapeutics.   
 
Histological Progression of Pancreatic Ductal Adenocarcinoma  
Pancreatic Ductal Adenocarcinoma (PDAC) comprises the majority of pancreatic 
cancers, is thought to arise from pancreatic ductal epithelial cells, and has been shown to 
develop through a series of precursor lesions marked by characteristic morphological and 
genetic changes (Hruban, Goggins et al. 2000).   These precursor lesions, known as 
Pancreatic intraepithelial neoplasia, or PanINs, are divided into three grades that progress 
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from least severe to most severe: PanIN-1A/1B, PanIN-2, and PanIN-3 (Hruban, Adsay 
et al. 2001).  PDAC typically arises in the head of the pancreas, and invades surrounding 
tissues with common sites of metastasis including the liver and lungs (Hezel, 
Kimmelman et al. 2006).   PDAC frequently displays desmoplasia, or a dense stroma of 
fibroblasts and inflammatory cells (Hezel, Kimmelman et al. 2006).   
Typically, normal pancreatic ductal cells show cuboidal and low columnar 
epithelium absent of mucinous cytoplasm (Hruban, Adsay et al. 2001).   PanIN-1A 
lesions display tall columnar cells, basally located nuclei, and supranuclear mucin, while 
PanIN-1B lesions have papillary, micropapillary, or basally pseudostratified architecture 
(Hruban, Adsay et al. 2001).  PanIN-2 lesions are marked by nuclear abnormalities (such 
as loss of polarity or enlarged nuclei) and can be flat or papillary (Hruban, Adsay et al. 
2001).  PanIN-3 lesions show budding into the lumen, and are typically papillary or 
micropapillary, with loss of polarity and prominent nucleoli (Hruban, Adsay et al. 2001).  
PanIN-3 lesions represent carcinoma in situ, and progression from PanIN 3 to PDAC is 
characterized by invasion into the surrounding tissues (Hezel, Kimmelman et al. 2006).   
Although the majority of PDAC appears to arise as the result of PanIN lesions, 
there are two other precursor lesions that have been characterized: mucinous neoplasms 
(MCN) and intraductal papillary mucinous neoplasms (IPMN) (Hezel, Kimmelman et al. 
2006).  These and other cystic lesions contribute less than 1% of all pancreatic tumors, 
but they are increasingly common in tumors that are surgically resected, and comprise up 
to 15% of those lesions (Adsay 2007).   
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IPMNs are characterized by mucin production resulting in dilation of the 
pancreatic ducts.  These lesions occur predominantly in the head of the pancreas, and are 
divided into main duct and branch duct classification (Tanaka, Chari et al. 2006). Overall, 
IPMNs comprise approximately 5% of all pancreatic neoplasms (Adsay 2003).  
Genetically, IPMNs are more stable than PanIN lesions, with fewer KRAS, INK4A, and 
TRP53 mutations overall (Sessa, Solcia et al. 1994).  Mutation of KRAS has been shown 
to correlate with the progression of IPMN lesions, however, and has been detected in up 
to 60% of IPMNs (Tada, Omata et al. 1991).  In addition, approximately 30% of IPMNs 
have inactivation of LKB1, the gene that has been shown to be inactivated in Peutz-
Jeghers syndrome, a disease associated with increased risk of pancreatic cancer (Sato, 
Rosty et al. 2001).  Most IPMNs have also been found to frequently express MUC2 and 
CDX2, which have both been shown to have tumor suppressor activity (Adsay 2007). 
IPMNs can be classified into main duct and branch duct subtypes based on imaging or 
histological analysis (Furukawa, Takahashi et al. 1992).  Although the majority IPMNs 
are non-invasive, main duct IPMNs have been found to be more likely to progress to 
invasive adenocarcinoma or colloid carcinoma, and therefore the classification of branch 
duct versus main duct can impact disease prognosis and treatment (Tanaka, Chari et al. 
2006).   
MCNs are characterized by an ovarian stroma and are lined with a mucin 
producing epithelium (Tanaka, Chari et al. 2006; Adsay 2007).  The ovarian stroma is 
both ER and PR positive, and is considered a hallmark of MCNs (Izumo, Yamaguchi et 
al. 2003).  These lesions are almost always found in the body and tail of the pancreas, and 
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occur predominantly in women (Zamboni, Scarpa et al. 1999; Reddy, Smyrk et al. 2004).  
Up to one third of all MCNs have been found to progress to invasive carcinoma, however 
they are typically less aggressive than other forms of invasive carcinoma in the pancreas 
(Thompson, Becker et al. 1999; Zamboni, Scarpa et al. 1999; Reddy, Smyrk et al. 2004). 
In contrast to most IPMNs, MCNs do not typically express MUC2 and CDX2, but often 
express MUC1 (Adsay 2007).  In addition, 46% of MCNs have mutations in KRAS, and 
almost all malignant MCNs were found to have KRAS mutations, indicating a correlation 
between mutation of KRAS and disease progression (Jimenez, Warshaw et al. 1999).  
 
Genetic Progression of PDAC 
The progression from normal pancreas to PanINs and PDAC is marked by a well-
established series of genetic alterations as illustrated in Figure 1.1 (Bardeesy and 
DePinho 2002).  One of the earliest changes in the progression to PDAC is activating 
mutations in the KRAS2 oncogene, which have been detected in a small number of 
normal pancreas tissue, occur in approximately 30% of early PanIN lesions, and in over 
95% of all cases of PDAC (Hezel, Kimmelman et al. 2006).  KRAS mutations have also 
been detected in up to 30% of patients with chronic pancreatitis, a condition that has been 
shown to increase the risk of pancreatic cancer (Lohr, Maisonneuve et al. 2000).  Since 
activation of KRAS is both an early and prevalent event in the formation of pancreatic 
cancer, it is considered to have a critical role in the formation of pancreatic tumors. 
Overexpression of ERBB2 (HER2/NEU) and the EGFR also occur early in the formation 
of pancreatic tumors (Bardeesy and DePinho 2002).  The EGFR is overexpressed in up to 
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60% of all pancreatic tumors, while ERBB2 is overexpressed in 70% of PDAC 
(Lemoine, Hughes, et al. 1992 and Hruban, Wilentz et al. 2000).   
These initial genetic alterations are followed by the subsequent loss of the INK4A 
tumor suppressor, which occurs in over 85% of pancreatic tumors (Rozenblum, Schutte et 
al. 1997).  As loss of INK4A is observed in approximately 30% of low-grade precursor 
lesions, this change is thought to occur only slightly later in the formation of PDAC than 
activation of KRAS, and increases in incidence to occur in nearly all cases of PDAC 
(Hruban, Wilentz et al. 2000).   
Mutation of the TRP53 tumor suppressor has been identified in in over 50% of 
pancreatic tumors (Bardeesy and DePinho 2002).  However, abnormal expression of p53 
was only detected in 12% of high-grade precursor lesions, and was not detected at all in 
low-grade precursor lesions, indicating that the inactivation of TRP53 occurs late in the 
progression of PDAC (Hruban, Wilentz et al. 2000).  Most often in PDAC, p53 is 
mutated within its DNA-binding domain (Hezel, Kimmelman et al. 2006).  
As PDAC progresses, there is also eventual loss of the SMAD4 (DPC4) and 
BRCA2 tumor suppressor genes (Hruban, Wilentz et al. 2000).  While the inactivation of 
SMAD4 occurs in up to 50% of all pancreatic tumors, it is not observed in low-grade 
precursor lesions, and is only observed in approximately 30% of high-grade precursor 
lesions, indicating that this is a later event in the formation of PDAC (Hruban, Wilentz et 
al. 2000).  Similarly, inactivation of BRCA2 has been shown to occur in up to 10% of 
PDAC, but is not present in low-grade precursor lesions, also indicating that this is a late 
event in the formation of pancreatic tumors (Hruban, Wilentz et al. 2000). 
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Figure 1.1: Genetic Progression Model of Pancreatic Adenocarcinoma (Adapted 
from Bardeesy and DePinho 2002) 
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Ink4a/Arf Tumor Suppressors 
INK4A and ARF are two tumor suppressors that are encoded in an overlapping 
region of the 9q21 locus (Sherr 2001).  In PDAC, loss of INK4A has been found to occur 
in over 85% of all tumors through mutation, deletion, or promoter hypermethylation 
(Rozenblum, Schutte et al. 1997).  Due to the shared gene locus, many pancreatic tumors 
are deficient for both INK4A and ARF, however point mutations in ARF are not detected 
in pancreatic tumors, indicating that INK4A is the primary target of inactivation in PDAC 
(Rozenblum, Schutte et al. 1997).   
INK4A functions as a tumor suppressor by inhibiting the kinase activity of CDK4 
and CDK6 (Serrano, Hannon et al. 1993).  This inhibition is achieved by preventing 
CDK4 and CDK6 from interacting with Cyclin D, which is required for the kinase 
activity of CDK4 and CDK6 (Russo, Tong et al. 1998).  This interference therefore 
causes hypophosphorylation of RB, and ultimately results in cell cycle arrest due to 
repression of E2F by RB (Dyson 1998).  
ARF is encoded by an alternative first exon at this gene locus (exon 1β) but shares 
exons 2 and 3 with INK4A (Quelle, Zindy et al. 1995).  As the name implies, ARF is 
encoded by an alternate reading frame from INK4A, and as a result, the two proteins 
share no amino acid homology.  ARF has been found to function as a tumor suppressor 
by binding to MDM2 and inhibiting the ubiquitination of the p53 tumor suppressor 
(Kamijo, Weber et al. 1998; Pomerantz, Schreiber-Agus et al. 1998; Stott, Bates et al. 
1998; Zhang, Xiong et al. 1998).   
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Trp53 Tumor Suppressor 
 p53 is a transcription factor that has been shown to function as a tumor suppressor 
through its transcriptional regulation of p21, MDM2, CYCLIN G, and BAX (Levine 
1997). Mutations in p53 occur in over 50% of all human tumors (Hollstein, Rice et al. 
1994).  Most frequently, these mutations are missense mutations in a single allele of p53 
that are followed by loss of the wild type allele (loss of heterozygozity).  Consistent with 
this, p53 is mutated in over 50% of pancreatic tumors, and the majority of these 
mutations occur in the DNA binding domain (Rozenblum, Schutte et al. 1997).   
p53 functions as a tetramer and is activated during cell stress, such as DNA 
damage, including double strand breaks, and hypoxia (Graeber, Osmanian et al. 1996; 
Guidos, Williams et al. 1996). Upon activation, p53 is able to affect multiple cellular 
processes through enhancing the transcription of many genes, including p21 and PUMA, 
which in turn function to induce cell cycle arrest, programmed cell death or senescence 
(Vousden and Prives 2009).  In addition, p53 has also been found to cause cell cycle 
arrest and apoptosis through the transcriptional repression of other genes, such as BCL2 
(Vousden and Prives 2009).   
p53 has a short half-life and is regulated by the E3 ubiquitin ligase MDM2, which 
binds to p53 and targets it for ubiquitin mediated degradation (Marine, Francoz et al. 
2006). Since MDM2 is itself transcriptionally regulated by p53, increased p53 expression 
results in a regulatory feedback loop involving increased expression of MDM2, and 
increased ubiquitination and degradation of p53 (Barak, Juven et al. 1993; Wu, Bayle et 
al. 1993).  Because of its role in the regulation of p53, MDM2 has been found to be an 
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oncogene that is amplified in 7% of human tumors (Momand, Jung et al. 1998).  As 
mentioned above, MDM2 also serves as a link between the p53 pathway and the ARF 
tumor suppressor, as ARF binds to MDM2 and stabilizes p53 (Kamijo, Weber et al. 
1998; Pomerantz, Schreiber-Agus et al. 1998; Stott, Bates et al. 1998; Zhang, Xiong et al. 
1998).   
 
SMAD4 
Of all human tumors, PDAC has the largest number of inactivating mutations in 
SMAD4, a tumor suppressor that has been shown to be involved in TGF-β signaling 
(Hahn, Schutte et al. 1996). Upon activation of receptor SMADs by TGF-β, SMAD4 is 
bound and translocates to the nucleus where it functions as a transcription factor (He, 
Dorn et al. 2006).  SMAD4 is inactivated in over 50% of all pancreatic tumors, and this 
inactivation is due to either point mutation or, in approximately 30% of pancreatic 
tumors, deletion of the SMAD4 gene (Hahn, Schutte et al. 1996; Hansel, Kern et al. 
2003). A recent study demonstrated that Smad4 expression is not needed for normal 
pancreas development, but that the loss of Smad4 results in an acceleration of KRAS-
mediated pancreatic tumor formation, and shifted the tumors towards a progression 
through IPMNs rather than PanIN lesions (Bardeesy, Cheng et al. 2006).  These findings 
demonstrate a role for SMAD4 loss in the progression of pancreatic tumors, as well as 
indicate a role for the loss of TGF-β signaling in PDAC.   
 
 
  11 
TGF-β  
TGF-β is able to function as both a tumor suppressor as well as an enhancer of 
cell growth (Zavadil and Bottinger 2005).  While it has been shown that TGF-β and 
SMAD signaling can inhibit the growth of epithelial cells, increased TGF-β signaling can 
result in increased cell migration and EMT (Miyazono, ten Dijke et al. 2000; Zavadil and 
Bottinger 2005).  In addition to the involvement of TGF-β signaling in PDAC that is 
implicated by the loss of SMAD4 in these tumors, mutations in the type II TGF-β 
receptor have also been identified in PDAC (Goggins, Shekher et al. 1998).  A mouse 
model with pancreas specific loss of the TGF-β receptor 2 in conjunction with activation 
of KRAS demonstrated acceleration of tumor formation and a progression through PanIN 
lesions to PDAC, even without the loss of Ink4a or Trp53 (Ijichi, Chytil et al. 2006).  
Although the complete mechanisms of how TGF-β and SMAD4 loss contributes to 
PDAC are still largely unknown, these findings further support the role of TGF-β 
signaling loss in the formation of pancreatic tumors. 
 
IGF1R in Cancer 
The IGF receptor family of receptor tyrosine kinases includes the IGF1R, IGF2R 
and the IR.  The IR and IGF1R share 70% of their amino acid sequence, while the IGF2R 
does not, and instead acts as a negative regulator of IGF signaling due to its lack of 
intrinsic signaling (Riedemann and Macaulay 2006).  The IGF1R is a heterotetramer with 
two alpha and two beta subunits, and can be activated by either IGF1 or IGF2 (Zha and 
Lackner 2010).  Upon activation, the IGF1R is autophosphorylated and recruits the 
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docking proteins IRS1, IRS2, and SHC to the membrane (Baserga, Hongo et al. 1997; 
Pollak, Schernhammer et al. 2004).   Through these docking proteins, the IGF1R is able 
to activate numerous signaling cascades, including PI3K/AKT and RAS/RAF/MEK/ERK 
(Pollak 2008).   
In addition to the genetic lesions listed above for the progression of PDAC, it has 
also been demonstrated that both the IGF1R and IGF1 are aberrantly expressed in PDAC 
tumor cells, suggesting a possible role for IGF1R signaling in pancreatic tumorigenesis 
(Bergmann, Funatomi et al. 1995; Ouban, Muraca et al. 2003; Stoeltzing, Liu et al. 2003).  
In addition to increased expression of the IGF1R and IGF1 in pancreatic tumors, 
increased levels of IRS1 mRNA and IRS1 protein have been detected in human 
pancreatic tumor tissue, further implicating IGF1R signaling in pancreatic tumorigenesis 
(Bergmann, Funatomi et al. 1996).   In support of this, a recent study demonstrated that 
inhibition of the IGF1R decreased orthotopic tumor formation following transplant of 
human pancreatic cell lines (Moser, Schachtschneider et al. 2008).   
 
Current Pancreatic Cancer Therapeutics 
 Despite the increase in knowledge about the histological and genetic progression 
of PDAC, little progress has been made in the development of effective chemotherapies 
to target pancreatic tumors.  The current standard of care, Gemcitabine, is a nucleoside 
analog that has been shown to increase survival in patients when compared with the 
previous therapeutic option, 5-FU (Burris and Storniolo 1997).  However, many 
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pancreatic tumors become resistant to treatment with gemcitabine, and it has done little as 
a chemotherapy agent to increase overall patient survival.   
Several studies have attempted to combine gemcitabine with other therapeutics in 
an attempt to increase their efficacy.  Examples of these include a combination with 
erlotinib, an inhibitor of the EGFR (Moore, Goldstein et al. 2007).  A recent development 
in the treatment of PDAC is folfirinox, a four-drug combination therapy (Conroy, 
Desseigne et al. 2011).  Unfortunately, while these combinations have fared better than 
the use of gemcitabine alone, they still have only showed marginal improvement in 
survival rates, or in the case of folfirinox, have an increased number of detrimental side 
effects, and therefore have done little to improve the outlook of PDAC.   
 Due to this ineffectiveness of DNA-analogs, either alone or in combination, and 
the dire need for more effective therapies, research has moved toward targeted therapy 
options.  As mutational activation of KRAS2 is one of the most common changes detected 
in PDAC, much research has focused on a more intense study of activated KRAS, its 
consequences in PDAC, and potential therapeutics to target the effects of activated 
KRAS in tumor initiation and progression.   
 
The RAS Family of Proteins 
 There are over 150 members of the human RAS superfamily of small GTPases, 
and members of this family are conserved across many species, including C. elegans and 
S. pombe (Colicelli 2004).  These proteins function as monomeric G proteins, serving as 
GDP/GTP regulated molecular switches (Vetter and Wittinghofer 2001), and all Ras 
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superfamily members share a common and conserved G-box GDP/GTP binding domain 
(Wennerberg, Rossman et al. 2005).  As GTPases, Ras proteins bind GDP and GTP with 
high affinity and are regulated by Guanine-nucleotide exchange factors (GEFs), which 
promote the exchange of Ras bound GDP for GTP, and GTPase activating proteins 
(GAPs), which promote GTP hydrolysis (Bernards and Settleman 2004).  The binding of 
GTP to Ras proteins results in conformation changes in the Switch I (aa 30- 38) and 
Switch II (aa 59- 67) regions of the proteins, thus allowing the GTP bound Ras protein to 
bind effectors (Bishop and Hall 2000; Repasky, Chenette et al. 2004).  
There are five subfamilies of the Ras superfamily, which have largely been 
determined through both structure and function analysis: Ras, Rho, Rab, Ran, and Arf.  
The three Ras oncogenes, HRAS, NRAS, and KRAS, are the founding members of the Ras 
subfamily.    These three genes encode four Ras proteins: HRAS, NRAS, KRAS4A, and 
KRAS4B, with the two KRAS proteins resulting from alternative splicing.   
The Ras proteins are initially synthesized in the cytosol on free polysomes, and 
then are post-translationally modified for targeting to the plasma membrane(Cox and Der 
2002).  This modification occurs due to the CAAX (Cysteine, Aliphatic, Aliphatic, Any 
Amino Acid) motif at the C terminus of RAS, which signals farnesyltransferase to 
farnesylate the cysteine (Reuther and Der 2000; Cox and Der 2002).  These proteins are 
then trafficked to the endoplasmic reticulum, where cleavage of the AAX occurs, and the 
C terminus is methylated (Buday and Downward 2008). HRAS, NRAS, and KRAS4A 
are then transported to the Golgi and palmitoylated at the C terminus, and this 
modification results in the targeting of these proteins to the plasma membrane (Hancock, 
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Paterson et al. 1990).   Instead of the palmitoylation, KRAS4B is targeted to the plasma 
membrane by the polybasic region at its C terminus (Hancock, Paterson et al. 1990). 
Recent evidence suggests that the three RAS isoforms may be targeted to different areas 
of the plasma membrane, and that this specific targeting could impact the ability of RAS 
to stimulate its downstream effectors.   
  The three isoforms of Ras (H, N, and K) are very closely related, and have been 
found to share 85% of their amino acid sequences (Downward 2003).  This high degree 
of similarity between the proteins, as well as their shared downstream effectors, led to the 
belief that the three isoforms of RAS share the same functions.  However, recent 
evidence is uncovering distinct roles and functions for each of the RAS isoforms.  While 
mouse models have demonstrated that Hras and Nras are dispensable for normal mouse 
development, and can even be ablated in combination, loss of Kras expression results in 
embryonic lethality in the developing mouse (Johnson, Greenbaum et al. 1997).   In 
addition, one study has demonstrated differences in the ability of each RAS isoform to 
stimulate downstream effectors, with KRAS showing increased ability to bind and 
activate RAF, while HRAS was more capable of activating PI3K (Yan, Roy et al. 1998).  
These studies argue that the hypervariable region of RAS may in fact lead to differential 
functions of each isoform.  Additional studies have recently shown that the localization of 
the RAS proteins may specify downstream effectors and signaling.  In addition to the 
plasma membrane, signaling from RAS has been detected on endosomes, mitochondria, 
the Golgi apparatus, and the endoplasmic reticulum (Fehrenbacher, Bar-Sagi et al. 2009).  
While much remains unclear about the impact of RAS localization on its downstream 
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signaling, recent work has demonstrated that the ultimate effects of ERK activation may 
differ based upon the localization of its upstream activators (Harding, Tian et al. 2005).  
Therefore, it is possible that sub-cellular localization of the RAS proteins may provide an 
additional means of regulating the differential functions of the RAS proteins.   
One of the most widely accepted mechanisms of RAS activation is by receptor 
tyrosine kinases (RTKs), such as the EGFR (Repasky, Chenette et al. 2004).  In this 
model, EGFR is activated via ligand binding, is autophosphorylated, and binds GRB2, 
which is bound to the RAS-GEF SOS.  This results in recruitment of SOS to the plasma 
membrane, bringing it in close proximity to RAS.  This co-localization of SOS and RAS 
at the plasma membrane results in increased exchange of GDP for GTP bound to RAS, 
and increased activation of RAS (Downward 2003).   
 
The Role of Activated RAS in Cancer 
 RAS proteins are among the most frequently mutated proteins in human cancer, 
with mutations present in approximately 30% of all human cancers (Cox and Der 2002).  
The most commonly mutated of the Ras proteins is KRAS, followed by NRAS, with HRAS 
mutations occurring in less than 1% of all tumors (Downward 2003).  Mutations in Ras 
family members that disrupt the GTPase activity of these proteins, thus rendering them 
constitutively bound to GTP and activated, are commonly found in human malignancies, 
and hot spot mutations at codons 12, 13, and 61 are commonly observed in pancreatic 
cancer (Bos 1989).   
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 Based upon the frequency of RAS mutations in human cancers, as well as 
evidence indicating that activation of RAS is key to the formation of many different 
tumor types, previous research has attempted to inhibit activated RAS through various 
mechanisms.  One of the most well known attempts at inhibiting RAS was the generation 
of compounds intended to inhibit the targeting of RAS to the plasma membrane, as 
improperly targeted RAS proteins have been shown to be inactive (Downward 2003).  As 
described above, the enzyme farnesyltransferase post-translationally modifies RAS 
proteins to target them to the plasma membrane.  Based upon this, farnesyltransferase 
inhibitors (FTIs) were generated to prevent targeting of RAS to the plasma membrane, 
and thus prevent RAS from its ability to activate cytoplasmic signaling cascades.   While 
effective against HRAS farnesylation and activity, further studies revealed that FTIs were 
ineffective at preventing KRAS and NRAS targeting to the plasma membrane (Lerner, 
Zhang et al. 1997).  This is due to the fact that these two isoforms are also substrates for 
geranylgeranyltransferase, which adds a geranylgeranyl isoprenoid and therefore enables 
membrane targeting of the NRAS and KRAS proteins (Rowell, Kowalczyk et al. 1997; 
Whyte, Kirschmeier et al. 1997; Zhang, Burris et al. 1997).   
In addition to attempts to prevent the targeting of RAS to the plasma membrane, 
inhibition of RAS activity has been attempted through targeting RAS protein expression, 
as well as through inhibiting upstream signaling pathways to counter RAS stimulated 
production of autocrine growth factors (Sibilia, Fleischmann et al. 2000; Dancey 2002).  
To date, however, none of these strategies have proven effective means of treating tumors 
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with RAS mutations, and many researchers have moved towards inhibiting the pathways 
activated downstream of the RAS proteins instead.   
 
RAS-Stimulated Signaling Pathways 
Stimulation of activated receptor tyrosine kinase results in the recruitment of RAS 
to the membrane, where it binds effector proteins resulting in the activation of 
downstream signaling cascades including, but not limited to, the RAF/MEK/ERK 
signaling cascade, the PI3K/AKT signaling cascade, the RAL/GDS pathway, and PLC-ε–
induced calcium signaling (Shown in Figure 1.2, Adapted from Downward 2003).  
Through the activation of these various signaling cascades, activated RAS is able to 
impact multiple cellular processes that are critical to tumor progression, including 
proliferation and survival, as well as cell polarity and movement (Vigil, Cherfils et al. 
2010).   
 The first of the RAS stimulated signaling pathways to be characterized was the 
RAF-MEK-ERK signaling cascade.  The RAF family of proteins consists of three 
serine/threonine kinases: ARAF, BRAF, and CRAF (or RAF-1).  These proteins bind to 
activated RAS at its RAF binding domain, and as a result are recruited to the plasma 
membrane and further phosphorylated.  Once RAF kinase activity has been stimulated, 
RAF phosphorylates and activates MEK1 and MEK2, which in turn phosphorylate and 
activate the mitogen activated protein kinases (MAPK) ERK1 and ERK2.  Once 
activated, ERK1 and ERK2 translocate to the nucleus and phosphorylate the Ets family of 
transcription factors and other targets (Downward 2003).  As a result of the downstream 
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activation of cell cycle regulators such as CYCLIN D, the activation of the RAF-MEK-
ERK signaling cascade has been associated with the increased cell proliferation (Pruitt 
and Der 2001).    In support of this, the inhibition of MEK has been shown to result in the 
decreased proliferation of PDAC cell lines (Gysin, Lee et al. 2005).   
 The next of the RAS effector pathways to be characterized was the PI3K-AKT 
signaling cascade.  Activation of PI3K-AKT by RAS was confirmed when the catalytic 
(p110) subunit of PI3K was shown to directly interact with and bind to RAS (Rodriguez-
Viciana, Warne et al. 1994; Pacold, Suire et al. 2000).  This results in the translocation of 
PI3K to the plasma membrane, where it phosphorylates PtdIns (4,5) to PtdIns (3,4,5).  
This results in the accumulation of AKT and PDK1 at the plasma membrane due to the 
binding of their pleckstrin-homology (PH) domains to PtdIns (3,4,5), and this close 
proximity results in the phosphorylation of AKT by PDK1 (Lawlor and Alessi 2001).   
Once phosphorylated, AKT phosphorylates multiple targets, including TSC2, 
PRAS40, BAD, GSK3, and the Forkhead-related transcription factor 1 (FOXO1) (Brunet, 
Park et al. 2001).  Phosphorylation of TSC2 or PRAS40 by AKT results in the inability of 
these proteins to inhibit mTORC1, leading to increased activation of mTORC1 and 
ultimately to increased phosphorylation of S6K and 4E-BP1, which results in mRNA 
translation and cell growth (Ma and Blenis 2009). Phosphorylation of pro-apoptotic BAD 
by AKT prevents its dimerization with Bcl-XL, which in turn enables Bcl-XL to inhibit 
apoptosis through the inhibition of cytochrome C (Datta, Dudek et al. 1997).  
Phosphorylation of GSK3 by AKT results in inhibition of this kinase, and this results in 
the accumulation of Cyclin D1 and increased cell proliferation (Diehl, Cheng et al. 1998).  
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The phosphorylation of FOXO1 results in its export from the nucleus, and thereby 
prevents the transcription of several pro-apoptotic genes, including BIM (Brunet, Bonni 
et al. 1999).  Therefore, through these and other targets, activated AKT is able to impact 
cell growth, cell proliferation and cell survival, indicating a key role for this signaling 
cascade in cancer biology.   
In addition to the many downstream targets of AKT that can contribute to tumor 
cell growth and survival, PDK1 has also been shown to phosphorylate and activates S6 
kinase, further increasing the impact of this pathway on cell growth (Pullen, Dennis et al. 
1998).    Further supporting a role for this signaling cascade in pancreatic cancer is 
evidence of decreased expression of the PtdIns (3,4,5) phosphatase PTEN in human 
PDAC (Sakurada, Suzuki et al. 1997; Asano, Yao et al. 2004).  Loss of PTEN leads to 
increased expression of PtdIns (3,4,5), and thus results in increased activation of PI3K 
(Di Cristofano and Pandolfi 2000).  
Both RAF-MEK-ERK and PI3K-AKT signaling cascades can also be activated 
downstream of receptor tyrosine kinases, such as the IGF1R (Baserga, Hongo et al. 
1997).  In addition, many studies have also demonstrated extensive cross talk between the 
RAF-MEK-ERK and PI3K-AKT signaling cascades.  One way such interactions occur is 
through the phosphorylation of TSC2 by ERK (Zoncu, Efeyan et al. 2011).  As 
mentioned above, TSC2 is part of a complex that negatively regulates mTORC1, and its 
phosphorylation and inhibition by ERK results in increased activity of mTORC1 (Zoncu, 
Efeyan et al. 2011).  ERK has also been shown to phosphorylate and activate RAPTOR, a 
member of the mTORC1 complex, thereby further increasing mTORC1 activity (Pearce, 
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Komander et al. 2010).  Further demonstrating the complex interactions of these two 
signaling cascades, AKT has been found to negatively regulate RAF through 
phosphorylation of its N-terminal region, and it is hypothesized that this regulation may 
function to prevent cell cycle arrest due to high levels of MEK-ERK signaling (Cheung, 
Sharma et al. 2008). 
 It has also been shown that RAS activates the RAL GEFs RALGDS, RGL, 
RGL2/RIF, and RGL3 thereby leading to the increased activation of the Ras-family 
GTPases RAL A and RAL B.  (Feng, Ouyang et al. 1996; Wolthuis and Bos 1999; Xu, 
Shi et al. 2007).  In addition to these 4 RAL GEFs that are able to interact with RAS, 
RAP and R-RAS small GTP-ases have also been shown to interact with RAS, but it is not 
known if R-RAS and RAP proteins are able to activate the RAL proteins (Rodriguez-
Viciana, Sabatier et al. 2004). Upon activation, RAL-GTP interacts with multiple 
downstream effectors, including proteins involved in cell proliferation and survival, 
endocytosis, and actin organization (Neel, Martin et al. 2011).   
The two RAL isoforms, A and B,  (named for being “Ras-like”) are encoded by 
two very similar genes, but have been shown to have distinct roles and functions in 
cancer cells (Neel, Martin et al. 2011).  One such study demonstrated that RAL A is 
needed for the anchorage independent growth of tumor cell lines, while RAL B is 
required for survival of those same cell lines (Chien and White 2003). Although much of 
the prior research into RAS stimulated signaling cascades has focused on RAF-MEK-
ERK and PI3K-AKT, these studies demonstrate that RAL A and RAL B may also be key 
regulations of cell proliferation and survival. In support of a role for this pathway in 
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pancreatic tumorigenesis, human pancreatic tumors show high levels of RAL A and RAL 
B as well as RALGEF and RGL2 (Lim, O'Hayer et al. 2006).  In addition, shRNA 
mediated knockdown of RAL A in PDAC cell lines resulted in decreased anchorage 
independent growth in vitro and decreased sub-cutaneous tumor formation in vivo, while 
shRNA mediated knockdown of RAL B resulted in decreased invasion of PDAC cell 
lines, demonstrating a role for these proteins in pancreatic tumor progression (Lim, 
O'Hayer et al. 2006).  
 Activation of the PLC-ε signaling cascades by RAS is less well understood, but 
recent studies have demonstrated stimulation of this pathway downstream of activated 
RAS, and indicate that this pathway may promote RAS induced activation of PKC and 
calcium mobilization (Downward 2003).   
In addition to these pathways, numerous other downstream effectors of Ras have 
been identified, although the effects of their activation by Ras are not yet well 
characterized.  These include AF6, NORE1, TIAM1, RIN1, RGS12, and IMP (Cox and 
Der 2010).   
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Figure 1.2:  
RAS Stimulated Signaling (Adapted from Downward 2003) 
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Mouse Models of Pancreatic Cancer 
In order to better study the genetic and morphological changes inherent to 
pancreatic cancer, numerous mouse models have been generated in an attempt to re-
capitulate the formation of PDAC and most specifically the progression from normal 
pancreas to PanIN lesions to adenocarcinoma that is observed in the human disease. The 
earliest mouse models of pancreatic cancer made use of the observation that the Rat 
Elastase I promoter could direct gene expression specifically within acinar cells (Swift, 
Hammer et al. 1984; Ornitz, Palmiter et al. 1985; Ornitz, Hammer et al. 1987; Quaife, 
Pinkert et al. 1987).   Using this, models were generated that targeted the expression of 
activated Hras or SV40 T-antigen to the pancreas through coupling these genes with the 
Elastase promoter (Ornitz, Hammer et al. 1987; Quaife, Pinkert et al. 1987). These 
models resulted in acinar cell neoplasms, whereas Elastase driven expression of c-myc 
resulted in a mixed acinar/ductal neoplasm (Sandgren, Quaife et al. 1991).  These models 
fell short of truly re-capitulating human disease, though, due to their generation of tumors 
largely comprised of acinar cells. 
In 2003, Lewis and colleagues developed a novel model of pancreatic cancer that 
utilized the RCAS-TVA mouse modeling system.  This model targeted expression of the 
PyMT and c-Myc oncogenes to the pancreas using the Elastase promoter, and found that 
PyMT induced acinar and ductal tumors, while c-Myc resulted in exclusively endocrine 
tumors (Lewis, Klimstra et al. 2003).  These findings revealed that different tumor types 
can arise from the same cell of origin, demonstrating the potential for pancreatic tumors 
to arise from common progenitors and that the type of tumor formed may depend upon 
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the genetic alterations that occur.  This concept was later confirmed by Tyler Jacks and 
colleagues, who demonstrated the existence of pancreatic progenitor cells through the 
targeted expression of Cre in adult acinar cells, and showed that the fate of these cells is 
regulated at least in part by oncogenic stress and the expression of KRASG12D (Gidekel 
Friedlander, Chu et al. 2009).   
In order to more effectively generate relevant mouse models of pancreatic cancer, 
the biology of the pancreas and its development needed to be established.  Lineage 
tracing experiments proved very useful in establishing the progression of pancreatic cell 
progenitors, and in providing lineage specific expression markers that could be used in 
mouse modeling.  These studies identified PDX1 as an early marker of pancreas cells, 
and demonstrated that it is expressed in all pancreatic progenitor cells (Gu, Dubauskaite 
et al. 2002).  Further research has since demonstrated that in the adult pancreas, 
expression of PDX1 is restricted to beta cells (Ashizawa, Brunicardi et al. 2004). 
Additional studies identified PTF1A as a second marker of pancreatic progenitor cells, 
and demonstrated that its expression is specific to the exocrine pancreas in the mature 
organ (Krapp, Knofler et al. 1996).  With the increased understanding in pancreas 
development and the discovery of lineage specific promoters and markers, it became 
possible to generate more clinically relevant PDAC mouse models.   
More recent models for PDAC generated through the pancreas-specific 
expression of an activated Kras allele result in the formation of PDAC and have 
confirmed the critical role of KRAS during pancreatic tumor initiation (Aguirre, 
Bardeesy et al. 2003; Guerra, Mijimolle et al. 2003; Hingorani, Petricoin et al. 2003; 
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Hingorani, Wang et al. 2005).  The first of these models demonstrates that the expression 
of a conditional KrasG12D expressed from the endogenous Kras promoter coupled with 
expression of a Pdx1-Cre or Ptf1-p48-Cre allele results in pancreas specific expression of 
KrasG12D and the formation of progressive PanIN lesions and occasional PDAC 
(Hingorani, Petricoin et al. 2003).  These models served to confirm the PanIN 
progression model that was originally proposed for human PDAC based upon the 
observation of tumor samples (Hruban, Goggins et al. 2000).   
As these models express activated Kras from the endogenous Kras promoter, 
these models provide a more relevant system to study the impact of activated KRAS 
expression in the pancreas, as KRAS is activated but not overexpressed in human 
pancreatic tumors.  Indeed, tumor progression in this model has been shown to be very 
similar to the progression of human pancreatic tumors (Hingorani, Petricoin et al. 2003).  
However, unlike the RCAS-TVA model, these models do not allow for the flexibility of 
using several different oncogenes or even combining oncogenes in the same mouse 
model without the need to generate a new transgenic mouse for each new oncogene.  
Unlike the RCAS-TVA model, the endogenous Kras model also does not result in the 
activation of Kras in only a small subset of pancreas cells, which is likely to occur in 
human tumor formation, but instead results in the widespread activation of Kras in the 
pancreas.   
Following the observation that pancreas specific activation of Kras results in 
PanINs and PDAC in mice, several labs have gone on to combine Kras activation with 
other genetic changes present in human PDAC and have observed an acceleration of 
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tumor development in mice. These models include a combination of Ink4a/Arf deficiency 
(Aguirre, Bardeesy et al. 2003), p53 mutation (Hingorani, Wang et al. 2005), loss of the 
TgfβR2 (Ijichi, Chytil et al. 2006), loss of Smad4 (Bardeesy, Cheng et al. 2006), and Pten 
inactivation (Iwanaga, Yang et al. 2008) with pancreas specific expression of KrasG12D.  
It is important to note that mouse models with pancreas specific loss of Ink4A/Arf in the 
absence of Kras activation do not result in the formation of PanIN lesions or PDAC, 
demonstrating that the ability to initiate pancreatic tumors is unique to the expression of 
activated Kras (Aguirre, Bardeesy et al. 2003).   Collectively, these models have 
confirmed the role of activated Kras in the initiation of PDAC, and have provided a 
tractable system to study the genetic events that cause PanIN lesions to progress to 
PDAC.  
However, despite clearly showing the role for activated KRAS in the formation of 
pancreatic tumors, these models have been unable to address the mechanisms by which 
activated KRAS initiates pancreatic tumors.  For this reason, an alternative model using 
pancreatic ductal epithelial cells, or PDECs, has proved useful in studying the earliest 
stages of pancreatic tumor initiation.  PDECs are the putative cell of origin for PDAC, 
and unlike pancreatic tumor cell lines, they are non-transformed and will not form tumors 
without the added expression of an oncogene such as KRASG12D (Hruban, Goggins et al. 
2000; Morton, Mongeau et al. 2007).   In addition, we and others have previously shown 
that PDECs embedded in matrigel after isolation will continue to form duct like 
structures, demonstrating that they retain the properties of ductal epithelial cells 
(Schreiber, Deramaudt et al. 2004; Morton, Mongeau et al. 2007).  As a result, PDECs 
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provide an excellent model for studying the earliest events of KRAS-mediated pancreatic 
tumor initiation.  Indeed, we have previously used this model to show that the expression 
of KRASG12D in PDECs results in increased proliferation, survival when challenged with 
apoptotic stimuli, and in the absence of Ink4a/Arf, the ability to form tumors following 
orthotopic transplant (Morton, Mongeau et al. 2007).  These data show a clear role for the 
activation of Kras in the transformation of pancreatic epithelial cells, and underscore its 
importance as a critical player in the initiation of pancreatic tumorigenesis. Using a 
similar experimental approach, Lee and Bar-Sagi recently demonstrated a role for TWIST 
in bypassing oncogenic KRAS-induced cellular senescence, further demonstrating the 
ability of this model to elucidate the early changes in KRAS-mediated pancreatic 
tumorigenesis (Lee and Bar-Sagi 2010). 
 
The Role of Ras-induced Signaling Pathways in Pancreatic Cancer 
Many studies have been conducted assessing the role for activated RAS and its 
downstream signaling cascades in the formation and progression of pancreatic tumors.  
To address the question of which of the RAS stimulated signaling cascades are most 
important to pancreatic tumorigenesis, a series of RAS mutants have been used which 
have mutations in their effector loop that result in the preferential binding of a single 
downstream effector.  These binding mutants were first characterized in HRAS using a 
yeast two-hybrid screen, which identified that the S35T mutant preferentially binds, RAF, 
while the C40Y mutant preferentially binds PI3K and the G37D mutant preferentially 
binds RALGDS (White, Nicolette et al. 1995).  It has since been discovered that a 
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mutation at N38D will preferentially signal through the PLC-e signaling cascade, and 
collectively these mutations have become a vital tool in the study of RAS stimulated 
signaling.    
Despite the availability of tools to assess signaling downstream of activated RAS, 
studies investigating the consequences of activated KRAS in pancreatic cancer have 
largely had conflicting results.  One study, by Hamad et al in 2002 identified that the 
importance of a particular RAS effector is highly dependent on the cell context being 
studied (Hamad, Elconin et al. 2002).  Through the expression of various HRAS effector 
binding mutants in human and murine cells, they determined that the signaling pathways 
required for anchorage independent growth can vary greatly from cell type to cell type.  
In murine fibroblasts, it was determined that the RAF-MEK-ERK, PI3K-AKT, and 
RALGDS signaling cascades all contribute to anchorage independent growth, with the 
greatest contribution coming from RAF-MEK-ERK signaling.  However, in human 
fibroblasts, they determined that it was only the RALGDS pathway that contributes to 
anchorage independent growth of the cells, and that even the combination of RAS 
stimulated RAF-MEK-ERK and PI3K-AKT signaling in these cells was not sufficient for 
transformation.  Yet when they continued this study by looking at the ability of human 
cells expressing the HRAS binding mutant that preferentially signals through RALGDS 
to form tumors following sub-cutaneous injection, they found that these cells are 
completely incapable of tumor formation (Lim and Counter 2005).  In fact, tumor 
formation only results from the combination of signaling through both RALGDS and 
RAF-MEK-ERK, or RALGDS, RAF-MEK-ERK, and PI3K-AKT, and even those 
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combinations of the effector mutants are unable to re-capitulate tumor formation in 
HRASG12V expressing cells.   
Additional studies have since been conducted to investigate the role of RAL A 
and RAL B downstream of activated KRAS in human pancreatic cancer cell lines.  These 
studies demonstrated that RAL A is required for anchorage independent growth of those 
cells, while RAL B is important for invasion in these cells (Lim, O'Hayer et al. 2006).  
However, these studies were still conducted in transformed cells, and as such fail to 
examine the role of RAL A and RAL B during KRAS-mediated pancreatic tumor 
initiation.   More recent studies have looked at the effect of signaling downstream of 
activated KRAS in human pancreatic ductal cells, a cell culture model intended to be 
more relevant to the initiation of pancreatic tumors, but which still required genetic 
alterations and immortalization before any experiments were conducted (Campbell, 
Groehler et al. 2007).  In contrast to the prior studies that implicated RAL as a key 
effector downstream of activated KRAS in the initiation of pancreatic tumors, this 
research found that RAF and PI3K were required for transformation and invasion of these 
cells (Campbell, Groehler et al. 2007).   
Collectively, these studies demonstrate the conflicting findings that result from 
studying RAS-stimulated signaling in multiple cell contexts and underscore the need to 
study RAS-stimulated signaling in the most relevant cell context possible.  In addition, as 
many of these previous studies involved the use of HRAS constructs and/or have been 
performed using transformed cells, there remains a need to understand the consequences 
of KRAS activation in the early stages of pancreatic tumor formation.   
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The Role of BRAF in Pancreatic Cancer 
As discussed above, one of the pathways stimulated downstream of activated 
KRAS is the RAF-MEK-ERK signaling cascade, and a key family of proteins involved in 
this signaling is the RAF family of serine-threonine kinases.  Previous studies have 
demonstrated that this signaling pathway is hyperactivated in approximately 30% of 
human cancers, indicating an important role for RAF-MEK-ERK signaling in 
tumorigenesis (Hoshino, Chatani et al. 1999).  To underscore the role of RAF in cancer, 
BRAF is commonly mutated in multiple human malignancies including malignant 
melanoma, thyroid cancer, and ovarian cancer (Davies, Bignell et al. 2002).  These 
mutations result in constitutive kinase activation of BRAF, often to a level significantly 
higher than that of wild type BRAF (Downward 2003).  The most common mutation is 
V600E, which accounts for 90% of all BRAF mutations (Wan, Garnett et al. 2004).  
These findings point to a role for RAF, and more specifically BRAF, in the formation and 
progression of these and other tumor types.   
However, BRAF gene mutations are almost always mutually exclusive with KRAS 
mutations, and thus given the high rate of KRAS mutations in PDAC, BRAF mutations are 
infrequently seen in this disease (Davies, Bignell et al. 2002).  Previous work by Kern 
and colleagues has shown, though, that in the small subset of tumors that do not have 
activating mutations within the KRAS2 oncogene, 33% have activating mutations in 
BRAF (Calhoun, Jones et al. 2003).  These findings raise the possibility that activating 
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BRAF mutations may functionally substitute for KRAS gene mutations during pancreatic 
tumor initiation. 
 
Summary 
It has been well established that activated KRAS has a key role in the formation of 
pancreatic tumors.  Yet there is a lack of understanding of how KRAS-stimulated 
signaling contributes to the initiation and progression of the disease, as prior studies have 
produced contradicting evidence on the importance of the multiple signaling cascades 
downstream of activated KRAS in the formation and progression of pancreatic tumors.  
What these studies have demonstrated is that the effects of signaling through activated 
KRAS are highly context dependent, and that a complete understanding of KRAS-
stimulated signaling requires research using the most relevant cell context possible.   
 Therefore, the goal of this work was to better address the question of the role of 
activated KRAS in pancreatic tumor initiation by investigating the roles of the 
RAF/MEK/ERK and PI3K/AKT signaling pathways in KRAS-mediated transformation 
of pancreatic epithelial cells, which are the putative cells of origin of PDAC.  Since the 
activation of BRAF lies downstream of activated KRAS, and BRAF is activated in 
numerous human malignancies, this work also sought to investigate whether an activated 
BRAF molecule functionally substitutes for activated KRAS in pancreatic ductal 
epithelial cells.  
The data provided in chapter 2 uncover an important role for the IGF1R in 
pancreatic tumor initiation and progression even in the context of KRAS or BRAF 
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activation, and show that MEK induced expression of IGF2 and subsequent activation of 
the IGF1R is necessary for pancreatic tumor formation.   These studies also demonstrate 
key differences between signaling downstream of activated KRAS or BRAF in PDECs 
compared with transformed tumor cell lines, and as a result, identify potential key 
differences between KRAS and BRAF stimulated signaling during tumor initiation versus 
tumor progression, underscoring the need to study signaling downstream of KRAS and 
BRAF activation in the most relevant cell context possible.    
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Chapter II: 
KRAS- and BRAF-Induced Pancreatic Tumor Formation Requires MEK-ERK 
Stimulated IGF1R Signaling 
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Jiu-Feng Cai provided the data in Figure 2.8, 2.9, 2.10 and Figure 2.25B.   
Leanne Ahronian provided the data in Figure 2.11, 2.31.   
Victoria Appleman provided the data for all other figures and tables in this chapter.  
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Introduction 
Over 90% of all cases of PDAC have activating mutations in the KRAS2 
oncogene, and activation of KRAS has been shown to be a very early event in the 
formation of pancreatic tumors (Hezel, Kimmelman et al. 2006).  In addition, recent 
mouse models of pancreatic cancer have demonstrated an important role for Kras 
activation in the formation of pancreatic tumors by showing that the pancreas specific 
expression of activated Kras results in PanIN lesions and PDAC (Aguirre, Bardeesy et al. 
2003; Guerra, Mijimolle et al. 2003; Hingorani, Petricoin et al. 2003; Hingorani, Wang et 
al. 2005).  Targeting activated KRAS for cancer treatment has proved challenging, 
though, and recent work has sought to elucidate signaling downstream of activated 
KRAS and determine which of the KRAS stimulated signaling pathways are important 
for the formation and progression of pancreatic tumors.  These studies have revealed that 
signaling downstream of activated KRAS is highly dependent on cell context, and that 
fully understanding the effects of activated KRAS in the initiation of pancreatic tumors 
requires the most relevant cell context possible (Lim and Counter 2005).   
To address the question of what the roles of activated KRAS and its downstream 
effectors are in the initiation of pancreatic tumors, I sought to investigate the effects of 
activated KRAS expression in pancreatic ductal epithelial cells (PDECs), the putative cell 
of origin for PDAC (Hruban, Goggins et al. 2000).  To further probe the role of the 
MEK/ERK signaling cascade, the best characterized of the KRAS downstream effectors, 
I also sought to determine the effect of expressing activated BRAF in PDECs. BRAF 
mutations are common in many types of human cancers, but are rare in pancreatic cancer, 
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due to the fact that BRAF and KRAS mutations are mutually exclusive (Davies, Bignell 
et al. 2002).  However, 33% of all pancreatic tumors that do not have KRAS mutations 
have been shown to have BRAF mutations, illustrating the importance of MEK/ERK 
signaling in PDAC, and raising the question of whether BRAF mutations are able to 
functionally substitute for KRAS mutations (Calhoun, Jones et al. 2003).    
To achieve expression of activated KRAS (KRASG12D) and activated BRAF 
(BRAFV600E) in PDECs, I utilized the RCAS-TVA mouse modeling system.  This system 
utilizes a subgroup-A avian leukosis-sarcoma virus (ALSV), a retrovirus that is normally 
only able to infect avian cells (Weiss, 1982).  Mammalian cells can be rendered 
susceptible to infection with ALSVs through the expression of the viral receptor for 
ASLVs, TVA, on the cell surface (Bates, Young et al. 1993; Young, Bates et al. 1993).  
Mouse models with tissue and cell specific expression of the TVA receptor can be 
generated through the expression of TVA under the control of a tissue specific promoter.  
In these models, all dividing cells that express the TVA receptor are therefore susceptible 
to infection with ASLVs.   
For these studies, the Rous Sarcoma Virus (RSV)- derived vector RCAS 
(replication competent ASLV long terminal repeat with splice acceptor) retroviruses were 
used for the expression of genes of interest (Hughes, Greenhouse et al. 1987; 
Greenhouse, Petropoulos et al. 1988; Petropoulos and Hughes 1991; Boerkoel, Federspiel 
et al. 1993).    These vectors were generated by replacing the src gene with a multi-
cloning site, which can accommodate up to 2.5kB of insert (Hughes, Greenhouse et al. 
1987; Greenhouse, Petropoulos et al. 1988; Petropoulos and Hughes 1991; Boerkoel, 
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Federspiel et al. 1993) These viruses can be propagated in DF1 chicken fibroblasts, 
which provide a high titer, replication-competent viral stock (Himly, Foster et al. 1998; 
Schaefer-Klein, Givol et al. 1998).  Following infection of these viruses into mammalian 
cells, the viral genome integrates into the host DNA, and the viral LTRs produce 
transcription of the provirus (Hughes, Greenhouse et al. 1987).  The mRNA, expressing 
the gene of interest that has been inserted into the multi-cloning site, is then processed via 
an artificial splice acceptor (Hughes, Greenhouse et al. 1987).  This system therefore 
allows the achievement of tissue or cell specific expression of genes of interest following 
RCAS virus infection of only those cells expressing the TVA receptor.   
For these studies, I isolated PDECs from mice expressing the TVA receptor under 
the regulation of the Keratin-19 (K19) gene promoter and enhancer elements (Bader and 
Franke 1990; Hu and Gudas 1994; Grippo and Sandgren 2000; Orsulic 2002; Morton, 
Mongeau et al. 2007). It has been previously shown that the expression of TVA under the 
K19 promoter and enhancer elements results in the expression of TVA specifically within 
the duct epithelium (B. Lewis and H. Varmus, unpublished).  Work within our lab has 
also demonstrated that PDECs embedded in matrigel after isolation will form duct like 
structures, demonstrating that they retain the properties of ductal epithelial cells 
(Schreiber, Deramaudt et al. 2004; Morton, Mongeau et al. 2007).   In addition, our lab 
has previously demonstrated that PDECs isolated from mice expressing K19-TVA are 
susceptible to infection by ALV-A-based RCAS retroviruses (Morton, Mongeau et al. 
2007). Therefore, these cells can be infected with RCAS-KRASG12D and RCAS-
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BRAFV600E, thereby providing a system to assess the effect of KRAS-stimulated signaling 
in pancreatic ductal epithelial cells.   
Here, I demonstrate that both KRAS and BRAF stimulate the proliferation and 
survival of PDECs in culture, and that the induced survival is dependent on signaling 
through both the MEK/ERK and PI3K/AKT signaling pathways. In addition, I 
demonstrate that activation of AKT occurs in a manner dependent on MEK/ERK and the 
IGF1R, and that cells expressing activated KRAS and BRAF depend upon IGF2-
stimulated IGF1R signaling for survival after exposure to apoptotic stimuli.  Moreover, I 
show that KRASG12D- and BRAFV600E-induced tumor formation in an orthotopic 
pancreatic tumor model is dependent on the IGF1R. Finally, I demonstrate that signaling 
in KRASG12D and BRAFV600E expressing tumor cell lines is not the same as in PDECs.  I 
show that while the tumor cell lines depend on PI3K, MEK, and the IGF1R for cell 
proliferation, they are less dependent than the PDECs on MEK and the IGF1R for their 
survival in response to an apoptotic stimulus.  Collectively, these data provide new 
insights into the mechanisms underlying KRAS-mediated initiation of pancreatic 
tumorigenesis, as well as the differences between signaling downstream of KRASG12D in 
pancreatic tumor initiation and tumor progression.   
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Results 
 
Expressing KRASG12D and BRAFV600E Within Pancreatic Ductal Epithelial Cells. 
To investigate the effects of activated KRAS and BRAF on pancreatic ductal 
epithelial cells (PDECs), I isolated PDECs from transgenic mice expressing the avian 
leukosis virus subgroup A (ALV-A) receptor, TVA, under the control of the Keratin-19 
(K19) gene promoter and enhancer elements (Bader and Franke 1990; Hu and Gudas 
1994; Grippo and Sandgren 2000; Orsulic 2002; Morton, Mongeau et al. 2007). PDECs 
were also isolated from K19-tv-a mice with pancreas specific deletion of the Ink4a/Arf, 
and/or Trp53 tumor suppressor genes (Jonkers, Meuwissen et al. 2001; Krimpenfort, 
Quon et al. 2001; Morton, Mongeau et al. 2007). TVA-positive PDECs were infected 
with RCAS viruses encoding Flag epitope-tagged KRASG12D, BRAFV600E, or GFP as a 
control (Morton, Mongeau et al. 2007).  Infection of PDECs by RCAS-KrasG12D was 
confirmed by immunoblotting for the Flag epitope tag (Figure 2.1A). Importantly, 
quantitative RT-PCR (qRT-PCR) showed that the expression of the ectopic KrasG12D 
resulted in only a 3-fold increase in mRNA levels, indicating that any phenotypes 
observed from the expression of RCAS-KRASG12D are not likely to be non-specific effects 
due to overexpression of Kras  (Figure 2.1B).  Elevated levels of BRAF in RCAS-
BRAFV600E infected cells relative to GFP infected cells were demonstrated by 
immunoblotting (Figure 2.2A).  This increased expression was specific to BRAF, as 
increased levels of ARAF and CRAF were not observed (Figure 2.2B).   
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Figure 2.1  
 
Infection of K19-TVA Expressing PDECs with RCAS-KRASG12D results in 
increased expression of Kras.  
 
(A) Western blot confirming expression of ectopic Flag epitope-tagged KRASG12D in 
Ink4a/Arf, Trp53 null PDECs infected with RCAS-KRASG12D.  β -actin is used as a 
loading control.    
 
(B) Quantitative RT-PCR analysis of the expression of murine Kras in Ink4a/Arf, Trp53 
null PDECs expressing RCAS-KRASG12D relative to Ink4a/Arf, Trp53 null PDECs 
expressing GFP.  Results shown are from two individual primer sets targeting murine 
Kras with the expression level normalized to β-actin.  
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Figure 2.2 
 
Infection of K19-TVA Expressing PDECs with RCAS-BRAFV600E results in 
increased expression of BRAF.  
 
(A) Western blot confirming elevated expression of BRAF in Ink4a/Arf, Trp53 null 
PDECs infected with RCAS-BRAFV600E relative to Ink4a/Arf, Trp53 null PDECs infected 
with GFP.  β -actin is used as a loading control.  Values indicate the ratio of BRAF levels 
relative to β -actin levels as measured by densitometry and normalized such that GFP 
expressing PDECs have a ratio of 1.    
 
(B) Western blot analysis showing similar levels of ARAF and CRAF expression in 
Ink4a/Arf, Trp53 null PDECs infected with RCAS-BRAFV600E or RCAS-GFP. β-actin is 
used as a loading control. 
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Expression of KrasG12D and BRAFV600E increases PDEC proliferation and survival 
Following infection of PDECs with RCAS-KRASG12D, RCAS-BRAFV600E, and 
RCAS-GFP, I next investigated the effect of activated KRAS and mutant BRAF had on 
the proliferation of PDECs.  As previously shown within our lab, expression of activated 
KRAS in these cells resulted in increased proliferation over control cells, and this effect 
was similar in both tumor suppressor wild type as well as Ink4a/Arf, Trp53 null PDECs 
(Figure 2.3A and 2.4A) (Morton, Mongeau et al. 2007).  Expression of mutant BRAF in 
PDECs also resulted in increased proliferation relative to control cells, but notably, this 
increase was not as great as in KRASG12D expressing PDECs, both in tumor suppressor 
wild type and Ink4a/Arf, Trp53 null cells (Figure 2.3A and 2.4A).  The ability of mutant 
BRAF to partially recapitulate the phenotype observed in KRASG12D expressing PDECs 
indicates that increased proliferation downstream of activated KRAS is due in part to the 
RAF/MEK/ERK signaling pathway.  However, BRAFV600E’s inability to completely 
mimic the KRASG12D phenotype may also suggest that the increased proliferation 
downstream of activated KRAS depends on other signaling cascades which are not 
activated downstream of mutant BRAF.  It is possible, however, that the expression of 
BRAFV600E results in RAF/MEK/ERK signaling that either quantitatively or qualitatively 
differs from that downstream of KRASG12D and this results in the differences seen in 
proliferation rates.  In addition, I observed that PDECs expressing a wild type BRAF 
molecule had a similar level of proliferation as GFP expressing PDECs, indicating that 
the mutational status of BRAF is important for the increased proliferation observed in 
BRAFV600E expressing cells (Figure 2.5A and 2.6A).   
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I next sought to determine the effect of KRASG12D and BRAFV600E expression on 
PDEC survival when challenged with an apoptotic stimulus.  For these assays, PDECs 
were treated with ultraviolet (UV) irradiation or cycloheximide, a cytotoxic agent that has 
been previously shown to cause apoptosis in PDECs and pancreatic cancer cells (Koehler 
and Drucker 2006; Morton, Mongeau et al. 2007).  I found increased survival in both 
KRASG12D and BRAFV600E expressing PDECs relative to control cells when treated with 
either ultraviolet (UV) irradiation or cycloheximide (Figure 2.3B, 2.3C, 2.4B, and 2.4C).  
As observed in the proliferation studies, these effects were irrespective of tumor 
suppressor status, and similar results were obtained in wild type (Figure 2.3B and 2.3C) 
as well as Ink4a/Arf (Figure 2.4C) and Ink4a/Arf, Trp53 null PDECs (Figure 2.4B).  It 
should be noted, though, that apoptosis following treatment with UV irradiation depends 
upon wild type p53 in the cells. As a result, UV irradiation was only used for tumor 
suppressor wild type or Ink4a/Arf null PDECs, and any survival assays involving 
Ink4a/Arf, Trp53 null PDECs were conducted using only cycloheximide as an apoptotic 
stimulus.     
In addition, I observed increased survival relative to control cells in PDECs 
expressing wild type BRAF when treated with cycloheximide in both tumor suppressor 
wild type and Ink4a/Arf, Trp53 null cells (Figure 2.5B and 2.6B, respectively).  These 
findings suggest that the expression of BRAF, both mutant and wild type, is able to 
functionally substitute for activated KRAS expression with regards to survival in PDECs, 
and therefore indicate that signaling downstream of the RAF/MEK/ERK pathway may be 
key to survival of pancreatic epithelial cells. 
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Figure 2.3  
 
The expression of KRASG12D and BRAFV600E in tumor suppressor wild type PDECs 
results in increased proliferation and survival when challenged with apoptotic 
stimuli.  
 
(A) Cell numbers of tumor suppressor wild type PDECs showing increased proliferation 
at 15 days of KRASG12D and BRAFV600Eexpressing PDECs relative to GFP expressing 
control cells.   
 
(B) Viability (as measured by trypan blue exclusion) of tumor suppressor wild type 
PDECs showing increased survival of KRASG12D and BRAFV600E expressing cells 
relative to GFP controls following treatment with 100µM cycloheximide. Values are 
normalized such that that viability of untreated cells is 1.  *p < 0.01 for CHX treated 
KRASG12D or BRAFV600E expressing PDECs compared with CHX treated GFP 
expressing controls 
 
(C) Viability (as measured by trypan blue exclusion) of tumor suppressor wild type 
PDECs showing increased survival of KRASG12D and BRAFV600E expressing cells 
relative to GFP controls following treatment with UV irradiation. Values are normalized 
such that that viability of untreated cells is 1. *p < 0.01 for UV treated KRASG12D or 
BRAFV600E expressing PDECs compared with UV treated GFP expressing controls 
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Figure 2.4 
The expression of KRASG12D and BRAFV600E in Ink4a/Arf, Trp53 and Ink4a/Arf null 
PDECs results in increased proliferation and survival when challenged with 
apoptotic stimuli.  
 
(A) Cell numbers of Ink4a/Arf, Trp53 null PDECs showing increased proliferation at 15 
days of KRASG12D and BRAFV600Eexpressing PDECs relative to GFP expressing control 
cells.   
 
(B) Viability (as measured by trypan blue exclusion) of Ink4a/Arf, Trp53 null PDECs 
showing increased survival of KRASG12D and BRAFV600E expressing cells relative to GFP 
controls following treatment with 100µM cycloheximide. Values are normalized such 
that that viability of untreated cells is 1. *p < 0.01 for CHX treated KRASG12D or 
BRAFV600E expressing PDECs compared with CHX treated GFP expressing controls 
 
(C) Viability (as measured by trypan blue exclusion) of Ink4a/Arf null PDECs showing 
increased survival of KRASG12D and BRAFV600E expressing cells relative to GFP controls 
following treatment with UV irradiation. Values are normalized such that that viability of 
untreated cells is 1. *p < 0.01 for UV treated KRASG12D or BRAFV600E expressing PDECs 
compared with UV treated GFP expressing controls 
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Figure 2.5 
 
The expression of wild type BRAF in tumor suppressor wild type PDECs does not 
result in increased proliferation, but does result in increased survival when 
challenged with an apoptotic stimulus.  
 
(A) Cell numbers of tumor suppressor wild type PDECs showing increased proliferation 
at 15 days of BRAFV600E expressing cells, but not wild type BRAF expressing cells, 
relative to GFP controls.   
 
(B) Viability (as measured by trypan blue exclusion) of tumor suppressor wild type 
PDECs showing increased survival of BRAFV600E (V5 tagged) and wild type BRAF 
expressing cells relative to GFP controls following treatment with 100µM cycloheximide. 
Values are normalized such that that viability of untreated cells is 1.  
*p < 0.01 for CHX treated WT BRAF or BRAFV600E expressing PDECs compared with 
CHX treated GFP expressing controls 
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Figure 2.6 
 
The expression of wild type BRAF in Ink4a/Arf, Trp53 null PDECs does not result in 
increased proliferation, but does result in increased survival when challenged with 
an apoptotic stimulus.  
 
(A) Cell numbers of Ink4a/Arf, Trp53 null PDECs showing increased proliferation at 15 
days of BRAFV600E expressing cells, but not wild type BRAF expressing cells relative to 
GFP expressing control cells.  
 
(B) Viability (as measured by trypan blue exclusion) of Ink4a/Arf, Trp53 null PDECs 
showing increased survival of BRAFV600E (V5 tag) and wild type BRAF expressing cells 
relative to GFP expressing control cells following treatment with 100µM cycloheximide. 
Values are normalized such that that viability of untreated cells is 1.  
*p < 0.05 for CHX treated WT BRAF or BRAFV600E expressing PDECs compared with 
CHX treated GFP expressing controls 
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Expression of either KRASG12D or BRAFV600E in Ink4a/Arf, Trp53 deficient PDECs 
results in tumor formation following orthotopic transplant 
Having shown that BRAFV600E expression in PDECs results in increased 
proliferation and survival of those cells, I next sought to determine if the expression of 
BRAFV600E in PDECs was sufficient to induce tumor formation following orthotopic 
transplant.  Previous studies within our lab have shown that the expression of KRASG12D 
in Ink4a/Arf, Trp53 null PDECs is sufficient to induce tumor formation following 
orthotopic transplant (Morton, Mongeau et al. 2007), and in this study, I assessed if the 
same was true for BRAFV600E expressing PDECs null for Ink4a/Arf and Trp53.  I found 
that implantation of KRASG12D- and BRAFV600E-expressing PDECs resulted in efficient 
pancreatic tumor formation, whereas the implantation of GFP expressing cells did not 
efficiently result in tumor formation (Table 2.1).  It should be noted that although in this 
cohort of mice, KRASG12D expressing cells did form tumors sooner than BRAFV600E 
expressing cells (4 weeks versus 8 weeks) and tumors formed from KRASG12D expressing 
cells were slightly larger than those from BRAFV600E expressing cells (average tumor 
volume of 1679 mm3 versus 1197 mm3), multiple orthotopic transplant experiments with 
KRASG12D and BRAFV600E expressing PDECs have demonstrated that this is not 
consistently the case. 
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Table 2.1 
 
Tumor induction by 1x106 KRASG12D and BRAFV600E expressing Ink4a/Arf, Trp53 
null PDECs following orthotopic transplant.  
 
 
 
Tumor Formation Following Orthotopic  
Transplant of Ink4a/Arf, Trp53 Null PDECs 
        
Cells Implanted Tumor Incidence 
Time to Tumor 
Development 
(Weeks) 
Average 
Tumor 
Volume 
(SEM) 
      
GFP 1/6 8 400mm
3             
( ±0) 
KRASG12D  6/6 4 1679mm
3             
( ±607) 
BRAFV600E 5/6 8 1197mm
3                
( ±430) 
Tumor Volume Calculated Using the Formula LxWxH 
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Subtle Differences Exist in the Tumors Formed from orthotopic transplant of 
KRASG12D and BRAFV600E Expression PDECs 
Next, I investigated whether the tumors formed following orthotopic transplant 
differed between mice transplanted with KRASG12D or BRAFV600E expressing PDECs.  
Hematoxylin and eosin staining of tumor tissue showed that transplantation of both 
KRASG12D and BRAFV600E expressing cells primarily resulted in the formation of 
undifferentiated carcinomas, consistent with our previously published findings (Figure 
2.7) (Morton, Mongeau et al. 2007).  Surprisingly, tumors formed after the injection of 
BRAFV600E-expressing PDECs additionally contained regions with features of skeletal, 
cartilaginous, or bone differentiation, traits consistent with mesenchymal differentiation 
(Figure 2.7C and 2.7D). Consistent with this, KRAS-induced tumors displayed 
cytokeratin 8 staining throughout the tumor, whereas BRAF-induced tumors displayed 
cytokeratin 8 staining only in regions displaying glandular differentiation (Figure 2.8). 
The mechanisms underlying this mesenchymal-like differentiation remain undetermined.  
I evaluated proliferation within the various tumors via staining for Ki67, and 
observed that transplantation of both KRASG12D and BRAFV600E expressing PDECs 
resulted in tumors with similar levels of proliferation (2.9).  Interestingly, tumors 
obtained from mice transplanted with KRASG12D expressing PDECs, though, frequently 
displayed regions of highly proliferative cells and other regions with very little 
proliferation (Figure 2.9A and 2.9B), while tumors from mice transplanted with 
BRAFV600E expressing PDECs appeared to have a moderate level of proliferating cells 
dispersed throughout much of the tumor tissue (Figure 2.9C and 2.9D).  Staining for the 
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pancreatic epithelial cell marker Pdx-1 showed Pdx-1 expression in regions of both 
KRASG12D and BRAFV600E expressing tumors, particularly within ductal cells (Figure 
2.10A and 2.10C), as well as regions of both KRASG12D and BRAFV600E expressing 
tumors that were Pdx-1 negative (Figure 2.10B and 2.10D).  These findings show that 
while a portion of the tumors retains expression of this epithelial cell marker, there are 
also cells present in the tumor that have either lost this epithelial marker during 
tumorigenesis, or are non-epithelial cells recruited to the tumor after initiation.    
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Figure 2.7 
Tumors formed from orthotopic transplant of KRASG12D and BRAFV600E expressing 
Ink4a/Arf, Trp53 null PDECs have similar tumor histology.  
 
Staining of tissue sections from orthotopic transplant tumors Hematoxylin and Eosin 
illustrating the similarities and differences between KrasG12D (A and B) and BrafV600E (C 
and D) induced tumors.  KRASG12D induced tumors display undifferentiated histology, 
while BRAFV600E induced tumors display both regions of undifferentiated histology (C 
and D) as well as regions of glandular differentiation (C, white arrow) and bone 
differentiation (D, white arrow).   
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Figure 2.8 
Tumors formed from orthotopic transplant of KRASG12D and BRAFV600E expressing 
Ink4a/Arf, Trp53 null PDECs show different patterns of Troma1 staining. 
 
Staining of tissue sections from orthotopic transplant tumors with Troma1 (cytokeratin 8) 
illustrating the consistent cytokeratin 8 staining throughout KrasG12D induced tumors (A) 
in contrast to the presence of Troma1 positive cells only in the glandular regions of 
BrafV600E induced tumors (B).  
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Figure 2.9 
Tumors formed from orthotopic transplant of KRASG12D and BRAFV600E expressing 
Ink4a/Arf, Trp53 null PDECs show similar overall levels of proliferation. 
 
Staining of tissue sections from orthotopic transplant tumors with Ki67 illustrating the 
similarities in levels of proliferation in KrasG12D (A and B) and BrafV600E (C and D) 
induced tumors.  However, KRASG12D induced tumors displayed regions of highly 
proliferative cells (A) and regions with low proliferation (B), while BRAFV600E induced 
tumors display moderate levels of proliferation through the entire tumor tissue (C and 
D).   
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Figure 2.10 
Tumors formed from orthotopic transplant of KRASG12D and BRAFV600E expressing 
Ink4a/Arf, Trp53 null PDECs show different patterns of Pdx1 staining. 
 
Staining of tissue sections from orthotopic transplant tumors with Pdx1 illustrating the 
similarity between KrasG12D (A and B) and BrafV600E (C and D) induced tumors.  Both 
KRASG12D and BRAFV600E induced tumors display regions with pdx1 positive cells (A 
and C) as well as regions that are pdx1 negative (B and D).  
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KRASG12D and BRAFV600E Expressing Tumor Cell Lines Have Differing Levels of 
Anchorage Independent Growth and Migration 
I additionally analyzed the transformation-associated phenotypes of cell lines 
derived from KRASG12D- and BRAFV600E expressing tumors. I found that while there was 
variation within each group, overall KRASG12D expressing cell lines had enhanced 
anchorage-independent growth capacity relative to tumor cell lines expressing 
BRAFV600E (Figure 2.11A). In addition, KRASG12D expressing cell lines had enhanced 
migration activity relative to BRAFV600E expressing cell lines (Figure 2.11B). Together, 
these data suggest that signaling pathways stimulated by activated KRAS, but not BRAF, 
contribute to the transformed phenotype in pancreatic cancer cells. These data also 
suggest that although activated BRAF is able to largely recapitulate the phenotype of 
activated KRAS in PDECs, there are subtle differences between the signaling 
downstream of these two oncogenes, and these differences may impact tumor 
progression.   
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Figure 2.11  
 
KRASG12D expressing tumor cell lines have enhanced migration and anchorage 
independent growth when compared with BRAFV600E expressing tumor cell lines.  
 
(A) Average number of colonies formed in soft agar showing enhanced anchorage 
independent growth of three KRASG12D expressing cell Ink4a/Arf, Trp53 null tumor cell 
lines compared with three BRAFV600E expressing Ink4a/Arf, Trp53 null tumor cell lines.  
 
(B) Average number of migrating cells as assessed with BD Matrigel Migration 
Chambers showing enhanced migration of three KRASG12D expressing cell Ink4a/Arf, 
Trp53 null tumor cell lines compared with three BRAFV600E expressing Ink4a/Arf, Trp53 
null tumor cell lines. 
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Signaling downstream of MEK and PI3K is necessary for survival in KRASG12D and 
BRAFV600E expressing PDECs 
The PI3K/AKT signaling cascade is typically viewed as the survival-inducing 
pathway downstream of activated KRAS.  As activated BRAF signals primarily through 
the MEK/ERK signaling cascade, it was surprising to observe similar levels of cell 
survival in KRASG12D and BRAFV600E expressing PDECs after challenge with apoptotic 
stimuli.  As a result, I next probed the signaling requirements of PDEC survival 
downstream of both activated KRAS and mutant BRAF, and investigated the effects of 
inhibiting either MEK or PI3K on survival in cells expressing KRASG12D or BRAFV600E.   
Surprisingly, I found that when PDECs were treated with the MEK inhibitor PD98059 or 
the PI3K inhibitor LY294002, survival in response to cycloheximide or UV irradiation in 
both KRASG12D and BRAFV600E expressing PDECs dropped to the level of GFP 
expressing cells (Figure 2.12A and 2.12B, respectively). These data indicate that both the 
MEK/ERK and the PI3K/AKT signaling cascades are necessary for the survival 
phenotype observed in KRASG12D and BRAFV600E expressing PDECs.  Similar results 
were found when PDECs were treated with rapamycin, an inhibitor of mTOR, as survival 
in both KRASG12D and BRAFV600E expressing PDECs dropped to that of GFP expressing 
cells (Figure 2.13), indicating that signaling through mTOR downstream of PI3K is 
needed for survival in these cells. When PDECs were treated simultaneously with both 
the MEK and PI3K inhibitors, survival in KRASG12D and BRAFV600E expressing PDECs 
was once again decreased to the level of GFP expressing cells, but no additional decrease 
was seen with the combination of inhibitors, indicating that inhibition of either pathway 
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resulted in the maximum impairment in survival measurable by this assay (Figure 2.14 
and 2.15). 
As a control to confirm that any observed loss of survival is not simply due to the 
addition of small chemical inhibitors, these survival assays also included PDECs that 
expressed Sonic Hedgehog (SHH).  Our lab has previously demonstrated that SHH 
expressing PDECs have increased survival relative to GFP expressing cells, as well as 
increased activation of both RAF/MEK/ERK and PI3K/AKT signaling.  (Morton, 
Mongeau et al. 2007).    Despite activation of both of these pathways, SHH-induced 
survival is dependent on PI3K/AKT signaling, but not the MEK/ERK signaling cascade 
(Figure 2.12A and 2.12B) (Morton, Mongeau et al. 2007). 
Our findings are consistent with previous studies implicating the PI3K/AKT 
pathway in survival downstream of activated KRAS, but differ from those studies by 
demonstrating that the RAF/MEK/ERK signaling cascade is also needed for survival in 
these cells. In addition, they present a novel finding demonstrating that activated BRAF 
depends on signaling through PI3K/AKT and does not rely solely on MEK/ERK 
signaling for its oncogenic effects.   
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Figure 2.12 
 
Inhibition of MEK or PI3K results in decreased survival of KRASG12D and 
BRAFV600E expressing PDECs when challenged with apoptotic stimuli.   
 
(A) Viability (as measured by trypan blue exclusion) of Ink4a/Arf, Trp53 null PDECs 
expressing KRASG12D, BRAFV600E, SHH, or GFP.  For these assays, cells were first 
vehicle treated or treated with the MEK inhibitor PD98059 or the PI3K inhibitor 
LY2900042, and then one hour later either vehicle treated or treated with 100µM 
cycloheximide.  Values are normalized such that viability of untreated cells is 1.  
*p < 0.05 for inhibitor treated plus CHX compared with CHX alone 
 
(B) Viability (as measured by trypan blue exclusion) of Ink4a/Arf null PDECs expressing 
KRASG12D, BRAFV600E, SHH, or GFP.  For these assays, cells were first vehicle treated 
or treated with the MEK inhibitor PD98059 or the PI3K inhibitor LY2900042, and then 
one hour later either left untreated or treated with ultraviolet (UV) irradiation.  Values are 
normalized such that viability of untreated cells is 1.  
*p < 0.05 for inhibitor treated plus UV compared with UV alone 
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Figure 2.13 
 
Inhibition of mTOR results in decreased survival of KRASG12D and BRAFV600E 
expressing PDECs when challenged with an apoptotic stimulus.   
 
(A) Viability (as measured by trypan blue exclusion) of Ink4a/Arf, Trp53 null PDECs 
expressing KRASG12D, BRAFV600E, or GFP.  For this assay, cells were first either vehicle 
treated, treated with the mTOR inhibitor rapamycin, or treated with the PI3K inhibitor 
LY294002, and then one hour later either vehicle treated or treated with 100µM 
cycloheximide.  Values are normalized such that that viability of untreated cells is 1.  
*p < 0.05 for inhibitor treated plus CHX compared with CHX alone 
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Figure 2.14  
 
The combined inhibition of MEK and PI3K in KRASG12D and BRAFV600E expressing 
PDECs does not further decrease survival in response to cycloheximide when 
compared with either MEK or PI3K inhibition alone.  
 
(A) Viability (as measured by trypan blue exclusion) of Ink4a/Arf, Trp53 null PDECs 
expressing KRASG12D, BRAFV600E, or GFP.  For these assays, cells were first vehicle 
treated or treated with the MEK inhibitor PD98059, the PI3K inhibitor LY2900042, or 
both PD98059 and LY294002, and then one hour later either vehicle treated or treated 
with 100µM cycloheximide.  Values are normalized such that viability of untreated cells 
is 1.  
*p < 0.05 for inhibitor treated plus CHX compared with CHX alone 
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Figure 2.15 
 
The combined inhibition of MEK and PI3K in KRASG12D and BRAFV600E expressing 
PDECs does not further decrease survival in response to UV irradiation when 
compared with either MEK or PI3K inhibition alone.  
 
(A) Viability (as measured by trypan blue exclusion) of Ink4a/Arf null PDECs expressing 
KRASG12D, BRAFV600E, or GFP.  For these assays, cells were first vehicle treated or 
treated with the MEK inhibitor PD98059, the PI3K inhibitor LY2900042, or both 
PD98059 and LY294002, and then one hour later either left untreated or treated with 
ultraviolet (UV) irradiation.  Values are normalized such that viability of untreated cells 
is 1.  
*p < 0.05 for inhibitor treated plus UV compared with UV alone 
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Expression of KRASG12D and BRAFV600E results in activation of RAF/MEK/ERK 
and PI3K/AKT signaling cascades 
The dependence of KRASG12D and BRAFV600E expressing PDECs on both the 
RAF/MEK/ERK and PI3K/AKT pathways for survival was unexpected, since BRAFV600E 
has been previously shown to directly stimulate the MEK/ERK signaling cascade, but not 
the PI3K/AKT pathway.  Because of this, I next sought to determine the activation status 
of these signaling pathways in KRASG12D and BRAFV600E expressing PDECs.  PDECs 
were serum starved for 48 hours to eliminate pathway activation induced by exogenous 
growth factors, and protein lysates were generated from the serum-starved cells. 
Immunoblotting of these lysates showed increased ratios of phosphorylated AKT (pAKT; 
at ser473) to total AKT, and phosphorylated ERK1 and ERK2 (pERK; at Thr202/Tyr204) 
to total ERK, in KRASG12D- and BRAFV600E-expressing PDECs relative to GFP 
expressing controls, indicating that both the MEK/ERK and PI3K/AKT signaling 
pathways are activated in these cells (Figure 2.16). As BRAFV600E is not known to signal 
through AKT directly, these data suggest that BRAFV600E, and potentially also 
KRASG12D, stimulates PI3K/AKT signaling in an indirect manner.  
In addition, I found that KRASG12D and BRAFV600E expressing PDECs had 
increased levels of total AKT when compared with GFP expressing cells (Figure 2.17A).  
Immunoblotting for AKT1, AKT2, and AKT3 found that this increase in total AKT was 
due primarily to an increase in AKT1 in KRASG12D expressing PDECs, and an increase in 
AKT1 and AKT3 in BRAFV600E expressing PDECs relative to GFP expressing PDECs 
(Figure 2.17A). KRASG12D expressing cells also displayed a slight decrease in both 
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AKT2 and AKT3 relative to GFP expressing PDECs (Figure 2.17A).  Analysis of Akt 
family member gene expression via quantitative RT-PCR showed that KRASG12D 
expressing PDECs had an increase in Akt3 message level relative to GFP expressing 
cells, and a decrease in Akt2 message level relative to GFP expressing cells, while Akt1 
gene expression was unchanged relative to GFP expressing cells (Figure 2.17B).  In 
contrast to KRASG12D expressing PDECs, qRT-PCR analysis of BRAFV600E expressing 
PDECs showed increased levels of expression of all three Akt family members relative to 
GFP expressing PDECs (Figure 2.17B). These findings demonstrate that the changes in 
AKT family member protein expression in KRASG12D and BRAFV600E do not coincide 
with the changes in gene expression, and indicate that the regulation of AKT protein 
translation and/or stability may differ downstream of activated KRAS versus activated 
BRAF.   
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Figure 2.16  
 
KRASG12D and BRAFV600E expressing PDECs have increased pERK (1/2) and pAKT 
(ser473) expression when compared to control cells.  
 
(A) Western blot analysis of showing increased ERK (p42/44) and AKT (ser473) 
phosphorylation in serum starved KRASG12D and BRAFV600E expressing Ink4a/Arf, Trp53 
null PDECs relative to GFP expressing controls. Values indicate the atio of 
phosphorylated AKT relative to total AKT as measured by densitometry and normalized 
such that GFP expressing controls have a ratio of 1.    
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Figure 2.17 
 
KRASG12D and BRAFV600E expressing PDECs have increased total AKT expression 
and differential expression of AKT family members when compared to control cells.   
  
(A) Western blot analysis of AKT isoform expression in KrasG12D, BrafV600E, and GFP 
expressing Ink4a/Arf, Trp53 null PDECs showing increased expression of total AKT in 
KrasG12D and BrafV600E expressing cells relative to GFP expressing controls.  
 
(B) Quantitative RT-PCR for murine Akt1, Akt2, and Akt3 isoforms in KrasG12D and 
BrafV600E expressing Ink4a/Arf, Trp53 null PDECs relative to GFP expressing Ink4a/Arf, 
Trp53 null PDECs.  β-actin is used as an endogenous control, and for all data, AKT 
isoform expression in GFP expressing cells is normalized to 1. 
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Activation of PI3K/AKT signaling in KRASG12D and BRAFV600E expressing PDECs 
depends on signaling through the IGF1R 
Since BRAF has not been previously shown to directly activate PI3K, I next 
sought to determine the mechanism by which BRAFV600E stimulates signaling through the 
PI3K/AKT pathway in PDECs.  I hypothesized that the activation of PI3K/AKT in these 
cells was downstream of the RAF/MEK/ERK signaling cascade, potentially through the 
activation of autocrine growth factor signaling. Previous studies have demonstrated 
increased expression of IGF1 in pancreatic tumors, indicating that the Insulin-Like 
Growth Factors and the IGF1R may play a role in pancreatic tumorigenesis (Bergmann, 
Funatomi et al. 1995).  Based upon this, I hypothesized that the IGF1R could be activated 
downstream of RAF/MEK/ERK signaling.  In support of this, a recent study 
demonstrated that melanoma cells expressing mutant NRAS or BRAF respond to 
treatment with an IGF1R inhibitor despite the activation of NRAS and BRAF (Yeh, 
Bohula et al. 2006). To further investigate this hypothesis, I next sought to determine if 
signaling through RAF/MEK/ERK induced the activation of the IGF1R in KRASG12D or 
BRAFV600E expressing PDECs. 
I first assessed the levels of IGF1R ligand expression in serum starved PDECs 
expressing KRASG12D, BRAFV600E, or GFP by qRT-PCR.  I found robustly increased 
levels of Igf2 in both KRASG12D and BRAFV600E expressing cells relative to GFP 
expressing cells, and a modest increase in Igf1 mRNA levels (Figure 2.18A).  
Interestingly, insulin mRNA levels were unaffected by the expression of activated KRAS 
and BRAF proteins.  In contrast to the results for IGF1R ligands, I did not see a similar 
  70 
increase in the expression level of any EGF family ligand in KRASG12D and BRAFV600E 
expressing PDECs by qRT-PCR (Figure 2.18B).  For this study, the ligands included 
were Epidermal Like Growth Factor (Egf), Amphiregulin (Amp), Betacellulin (Btc), 
Epigenin (Epi), Transforming Grwoth Factor Alpha (TGF-α), Heparain Binding EGF 
(Hb-Egf), and Epiregulin (Epr).  While it should be noted that the expression level of Egf 
was increased in BRAFV600E expressing PDECs, this was not true of KRASG12D 
expressing PDECs and the increased level observed was well below the increase 
observed in Igf2 expression in either cell type (Figure 2.18B).  These data indicate that 
this increase is specific to Igf1 and Igf2 and supporting our hypothesis that KRasG12D and 
BRAFV600E activate the IGF1R downstream of RAF/MEK/ERK.  
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Figure 2.18  
 
KRASG12D and BRAFV600E expressing PDECs greatly increased levels of IGF1R 
ligands and not EGFR ligands when compared with control cells.    
 
(A) Quantitative RT-PCR demonstrating increased expression of Igf2 in KRASG12D and 
BRAFV600E expressing Ink4a/Arf, Trp53 null PDECs relative to GFP expressing control 
cells.  β-actin is used as an endogenous control, and for all data, ligand expression in GFP 
expressing cells is normalized to 1.  
 
(B) Quantitative RT-PCR analyzing the expression of epidermal growth factor receptor 
(EGFR) ligands in KRASG12D and BRAFV600E expressing Ink4a/Arf, Trp53 null PDECs 
relative to GFP expressing control cells.  β-actin is used as an endogenous control, and 
for all data, ligand expression in GFP expressing cells is normalized to 1.  
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When I assessed IGF2 expression via western blot, I once again observed 
increased IGF2 levels in KRASG12D and BRAFV600E expressing PDECs relative to GFP 
expressing PDECS (Figure 2.19A).  Moreover, immunoblotting with specific antibodies 
against total and phosphorylated IGF1R in lysates from serum starved PDECs 
demonstrated increased total receptor levels as well as increased phosphorylation of the 
receptor in KRASG12D- and BRAFV600E-expressing cells (Figure 2.19B).  Of note, the 
increase in total receptor levels was much higher in KRASG12D expressing PDECs than in 
BRAFV600E expressing PDECs relative to control cells (Figure 2.19B).   
Consistent with the hypothesis that Igf2 gene expression is stimulated downstream 
of the MEK/ERK cascade, treatment of KRAS- and BRAF-expressing PDECs with the 
MEK inhibitor PD98059, but not the PI3K inhibitor LY294002 impaired the elevation of 
Igf2, but not Igf1 or Ins2, mRNA levels in KRASG12D- and BRAFV600E-expressing PDECs 
(Figure 2.20A and 2.20B).   
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Figure 2.19 
 
KRASG12D and BRAFV600E expressing PDECs increased levels of IGF2, IGF1R, and 
pIGF1R when compared with control cells.    
 
 
(A) Western blot analysis showing increased IGF2 in serum starved KRASG12D and 
BRAFV600E expressing Ink4a/Arf, Trp53 null PDECs relative to GFP expressing control 
cells. β -actin is used as a loading control.   
 
(B) Western blot analysis showing increased total and phosphorylated IGF1R in 
KRASG12D and BRAFV600E expressing Ink4a/Arf, Trp53 null PDECs relative to GFP 
expressing control cells.  β -actin is used as a loading control.   
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Figure 2.20 
 
Inhibition of MEK reduces the levels of Igf2, but not Igf1 or Ins2 in KRASG12D 
expressing PDECs.    
 
(A) Quantitative RT-PCR demonstrating decreased expression of Igf2 in KRASG12D 
expressing Ink4a/Arf, Trp53 null PDECs treated with the MEK inhibitor PD98059 or the 
IGF1R inhibitor AG1024 relative to vehicle (DMSO) treated cells.   β-actin is used as an 
endogenous control, and for all data, Igf2 expression in vehicle treated cells are 
normalized to 1. 
 
(B) Quantitative RT-PCR of Igf1 and Ins2 in serum starved in KRASG12D expressing 
Ink4a/Arf, Trp53 null PDECs following treatment with either vehicle (DMSO), or the 
MEK inhibitor PD98059, the PI3K inhibitor LY294002, or the IGF1R inhibitor AG1024. 
β -actin is used as an endogenous control, and for all data, ligand expression in vehicle 
treated cells is normalized to 1.   
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To investigate whether the activation of AKT within KRASG12D and BRAFV600E 
expressing cells depended upon signaling through MEK, and subsequently through the 
IGF1R, I inhibited MEK, PI3K, or IGF1R expression in KRASG12D and BRAFV600E 
expressing PDECs using small molecule inhibitors, and determined the effect on 
activation of ERK 1/2 (p42/44) and AKT via immunoblotting.  As expected, I found that 
in KRASG12D and BRAFV600E expressing PDECs, pERK 1/2 is dramatically reduced in 
the presence of a MEK inhibitor.  Surprisingly, I found that pERK 1/2 levels are also 
reduced in the presence of PI3K or IGF1R inhibitors in KRASG12D and BRAFV600E 
expressing PDECs, indicating a potential feedback loop between the RAF/MEK/ERK 
and PI3K/AKT pathways within these cells (Figure 2.21A).  In contrast, GFP expressing 
PDECs only showed a reduction in pERK 1/2 in the presence of the MEK inhibitor 
(Figure 2.21A).   These results suggest that the potential feedback between the 
RAF/MEK/ERK and PI3K/AKT pathways is specific to signaling downstream of 
KRASG12D and BRAFV600E.   
Analysis of pAKT (ser473) levels following treatment with the various inhibitors 
demonstrated a decrease in pAKT (ser473) when KRASG12D, BRAFV600E, and GFP cells 
were treated with the PI3K inhibitor, confirming efficient inhibition of this pathway 
downstream of PI3K inhibition (Figure 2.21A).  In the BRAFV600E cells, though, there 
was also decreased pAKT (ser473) following treatment with the MEK and IGF1R 
inhibitors (Figure 2.21A).  These data indicate that activation of PI3K/AKT signaling lies 
downstream of the MEK/ERK signaling cascade in BRAFV600E expressing PDECs.  In 
contrast, I found that while treatment with the PI3K inhibitor robustly reduced pAKT 
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levels in KRASG12D-expressing PDECs, treatment with the MEK or IGF1R inhibitors had 
a more modest impact (Figure 2.21A). These data suggest that in addition to activation of 
PI3K/AKT downstream of MEK/ERK signaling, KRASG12D may also directly activate 
the PI3K/AKT pathway in PDECs as demonstrated previously in other cell types 
(Rodriguez-Viciana, Warne et al. 1994; Pacold, Suire et al. 2000).   
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Figure 2.21 
 
The phosphorylation of AKT at ser473 in KRASG12D and BRAFV600E expressing 
PDECs depends on signaling through MEK and the IGF1R.   
 
(A) Western blot analysis of ERK (p42/44) and AKT (ser473) phosphorylation in serum 
starved in KRASG12D, BRAFV600E, and GFP expressing Ink4a/Arf, Trp53 null PDECs 
following treatment with either vehicle (X), the MEK inhibitor PD98059, the PI3K 
inhibitor LY294002, or the IGF1R inhibitor AG1024.  
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To further assess the impact of the IGF1R on the MEK/ERK and PI3K/AKT 
signaling pathways, I utilized shRNA-mediated knockdown to reduce IGF1R levels and 
downstream signaling.  Immunoblotting confirmed efficient knockdown of the IGF1R in 
PDECs infected with a lentivirus encoding an IGF1R-targeting shRNA relative to PDECs 
expressing a non-silencing control (Figure 2.22A).  Of note, KRASG12D expressing 
PDECs treated with control shRNA no longer showed increased expression of the IGF1R 
when compared with BRAFV600E expressing cells (Figure 2.22A).  The cause of this 
difference in expression of the IGF1R was not determined, but it is possible that it was 
due to the puromycin selection of these cells, as it reduced IGF1R expression was 
consistently seen in KRASG12D cells treated with control shRNA and subsequently 
selected in puromycin.   
Assessment of pERK and pAKT (ser473) levels by immunoblotting demonstrated 
that both the PI3K/AKT and MEK/ERK pathways were strongly inhibited in KRASG12D- 
and BRAFV600E-expressing PDECs following IGF1R knockdown (Figure 2.22A). The 
effect of IGF1R knockdown was more robust than that observed upon AG1024 treatment. 
While the reasons for these differences are unclear, the data suggest that knockdown of 
IGF1R more completely inhibits downstream signaling than treatment with AG1024 at 
the concentration utilized for these studies (20μM). In addition, Yeh and colleagues 
demonstrated that decreases in pAKT and pERK following IGF1R inhibition in 
BRAFV600E expressing melanoma cells required up to 4 days, indicating that the time of 
IGF1R inhibition, may impact the effect on the PI3K/AKT and MEK/ERK pathways 
(Yeh, Bohula et al. 2006).  Nonetheless, these findings suggest that AKT activation 
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occurs downstream of the IGF1R.  When coupled with our finding that IGF2 induction 
occurs downstream of MEK (Figure 2.20A), these data suggest that a MEK-IGF2-IGF1R 
signaling axis regulates AKT activation downstream of activated KRAS and BRAF in 
primary pancreatic ductal epithelial cells. 
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Figure 2.22 
 
Knockdown of the IGF1R inhibits the phosphorylation of AKT at ser473 in 
KRASG12D and BRAFV600E expressing PDECs  
 
(A) Western blot analysis showing decreased ERK (p42/44) and AKT (ser473) 
phosphorylation in serum starved KRASG12D and BRAFV600E expressing Ink4a/Arf, Trp53 
null PDECs with shRNA mediated knockdown of the IGF1R.  
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Inhibition of the IGF1R results in decreased survival in KRASG12D and BRAFV600E 
expression PDECs 
As the prior data has indicated that activation of the PI3K/AKT pathway lies 
downstream of the MEK/ERK signaling cascade and the IGF1R, and given the 
requirement for MEK/ERK and PI3K/AKT signaling for KRASG12D- and BRAFV600E-
induced survival, I next investigated the impact of IGF1R inhibition on this phenomenon.  
I found that both KRASG12D and BRAFV600E expressing PDECs treated with an IGF1R 
inhibitor had decreased survival following challenge with both cycloheximide (Figure 
2.23A) and UV irradiation (Figure 2.23B).  Importantly, survival in SHH-expressing 
PDECs was not impacted by IGF1R inhibition, consistent with SHH-enhanced survival 
occurring in a MEK-independent manner, and in line with the hypothesis that IGF1R 
activation occurs downstream of MEK (Figure 2.23A, B).   
If the hypothesis that IGF2 stimulates IGF1R-mediated signaling downstream of 
MEK was correct, then ectopic expression of IGF2 in KRASG12D and BRAFV600E-
expressing cells should rescue survival after apoptotic challenge in cells with inhibition 
of MEK but not PI3K. To test this hypothesis, I infected KRASG12D- and BRAFV600E-
expressing PDECs with RCAS viruses encoding IGF2 or GFP as a control, and 
ascertained the effect of ectopic IGF2 expression on cell survival after apoptotic 
challenge in the presence of specific signaling pathway inhibitors. I found that ectopic 
IGF2 expression rescued KRASG12D- and BRAFV600E-induced survival after challenge 
with cycloheximide in PDECs in which MEK was inhibited, but not in PDECs in which 
PI3K was inhibited (Figure 2.24A). Interestingly, IGF2 expression by itself was not 
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sufficient to promote the survival of PDECs after apoptotic challenge (Figure 2.24A), 
suggesting that other molecules and pathways regulated by oncogenic KRAS and BRAF 
are required to promote cell survival. 
 
 
  
  83 
Figure 2.23 
 
Inhibition of the IGF1R results in decreased survival of KRASG12D and BRAFV600E 
expressing PDECs in response to apoptotic stimuli.   
 
(A) Viability (as measured by trypan blue exclusion) of Ink4a/Arf, Trp53 null PDECs 
expressing KRASG12D, BRAFV600E, SHH, or GFP.  For these assays, cells were first 
vehicle treated or treated with the IGF1R inhibitor AG1024, and then one hour later 
either vehicle treated or treated with 100µM cycloheximide.  Values are normalized such 
that viability of untreated cells is 1. *p < 0.05 for inhibitor treated plus CHX compared 
with CHX alone 
 
(B) Viability (as measured by trypan blue exclusion) of Ink4a/Arf null PDECs expressing 
KRASG12D, BRAFV600E, SHH, or GFP.  For these assays, cells were first vehicle treated 
or treated with the IGF1R inhibitor AG1024, and then one hour later either left untreated 
or treated with ultraviolet (UV) irradiation.  Values are normalized such that viability of 
untreated cells is 1. *p < 0.05 for inhibitor treated plus UV compared with UV alone 
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Figure 2.24 
 
Expression of IGF2 rescues MEK inhibited survival in response to apoptotic stimuli 
in KRASG12D and BRAFV600E expressing PDECs.  
  
(A) Viability (as measured by trypan blue exclusion) of Ink4a/Arf, Trp53 null PDECs 
expressing KRASG12D, BRAFV600E, or GFP which have been additionally been 
retrovirally transduced to express either GFP or IGF2.  For these assays, cells were first 
vehicle treated or treated with the MEK inhibitor PD98059 or the PI3K inhibitor 
LY2900042, and then one hour later either vehicle treated or treated with 100µM 
cycloheximide.  Values are normalized such that viability of untreated cells is 1.  
*p < 0.05 for IGF2 expression plus inhibitor and CHX compared with inhibitor and CHX 
alone 
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IGF1R is required for KRASG12D- and BRAFV600E-induced pancreatic tumorigenesis 
The data above indicated a critical role for IGF1R-mediated signaling in the 
survival of PDECs. To determine whether this effect contributes to KRASG12D- and 
BRAFV600E-induced transformation of pancreatic epithelial cells, I used targeting shRNAs 
to knock down IGF1R expression in PDECs expressing either KRASG12D or BRAFV600E 
and additionally null at the Ink4a/Arf and Trp53 tumor suppressor loci. Effective shRNA-
mediated knockdown was confirmed by immunoblot (Figure 2.25A). Orthotopic 
implantation of 106 PDECs resulted in efficient tumor formation in activated KRAS and 
BRAF-expressing PDECs, whereas tumor formation was robustly inhibited in mice 
implanted with cells that simultaneously expressed IGF1R shRNA (Table 1.2).  
Interestingly, if mice implanted with cells expressing the IGF1R shRNA were 
allowed to remain on the study for a longer period of time, tumors eventually formed.  
Analysis of IGF1R expression in these tumors demonstrated equivalent IGF1R levels to 
tumors formed by cells expressing a non-silencing control (Figure 2.25B). Together, 
these data suggest that the IGF1R is required for KRASG12D- and BRAFV600E-induced 
pancreatic tumorigenesis.  
We next investigated by immunostaining whether tumors generated through the 
pancreas specific expression of a KRASG12D allele had increased levels of phosphorylated 
IGF1R.  In support of the requirement for signaling through the IGF1R in KRAS-
mediated pancreatic tumor initiation, tumor samples stained positive for phosphorylated 
IGF1R while normal pancreas tissues were negative for phosphorylated IGF1R staining 
(Figure 2.26A).   
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Table 2.2  
 
Tumor induction by 1x106 KRASG12D and BRAFV600E expressing Ink4a/Arf, Trp53 
null PDECs following knockdown of IGF1R and subsequent orthotopic transplant.  
 
 
 
Tumor Formation Following Orthotopic  
Transplant of Ink4a/Arf, Trp53 Null PDECs 
        
Cells Implanted Tumor Incidence 
Time to Tumor 
Development 
(Weeks) 
Average 
Tumor 
Volume 
(SEM) 
     
KRASG12D Control 4/5 7 576mm
3             
( ±436) 
KRASG12D IGF1R shRNA 0/6 7 N/A 
      
BRAFV600E Control 6/6 7 1211mm
3             
( ±239) 
BRAFV600E IGF1R shRNA 5/6 7 72mm
3                
( ±20) 
Tumor Volume Calculated Using the Formula LxWxH 
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Figure 2.25 
 
Tumors formed following orthotopic transplant of KRASG12D and BRAFV600E 
expressing PDECs with IGF1R knockdown demonstrate restored levels of IGF1R.   
 
(A) Western blot analysis showing decreased IGF1R expression in serum starved 
KRASG12D and BRAFV600E expressing Ink4a/Arf, Trp53 null PDECs infected with IGF1R 
shRNA. β -actin is used as a loading control.  
 
(B) Western blot analysis showing IGF1R expression in tumor tissue following 
orthotopic transplant of BRAFV600E Ink4a/Arf, Trp53 null PDECs infected with either 
control shRNA or IGF1R shRNA.  β -actin is used as a loading control. 
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Figure 2.26 
 
KRASG12D expressing pancreatic tumors exhibit strong expression of the IGF1R 
relative to normal pancreatic tissue.   
 
(A) Immunostaining showing strong levels of phosphorylated IGF1R (Y1161) in 
KRASG12D expressing pancreatic tumors relative to normal pancreas tissue.   
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Combined MEK and IGF1R inhibition impairs the survival of pancreatic cancer 
cells 
Given that the IGF1R is required for PDEC survival after apoptotic challenge, and 
the requirement for IGF1R for KRASG12D- and BRAFV600E-induced pancreatic 
tumorigenesis, I investigated whether IGF1R is similarly required for the survival of 
pancreatic cancer cells. I first assessed the effect of IGF1R inhibition on the proliferation 
of pancreatic cancer cells derived from our orthotopic model. Consistent with our 
previously published data (Morton, Mongeau et al. 2007), I found that inhibition of MEK 
or PI3K strongly impaired the proliferation of a tumor cell line that harbors KRASG12D 
expression and deletion of Ink4a/Arf and Trp53 (Figure 2.27A). Similarly, I found that 
the inhibition of IGF1R also reduced proliferation in this cell line (Figure 2.27A). 
I next determined the effect of MEK inhibition, PI3K inhibition, and IGF1R 
inhibition on the survival of pancreatic cancer cells. I found that inhibition of PI3K in 
these cells reduced survival after challenge with cycloheximide (Figure 2.28A). 
Interestingly, in contrast to the impact of MEK and IGF1R inhibition on survival in 
PDECs, I found that individual inhibition of these molecules did not significantly impact 
survival after apoptotic challenge in this cell line (Figure 2.28A). However, combined 
inhibition of MEK and IGF1R reduced survival to the levels seen with PI3K inhibition 
(Figure 2.28A). This finding is consistent with recent data from Engelman and colleagues 
who demonstrated an effect of combined MEK and IGF1R inhibition in colon cancer 
cells (Ebi, Corcoran et al. 2011).  
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To confirm that this phenomenon occurred following exposure to a clinically 
relevant compound, I treated the same tumor cell line with 50nM gemcitabine, a 
concentration that fails to elicit significant death in this cell line, in combination with 
inhibition of MEK, PI3K, and IGF1R. Consistent with our results following 
cycloheximide treatment, I found that PI3K inhibition, or combined inhibition of MEK 
and IGF1R (but not inhibition of MEK or IGF1R alone), sensitized cells to gemcitabine 
(Figure 2.28B). Similar results were obtained when IGF1R knockdown was combined 
with small molecule-mediated inhibition of MEK, demonstrating that these findings are 
not the consequence of toxicity induced by simultaneous exposure to the IGF1R and 
MEK chemical inhibitors (Figure 2.29B and 2.29C). 
To exclude the possibility that these phenomena are specific to the cell line used, 
or particular to murine pancreatic cancer cells, I repeated the cycloheximide challenge 
experiment in the human Panc1 pancreatic cancer cell line, which expresses KRASG12D.  
Consistent with the results above, I found that combined inhibition of MEK and IGF1R 
increased sensitivity to cycloheximide-induced death, whereas inhibition of either 
molecule alone did not induce cell death (Figure 2.30A). 
I next sought to determine if the decreased survival seen following the combined 
inhibition of MEK and the IGF1R in KRASG12D expressing cells was due to a decrease in 
the levels of pAKT at ser473.    Western blot analysis of these cells confirms that both 
pERK 1/2 and pAKT at ser473 were effectively and specifically inhibited in the assays 
including the MEK and PI3K inhibitors, respectively (Figure 2.31A and 2.31B).  In 
contrast, shRNA mediated knockdown of IGF1R or inhibition of the IGF1R did not affect 
  91 
either pERK 1/2 or pAKT at ser473 (Figure 2.13D and 2.14D).  Surprisingly, the 
combined inhibition of MEK and IGF1R, either by small molecule-mediated inhibition or 
shRNA-mediated knockdown, also did not impact the phosphorylation of AKT at ser473 
(Figure 2.31A and 2.31B).  These findings are interesting, as the combined inhibition of 
MEK and the IGF1R did lead to increased cell death, and all prior findings in our system 
have indicated that this corresponds with a decrease in the activation of AKT.  Further 
analysis into the signaling changes that occur in KRASG12D expressing tumor cells treated 
with both MEK and IGF1R inhibitors simultaneously is required to better understand the 
molecular consequences of this dual inhibitor treatment.   
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Figure 2.27 
 
The inhibition of PI3K, MEK, or the IGF1R in KRASG12D expressing tumor cell 
lines results in decreased cell proliferation.   
 
(A) Cell numbers showing decreased proliferation at 72 hours of RCAS-KRASG12D 
expressing, Ink4a/Arf, Trp53 null tumor cell lines treated with the MEK inhibtitor 
PD98059, the PI3K inhibitor LY294002, or the IGF1R inhibitor AG1024 relative to 
vehicle treated cells.  
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Figure 2.28 
 
The inhibition of PI3K or both MEK and the IGF1R in KRASG12D expressing tumor 
cell lines results in decreased survival when challenged with apoptotic stimuli.    
 
(A) Viability (as measured by trypan blue exclusion) of RCAS-KRASG12D expressing, 
Ink4a/Arf, Trp53 null tumor cell lines.  For this assay cells were treated with either 
vehicle, the MEK inhibitor PD98059, the PI3K inhibitor LY294002, the IGF1R inhibitor 
AG1024, PD98059 and LY294002, or PD98059+AG1024, and then either vehicle treated 
or treated with100µM cycloheximide.  Values are normalized such that that viability of 
vehicle treated cells is 1.  
*p < 0.05 for inhibitor treated plus CHX compared with CHX alone 
 
(B) Viability (as measured by trypan blue exclusion) of RCAS-KRASG12D expressing, 
Ink4a/Arf, Trp53 null tumor cell lines.  For this assay cells were treated with either 
vehicle, the MEK inhibitor PD98059, the PI3K inhibitor LY294002, the IGF1R inhibitor 
AG1024, PD98059 and LY294002, or PD98059+AG1024, and then either vehicle treated 
or treated with 50nM gemcitabine.  Values are normalized such that that viability of 
vehicle treated cells is 1.   
*p < 0.05 for inhibitor treated plus GEM compared with GEM alone 
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Figure 2.29 
 
Knockdown of the IGF1R in KRASG12D expressing cells results in decreased cell 
growth, and combined knockdown of the IGF1R with MEK inhibition results in 
decreased cell survival when challenged with an apoptotic stimulus.   
 
(A) Viability (as measured by trypan blue exclusion) of RCAS-KRASG12D expressing, 
Ink4a/Arf, Trp53 null tumor cell lines, following knockdown of IGF1R and treatment 
with vehicle, the MEK inhibitor PD98059, or the PI3K inhibitor LY294002, and then 
either vehicle treated or treated with100µM cycloheximide.  Values are normalized such 
that that viability of untreated cells is 1. *p < 0.05 for inhibitor treated plus CHX 
compared with CHX alone 
 
(B) Viability (as measured by trypan blue exclusion) of RCAS-KRASG12D expressing, 
Ink4a/Arf, Trp53 null tumor cell lines, following knockdown of IGF1R and treatment 
with vehicle, the MEK inhibitor PD98059, or the PI3K inhibitor LY294002, and then 
either vehicle treated or treated with 50nM gemcitabine.  Values are normalized such that 
that viability of untreated cells is 1.  
*p < 0.05 for inhibitor treated plus GEM compared with GEM alone 
 
 
 
   
  95 
Figure 2.30 
 
The inhibition of PI3K or both MEK and the IGF1R in a human KRASG12D 
expressing tumor cell line results in decreased survival when challenged with an 
apoptotic stimulus.   
 
(A) Viability (as measured by trypan blue exclusion) of Panc1 cells, a human tumor cell 
line.  For this assay cells were treated with either vehicle, the MEK inhibitor PD98059, 
the PI3K inhibitor LY294002, the IGF1R inhibitor AG1024, PD98059 and LY294002, or 
PD98059+AG1024, and then either vehicle treated or treated with100µM cycloheximide.  
Values are normalized such that that viability of vehicle treated cells is 1.  
*p < 0.05 for inhibitor treated plus CHX compared with CHX alone 
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Figure 2.31 
 
The inhibition of both MEK and the IGF1R in KRASG12D expressing tumor cell 
lines does not result in decreased phosphorylation of AKT at serine 473.   
 
 (A) Western blot analysis of ERK (p42/44) and AKT (ser473), phosphorylation in serum 
starved RCAS-KRASG12D expressing Ink4a/Arf, Trp53 null tumor cell lines following 
treatment with vehicle, the MEK inhibitor PD98059, the PI3K inhibitor LY294002, the 
IGF1R inhibitor AG1024, or both PD98059 and AG1024.   
 
(B) Western blot analysis of ERK (p42/44) and AKT (ser473) phosphorylation in serum 
starved RCAS-KRASG12D expressing Ink4a/Arf, Trp53 null tumor cell lines following 
shRNA mediated knockdown of the IGF1R and treatment with vehicle, the MEK 
inhibitor PD98059, or the PI3K inhibitor LY294002.  
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Summary 
  
These studies indicate that the expression of both activated KRAS and activated 
BRAF in PDECs results in increased proliferation, increased survival when challenged 
with apoptotic stimuli, and in cells lacking Ink4a/Arf and Trp53, the ability to form 
tumors following orthotopic transplant.  These findings show that activated BRAF is able 
to functionally substitute for activated KRAS, and indicate a critical role for 
RAF/MEK/ERK signaling in KRAS-mediated pancreatic tumorigenesis.  These findings 
further indicate that the increased survival in PDECs is dependent on signaling through 
MEK and PI3K, and consistent with this, that both the MEK/ERK and PI3K/AKT 
signaling cascades are activated downstream of KRASG12D and BRAFV600E.  In addition, 
these studies uncover a novel autocrine signaling loop in which MEK/ERK signaling 
downstream of activated KRAS and activated BRAF stimulates increased expression of 
IGF2 and subsequent activation of the IGF1R (Illustrated in Figure 2.32).  This signaling 
is necessary for the increased survival seen within KRASG12D and BRAFV600E expressing 
cells, and I find that the increased expression of IGF2 is sufficient to rescue that survival 
phenotype following MEK inhibition.  Finally, I show that signaling through the IGF1R 
downstream of activated KRAS and activated BRAF is needed for tumor formation 
following orthotopic transplant, as shRNA mediated knockdown of the IGF1R inhibits 
tumor formation.  These findings support a clear role for MEK/ERK stimulated IGF1R 
signaling in the initiation of pancreatic tumors, and identify a key role for receptor 
tyrosine kinase signaling even in the context of activated KRAS or BRAF.   
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 In contrast to the role for MEK/ERK induced IGF1R activation in PDECs, I show 
that KRASG12D expressing tumor cell lines do not depend on MEK or the IGF1R for 
survival, and only the inhibition of PI3K results in decreased survival of these cells.  
However, the combined inhibition of both MEK and the IGF1R does decrease cell 
survival, albeit in a manner that does not impact pAKT at ser473.  These findings show a 
clear difference in signaling between KRAS mediated tumor initiation (as illustrated by 
the studies in PDECs) and KRAS mediated tumor progression (as illustrated by the 
studies in tumor cell lines).  Lastly, I find that the inhibition of MEK, PI3K, and the 
IGF1R all result in decreased proliferation of the tumor cell lines, indicating that despite 
the differences in signaling of these cells, signaling through all three of these pathways is 
still important in these tumor cell lines and as such, all three are viable options for 
therapeutic targets.   
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Figure 2.32 
 
Activated KRAS and BRAF induce increased expression of IGF2, resulting in the 
activation of the IGF1R and signaling through PI3K/AKT.  (Adapted from 
Downward 2003) 
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Materials and Methods 
 
Transgenic mice and animal care.  
The keratin-19-tv-a, Ink4a/Arflox/lox, Trp53lox/lox, and Ptf1a-cre strains have been 
previously described (Bader and Franke 1990; Hu and Gudas 1994; Grippo and Sandgren 
2000; Jonkers, Meuwissen et al. 2001; Krimpenfort, Quon et al. 2001; Kawaguchi, 
Cooper et al. 2002; Orsulic 2002; Morton, Mongeau et al. 2007).  Nude mice were 
purchased from Charles River Laboratories (Wilmington MA).  All mice were housed in 
a specific pathogen-free facility with abundant food and water under guidelines approved 
by the University of Massachusetts Medical School Institutional Animal Care and Use 
Committee.  
 
Isolation, culture, and infection of mouse PDECs.  
Isolation, culture, and infection of mouse PDECs were performed as previously 
described (Lewis, Chinnasamy et al. 2001; Schreiber, Deramaudt et al. 2004; Morton, 
Mongeau et al. 2007). Details are provided in the protocols below.   
 
Isolation of PDECs:  The pancreas of a K19-TVA expressing mouse was 
harvested into ~30ml G solution {HBSS (Gibco, Invitrogen, Carlsbad CA) plus 0.9g/L D-
Glucose (Calbiochem, San Diego, CA) plus 1X Penicillin/Streptomycin (Gibco, 
Invitrogen, Carlsbad CA)} in a falcon tube on ice.  In a sterile tissue culture hood, 
aspirate G solution and transfer the pancreas into a 50ml beaker.  Add ~5ml G solution. 
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Cut up the pancreas with dissection scissors about 100 times (resulting in pieces ~1mm in 
size).  Resuspend the cut tissue in ~50ml G solution and transfer to a fresh 50ml falcon 
tube.  Allow tissue to settle and aspirate or decant G solution and any floating fatty tissue.  
Repeat the wash with G solution until all floating tissue has been removed.  Resuspend 
tissue in 15ml of filter-sterilized collagenase V solution {1mg/ml of Collagenase V 
(Sigma, St Louis MO) in DMEM (Invitrogen, Carlsbad CA) plus 10% FCS (Atlanta 
Biologicals, Atlanta GA)} and transfer to 100ml bottle with stir bar.  Digest tissue, with 
constant stirring, at 37°C for 20 minutes.  Use a beaker set on a stirrer hot plate if you 
don’t have a submersible stirrer.  Tissue should be free from large chunks at the end of 
digestion.  If necessary, tissue can be digested up to 45 minutes to remove large chunks.  
Add 20ml G solution to stop reaction.  Transfer the solution onto a 100µm nylon cell 
strainer over a waste container.  Rinse the bottle with G solution if necessary to collect all 
remaining tissue.  Invert the strainer over a fresh falcon tube and recover the undigested 
tissue by pipetting G solution onto the reverse side of the mesh and collecting washed off 
tissue/G solution in the falcon tube. If needed, top off the tissue solution to 50ml with G 
solution.  Allow tissue to settle and pour off G solution to remove floating cells.  (These 
are most likely acinar cells).  Repeat.  Add 50ml of G solution again and resuspend cells 
by inverting.  Centrifuge cells at 1000rpm at 4°C, but stop the spin as soon as the 
centrifuge reaches speed and allow the centrifuge to decelerate using the minimum 
deceleration speed.  Carefully decant or aspirate the supernatant.  Repeat this wash step 3 
times to remove all traces of collagenase.  Add 2ml trypsin-EDTA (Invitrogen, Carlsbad 
CA) and incubate at room temperature for 5 minutes.  Add 40mls DMEM plus 10% FCS 
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and invert to resuspend the cells. Centrifuge cells at 1000rpm 4°C and stop as soon as 
speed is reached (as in step 13). Remove the supernatant by decanting or by aspiration.   
Repeat this wash step 3 times. Resuspend the cells in 5ml PDEC medium and centrifuge 
at 1000rpm for 5 minutes at 4°C.  (Reset the brake to the usual setting).  Resuspend the 
tissue pellet in 12ml of PDEC medium (see description of media below) and plate 2ml 
onto each well of a 6-well plate.  Culture in humidified incubator at 37°C, 5%CO2.  Note: 
Up to two pancreata can be isolated into one falcon tube at the start of the protocol.  If 
this is done, the only change needed is to plate the cells onto two 6-well plates in step 20. 
Two days after isolation aspirate off medium and floating tissue.  Wash gently with PBS.  
Replace PDEC medium and incubate until confluent (at least 5-7 days).   
 
Culturing of PDECs: PDECs were cultured on collagen coated plates at 37 degrees 
Celsius with 5% CO2.   Cells were cultured in DMEM/F12 Medium (Gibco, Invitrogen, 
Carlsbad, CA) plus 5 mg/ml D-Glucose (Calbiochem, San Diego, CA), 0.1mg/mL 
Soybean Trypsin Inhibitor (Sigma, ), 5ml/L ITS+ (BD Biosciences, Billerica MA), 
25ug/ml Bovine Pituitary Extract (BD Biosciences, Billerica MA), 20ng/ml EGF (BD 
Biosciences, Billerica MA), 5nM 3, 3, 5 tri-iodo-L-thyronine (Sigma, St Louis MO),  
1uM dexamethasone (Sigma, St Louis MO), 1.22 mg/ml nicotinamide (Sigma, St Louis, 
MO), 5% Nu Serum (BD Biosciences, Billerica MA), and 1X Penicillin/Streptomycin 
(Gibco, Invitrogen, Carlsbad CA).  To passage PDECs when confluent, media was 
removed and the collagen layer was pipetted into a filter-sterilized 1mg/ml collagenase V 
solution (Sigma, St Louis MO) and then incubated for 15-20 minutes at 37°C.  Cells were 
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then pelleted by centrifugation at 1000rpm at 4°C for 5 minutes, and the supernatant 
removed by decanting or aspiration. 2ml trypsin-EDTA (Invitrogen, Carlsbad CA) were 
added to the cells, and the cells were incubated at room temperature for 5 minutes.  Next, 
40mls DMEM plus 10% FCS were added to the cells, and the cells were centrifuged at 
1000rpm for 5 minutes at 4°C.  Cells were washed twice more with DMEM plus 10% 
FCS and then resuspended into PDEC media and plated on collagen gel coated dishes.  
Infection of PDECs with RCAS Viruses:  Prior to infection, RCAS constructs were 
transfected into DF1 Chicken Fibroblasts using the Superfect Transfection Reagents 
(Qiagen, Valencia CA).  Briefly, 5µg of plasmid was mixed with DMEM (Gibco, 
Invitrogen, Carlsbad CA) to a total volume of 150µL.  To this mixture, 25µL of the 
Superfect reagent was added and the mixture was incubated at room temperature for 5 
minutes.  Following the incubation, 2mls of fresh DMEM plus 10% FCS plus 1% 
Penicillin/Streptomycin was added to the mixture, and the mixture was transferred onto 
DF1 cells.  The DF1 cells plus transfection mixture were incubated for 2-3 hours at 37°C, 
following which fresh DMEM plus 10% FCS plus 1% Penicillin/Streptomycin was added 
and the DF1 cells were cultured as usual.  At least one week after transfection of the 
RCAS constructs, the virus within the culture media from 3 confluent 10cm2 dishes of 
DF1 cells was concentrated by ultracentrifugation at 27,000 rpms for 90minutes at 4°C.  
Following centrifugation, the supernatant was decanted, and the virus was resuspended 
through repeated pipetting of the remaining media.  This virus mixture was then pipetted 
onto a single 10cm2 dish of TVA expressing PDECs.  For each virus, the infection 
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protocol was repeated so that the virus was added to PDECs a total of four times within 
48 hours.   
Generation of RCAS Vectors 
The RCAS-GFP, RCAS-KRASG12D-IRES-GFP, RCAS-BRAFV600E (V5 tag), and 
RCAS-BRAF (V5 tag) vectors have been described previously (Morton, Mongeau et al. 
2007; Robinson, VanBrocklin et al. 2010).   RCAS-BrafV600E (myc tag) was generated by 
using PCR to add an Xba1 restriction enzyme sequence (TCTAGA, 5’) and an EcoR1 
restriction enzyme sequence (GAATTC, 3’) to a myc-tagged B-RafV600E cDNA.  The 
resulting PCR product was cloned into the pCR-BluntII-TOPO vector (Invitrogen, 
Carlsbad CA).  The clone was then sequence verified, digested with Xba1 and EcoR1, 
and ligated into an Xba1/EcoR1 digested pYap6 vector.  The cDNA fragment containing 
the myc-tagged B-RafV600E was then excised with Pac1 and Pme1 and ligated into 
Pac1/Pme1 digested RCAS-X retroviral vector. 
 
ShRNA Mediated Knockdown of the IGF1R in PDECs  
For IGF1R knockdown, pGIPz shRNA targeting IGF1R (Open Biosystems, 
Huntsville AL, Clone ID V2LMM_188101), or a pGIPz empty vector control (Open 
Biosystems, Huntsville AL, Cat #RHS4349) was transfected into 293T cells using 
Effectene Transfection Reagents (Qiagen, Valencia CA).  Briefly, 293T cells were plated 
onto a 15cm2 dish, and the following day 2.5µg of the plasmid plus 1.55 µg of the pCMV 
del 8.2 plasmid and 1.0µg of the pMD.G plasmid were combined in EC Buffer to a total 
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volume of 370µL.  To this, 40µL of enhancer reagent was added, and the mixture was 
incubated for 2-5 minutes at room temperature.  Next, 125µL of Effectene reagent was 
added, and the mixture was incubated for 5-10 minutes at room temperature.  Following 
the incubation, 5mls of DMEM plus 10% FCS plus 1% Penicillin/Streptomycin was 
added to the mixture, and the mixture was transferred onto the 293T cells.  The cells plus 
transfection reagents were incubated overnight at 37°C and the next day fresh media was 
added to the cells.  Supernatant from the transfected 293T cells was harvested at both 48 
and 72 hours post transfection, concentrated by ultracentrifugation as described above for 
RCAS virus infection (Lewis, Chinnasamy et al. 2001), and the concentrated viral 
supernatant was added to a single 10cm2 dish of PDECs. Infected PDECs were selected 
in media containing 2µg/ml puromycin for at least 4 days.  For serum starved shRNA 
treated cells, puromycin was included in the media during serum starvation.   
 
PDEC Proliferation and Survival Assays  
All proliferation and survival assays were conducted as previously described 
(Morton, Mongeau et al. 2007). For proliferation assays, 1x105 PDECs were plated per 
well in a 6 well plate on day zero.  Fresh media was added to the cells every 5 days, and 
total cell numbers were counted on days 5, 10, and 15. For survival assays, 1x106 PDECs 
were plated per well in a 6 well plate and incubated at 37°C overnight.  The following 
day, the media was removed and fresh media was added.  For cells treated with 
cycloheximide, the fresh media contained 100µM cycloheximide.  For cells treated with 
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UV irradiation, following replacement of the media, the cells were treated with 40J/m2 of 
ultraviolet irradiation.  When inhibitors were used in the experiment, the inhibitors were 
added to the fresh media at the time it was changed, and cells were treated with either 
cycloheximide or UV irradiation one hour later.  The MEK inhibitor PD980059 
(Invitrogen, Carlsbad, CA) was used at a concentration of 25µM, the PI3 kinase inhibitor 
LY2940002 (Invitrogen, Carlsbad, CA) was used at a concentration of 20µM, and the 
IGF1R inhibitor AG1024 (BD Biosciences, San Diego CA) was used at a concentration 
of 20µM.  24 hours after treatment with either cycloheximide or UV irradiation, live and 
dead cells were counted by trypan blue exclusion and percent survival was calculated.   
 
Culture and Treatment of Tumor Cell Lines 
All tumor cell lines were cultured in DMEM (Gibco, Invitrogen, Carlsbad CA) 
plus 10% FCS (Atlanta Biologicals, Atlanta GA) plus 1% Penicillin/Streptomycin 
(Gibco, Invitrogen, Carlsbad CA) in a humidified incubator at 37°C with 5% CO2.  
 
Tumor Cell Line Proliferation and Survival Assays  
All proliferation and survival assays were conducted as previously described 
(Morton, Mongeau et al. 2007). For proliferation assays, 1x105 cells were plated per well 
in a 6 well plate on day zero. Total cell numbers were counted after 24, 48, and 72 hours. 
For survival assays, 1x106 cells were plated per well in a 6 well plate and incubated at 
37°C overnight.  The following day, the media was removed and fresh media was added.  
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For cells treated with cycloheximide, the fresh media contained 100µM cycloheximide. 
For cells treated with Gemcitibene (Gemzar, Eli Lilly, Indianapolis IN), the fresh media 
contained 50nM Gemcitibene.  When inhibitors were used in the experiment, the 
inhibitors were added to the fresh media at the time it was changed, and cells were treated 
with either cycloheximide or Gemcitibene one hour later.  The MEK inhibitor PD980059 
(Invitrogen, Carlsbad, CA) was used at a concentration of 25µM, the PI3 kinase inhibitor 
LY2940002 (Invitrogen, Carlsbad, CA) was used at a concentration of 20µM, and the 
IGF1R inhibitor AG1024 (BD Biosciences, San Diego CA) was used at a concentration 
of 20µM.  24 hours after treatment with either cycloheximide or UV irradiation, live and 
dead cells were counted by trypan blue exclusion and percent survival was calculated.  
ShRNA Mediated Knockdown of the IGF1R in Tumor Cell Lines  
For IGF1R knockdown, pGIPz shRNA targeting IGF1R (Open Biosystems, 
Huntsville AL, Clone ID V2LMM_188101), or a pGIPz empty vector control (Open 
Biosystems, Huntsville AL, Cat #RHS4349) was transfected into 293T cells using 
Effectene Transfection Reagents (Qiagen, Valencia CA).  Briefly, 5x105 293T cells were 
plated onto a 6-well plate, and the following day 0.5µg of the plasmid plus 0.33 µg of the 
pCMV del 8.2 plasmid and 0.2µg of the pMD.G plasmid were combined in EC Buffer to 
a total volume of 75µL.  To this, 8µL of enhancer reagent was added, and the mixture 
was incubated for 2-5 minutes at room temperature.  Next, 25µL of Effectene reagent was 
added, and the mixture was incubated for 5-10 minutes at room temperature.  Following 
the incubation, 0.5mls of DMEM plus 10% FCS plus 1% Penicillin/Streptomycin was 
added to the mixture, and the mixture was transferred onto the 293T cells.  The cells plus 
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transfection reagents were incubated overnight at 37°C and the next day fresh media was 
added to the cells.  Supernatant from the transfected 293T cells was harvested at both 48 
and 72 hours post transfection, and added to the tumor cell lines. Infected cells were in 
media containing 2µg/ml puromycin for at least 4 days.   
 
Isolation of Protein Lysates 
PDECs for lysates were isolated in a 1mg/mL collagenase V solution (Sigma, St 
Louis MO) incubated at 37°C for 10 minutes.  Cells were then pelleted by centrifugation 
at 1000 rpm for 5 minutes at 4°C, and the cell pellet was incubated in lysis buffer on ice 
for 30 minutes. Lysis buffer contained: 10mM KPO4/EDTA pH 7.05, 5mM EGTA pH 
7.2, 10mM MgCl2, 50mM b-glycerophosphate pH 7.2, 0.5% NP-40, 0.1% Brij-35, 
protease inhibitor mixture (Roche, San Francisco CA), 1mM DTT, 1mM Na3VaO4, and 
1mM PMSF (Yang, Xia et al. 2011). Where noted, cells were serum starved for 48 hours 
prior to the generation of protein lysates.  
Tumor cell lines for lysates washed once with PBS and then cells were scraped 
into 1mL of fresh PBS and transferred to an eppendorf tube.  Cells were then pelleted by 
centrifugation at 1000 rpm for 5 minutes at 4°C, and the cell pellet was incubated in lysis 
buffer on ice for 30 minutes. Where noted, cells were serum starved for 48 hours prior to 
the generation of protein lysates.  
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Immunoblotting 
Immunoblotting was performed as described previously (Lewis, Klimstra et al. 
2003) using the following protocol.  Protein lysates were subjected to SDS-PAGE and 
transferred to PVDF membranes (Amersham, Arlington Heights IL). PVDF membranes 
were then blocked in 1X TBS-T {1X TBS plus .1% Tween-20 (Sigma, St Louis MO)} 
plus 5% BSA for one hour at room temperature.  PVDF membranes were then incubated 
with primary antibody diluted in 1X TBS-T plus 5% BSA at 4°C overnight, and the next 
day membranes were washed three times for ten minutes each wash in 1X TBS-T.  
Following washes, membranes were incubated with a horse radish peroxidase conjugated 
secondary antibody diluted 1:5000 in 1X TBS-T plus 5% BSA for one hour at room 
temperature, and then washed three times for twenty minutes each wash in 1X TBS-T.  
ECL (Amersham, Arlington Heights IL) or Supersignal West Pico (Pierce, Rockford, IL) 
chemoluminescence reagents were then used to visualize horse radish peroxidase signal 
on film.   Primary antibody dilutions are listed in the following table. 
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Antibody Dilution Manufacturer 
Rabbit anti-A-RAF 1:1000 Santa Cruz Biotechnology, Santa Cruz, CA Cat #sc-408 
   
Rabbit anti-AKT 1:1000 Cell Signaling Technology, Beverly, MA Cat #9272 
   
Rabbit anti-phospho AKT(ser473) 1:1000 Cell Signaling Technology, Beverly, MA Cat #9271 
   
Rabbit anti-AKT1 1:1000 Cell Signaling Technology, Beverly, MA Cat #2938 
   
Rabbit anti-AKT2 1:1000 Cell Signaling Technology, Beverly, MA Cat #2964 
   
Rabbit anti-AKT3 1:500 Cell Signaling Technology, Beverly, MA Cat #4059 
   
Rabbit anti-β-ACTIN 1:1000 Santa Cruz Biotechnology, Santa Cruz, CA Cat #sc-1615-R 
   
Mouse anti-B-RAF 1:1000 Santa Cruz Biotechnology, Santa Cruz, CA Cat #sc-5284 
   
Mouse anti-C-RAF 1:1000 BD Biosciences, Billerica, MA Cat #610152 
   
Rabbit anti-ERK 1/2 1:1000 Cell Signaling Technology, Beverly, MA Cat #9102 
   
Rabbit anti-phospho ERK 1/2 1:1000 Cell Signaling Technology, Beverly, MA Cat #9101 
   
Mouse anti-FLAG 1:200 Sigma, St. Louis, MO Cat# F1804 
   
Rabbit anti-IGF1R 1:200 Santa Cruz Biotechnology,Santa Cruz, CA Cat #sc-713 
   
Rabbit anti-phospho IGF1R 1:500 Abcam, Cambridge, MA Cat #39398 
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Quantitative RT-PCR. RNA was extracted from serum starved PDECs using Trizol 
(Invitrogen, Carlsbad CA), purified with an RNeasy Mini Kit (Qiagen, Valencia CA), and 
treated with Turbo DNase (Ambion, Austin TX).  cDNA was then generated using the 
Superscript III First Strand Synthesis System (Invitrogen, Carlsbad CA).  For Kras 
expression analysis, 10ng of cDNA was mixed with TaqMan primers (Primer Set One: 
PN# Mm00517492_m1 and Primer Set Two PN# Mm01255197_m1) and TaqMan PCR 
Master Mix (Applied Biosystems, Foster City CA) using the Taqman standard protocol.  
For IGF- and EGF-family ligands, 10ng of cDNA was combined with SYBR Green 
Reaction Mix (Quanta Biosciences, Gaithersburg, MD), and 500nm of the appropriate 
primer pairs (IDT, Coralville, Iowa).  Primer sequences can be found at the end of this 
methods section.  PCR amplification was conducted using an ABI 7300 Real Time PCR 
system using Applied Biosystems standard conditions. 
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Gene  Sequence (5' to 3') 
Murine Amphiregulin Forward GCCATTATGCAGCTGCTTTGGAGC 
 Reverse TGTTTTTCTTGGGCTTAATCACCT 
Murine Betacellulin Forward CCCCAAGCAGTACAAGCATT 
 Reverse TGAACACCACCATGACCACT 
Murine Epigenin Forward TGGGTCTTGACGCTGCTTTGTCTA 
 Reverse AAGCAGTAGCCGTCCATGTCAGAA 
Murine Epiregulin Forward CACCGAGAAAGAAGGATGGA 
 Reverse GGGATCGTCTTCCATCTGAA 
Murine Epidermal Growth Factor Forward GCAACTCCGTCCGGGCGAGGA 
 Reverse GAAGATGACTGTGGTCCCGGG 
Murine Heparin Binding EGF Forward CTCCCACTGGATCCACAAAC 
 Reverse GGCATGGGTCTCTCTTCTTC 
Murine Insulin Like Growth Factor I Forward AAAATCAGCAGCCTTCCAACT 
 Reverse GTCTCTGGTCCAGCTGTGGT 
Murine Insulin Like Growth Factor II Forward GGCTTCTACTTCAGCAGGCCT 
 Reverse ACTCTTCCACGATGCC 
Murine Insulin II Forward GTCAAGCAGCACCTTTGTGGTTCC 
 Reverse ACAATGCCACGCTTCTGCTG 
Murine Transforming Growth Factor α Forward GTGGCTGCAGCACCCTGCGCT 
 Reverse GATCAGCACACAGGTGATAATGAGG 
Murine Akt1 Forward GTTTGTTGCTGTGTCCCATGC 
 Reverse TTGAATTTGGAGGGACAGTTTC 
Murine Akt2 Forward GTGATGCGAAGGAGGTCAT 
 Reverse TGCTTGTGTCCTGTGGTG 
Murine Akt2 Forward CCTTCCAGACAAAAGACCGTTT 
 Reverse CGCTCTCTCGACAAATGGAAA 
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Orthotopic implantation of PDECs 
For orthotopic transplant, 1x106 PDECs were resuspended in 10µL of matrigel 
and injected into the pancreata of nude mice as previously described (Morton, Mongeau 
et al. 2007).  Briefly, nude mice were anesthetized by IP injection of 100mg/kg ketamine 
(Henry Schein Inc., Melville NY) and 10mg/kg xylazine (Henry Schein Inc., Melville 
NY) diluted in sterile water.  Once anesthetized, buprenorphine (Henry Schein Inc., 
Melville NY) was administered sub-cutaneously peri-operatively, and the surgical site 
was prepared through cleansing the abdomen of the mouse with betadine followed by 
isopropyl alcohol.  A small incision was made in the abdomen and the pancreas was 
externalized, allowing for the injection of the PDEC and matrigel mixture using a 10µL 
Hamilton Syringe (Hamilton, Reno NV).  Following injection, the matrigel was allowed 
to set undisturbed for approximately 30 seconds and then the pancreas was returned to the 
abdominal cavity.  Lastly, Marcaine (Henry Schein Inc., Melville NY) was administered 
to the site of the wound, and the incision was closed with sutures on the body wall and 
wound clips in the skin.  Following orthotopic transplant of PDECs, mice were monitored 
daily for tumor development.   
 
Immunostaining 
Immunostaining was performed as previously described (Lewis, Klimstra et al. 
2003) using the following protocol:  Deparaffinization of the slides was conducted using 
two five minute washes with Clear Rite 3 (Fisher Scientific, Pittsburgh PA) followed by 
three three minute washes with 100% ethanol, one three minute wash with 95% ethanol, 
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one three minute wash with 70% ethanol, one three minute wash with 50% ethanol, one 
three minute wash with 20% ethanol, and a one minute wash with distilled water.  Next, 
slides were placed in a beaker with 7.5mL of Antigen Unmasking Solution (Vector Labs, 
Burlingame CA) mixed with 800mL of distilled water, and microwaved for 8 minutes on 
high power, followed by 15 minutes on low power.  Slides were then cooled to room 
temperature for 40 minutes, and rinsed in purified water.  Slides were then incubated for 
five to ten minutes in 3% Hydrogen Peroxide Solution, and then washed twice in TBS-T 
solution.  Slides were then incubated with blocking solution at room temperature for one 
hour.  Following blocking step, slides were washed twice in TBS-T solution.  Slides were 
then incubated with primary antibody at 4°C overnight, and the next day slides were 
washed twice with TBS-T solution.  Following washes, the slides were incubated with 
the secondary antibody at room temperature for thirty minutes, and then washed twice in 
TBS-T solution.  Next, the slides were net incubated for thirty minutes at room 
temperature with the Vector ABC Reagent (Vector Labs, Burlingame CA), and then 
washed once with TBS-T solution.  A NovaRed Peroxidase substrate (Vector Labs, 
Burlingame CA) was then added to the slides and slides were incubated five to ten 
minutes at room temperature until desired staining intensity had developed.  Following 
this step, the slides were washed for five minutes in running water.  Slides were then 
counterstained for five to ten seconds in Hematoxylin (Fisher Scientific, Pittsburgh PA) 
and then placed under running water until the water draining from the slides was clear.  
Slides were next placed into Bluing Solution (Fisher Scientific, Pittsburgh PA) for one 
minute, and then washed again in running water for five minutes.  Lastly, slides were 
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dehydrated with three five minute washes in 95% ethanol, then two five minute washes in 
100% ethanol, and lastly, three five minute washes in Clear Rite 3 (Fisher Scientific, 
Pittsburgh PA).  Following this, slides were mounted with Permount Mounting Medium 
(Fisher Scientific, Pittsburgh PA) and clear coverslips and allowed to dry at room 
temperature.   
Antibody dilutions for immunostaining were as follows:  Rabbit anti-Ki-67 
(1:1000, Novocastro, Cat #NCL-Ki67p), Rabbit anti-mouse Pdx-1 (1:5000, gift of Chris 
Wright), Rabbit anti-Keratin-8 (1:50, Developmental Studies Hybridoma Bank, 
University of Iowa).  Rabbit anti-pIGF1R-Y1161 (1:100, Abcam, Cat #ab39398). 
 
Soft agar and migration assays 
Soft agar colony formation and transwell migration assays were performed as 
previously described (Lewis, Shim et al. 1997; Chen, Klimstra et al. 2007).   
For soft agar colony formation, a hard agar layer was first prepared using a 1:1 
mixture of 1.5% agarose and 2X DMEM (Gibco, Invitrogren, Carlsbad CA) and allowed 
to set overnight.  The following day, 1x105 cells were resuspended in a soft agar layer 
comprised of 7% agarose and 2X DMEM, and this mixture was pipetted onto the hard 
agar layer.  Once this layer had set, fresh media (1X DMEM plus 10% FCS plus 1% 
Penicillin/Streptomycin) was added to the plate, and plates were cultured at 37°C  for 2-3 
weeks.  Following this incubation, the number of colonies per plate were counted.   
For transwell migration assays, fresh media (DMEM plus 10% FCS plus 1% 
Penicillin/Streptomycin) was plated into the lower chamber of a BD Matrigel Migration 
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Chamber (BD Biosciences, Billerica MA).  Next, 5x104 cells were resuspended in serum 
free media (DMEM plus 1% Penicillin/Streptomycin) and added to the upper portion of 
the migration chamber.  The migration chambers were then incubated at 37°C for 24 
hours, and then fixed in methanol and the cells were stained with Giemsa (Fisher 
Scientific, Pittsburgh PA).  The matrigel layer was then mounted onto a glass slide and 
the number of migrating cells were counted.   
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CHAPTER III:  
DISCUSSION 
  118 
Despite decades of research into pancreatic cancer progression and treatment, 
PDAC continues to have a dismal prognosis with few effective therapeutic options 
outside of surgical resection.  Over 90% of all pancreatic tumors have activating 
mutations in the KRAS2 oncogene, and a clear role for activated KRAS in the formation 
of pancreatic tumors has been established through multiple mouse models of PDAC 
(Aguirre, Bardeesy et al. 2003; Guerra, Mijimolle et al. 2003; Hingorani, Petricoin et al. 
2003; Hingorani, Wang et al. 2005; Hezel, Kimmelman et al. 2006).  However, efforts to 
therapeutically target activated KRAS have thus far proved unsuccessful, and recent work 
has turned towards investigating the role of signaling downstream of activated KRAS in 
the search for new therapeutic targets.  This recent research has highlighted the 
importance of taking cellular context into consideration when studying the consequences 
of signaling downstream of activated KRAS, as many of the studies used different cell 
types and resulted in conflicting reports regarding the significance of each of the KRAS 
activated signaling cascades on pancreatic tumorigenesis (Hamad, Elconin et al. 2002; 
Guerra, Mijimolle et al. 2003; Lim and Counter 2005; Campbell, Groehler et al. 2007).  
To better address the question of which signaling pathways downstream of activated 
KRAS are important for pancreatic tumor initiation, I investigated the effects of activated 
KRAS and mutant BRAF expression in pancreatic ductal epithelial cells.  As ductal 
epithelial cells are the putative targets of transformation in the initiation of pancreatic 
cancer, PDECs are a highly relevant model system to study the events of pancreatic 
tumor initiation (Hruban, Goggins et al. 2000).   
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Here, I determine that the expression of either KRASG12D or BRAFV600E in PDECs 
results in increased proliferation relative to GFP expressing PDECs.  These results were 
irrespective of tumor suppressor status, as the same results were observed in tumor 
suppressor wild type, Ink4a/Arf null, and Ink4a/Arf, Trp53 null PDECs.  These findings 
are consistent with the ability of BRAFV600E to stimulate the MEK/ERK signaling 
cascade, and support the role of MEK/ERK signaling in cell proliferation downstream of 
activated KRAS in PDECs.  In addition, I find that while both KRASG12D and BRAFV600E 
expression increases PDEC proliferation relative to GFP expressing cells, this increase is 
greater in KRASG12D expressing PDECs compared with BRAFV600E expressing PDECs. 
As BRAFV600E expression in PDECs does not fully mimic the expression of activated 
KRAS, these findings suggest that other signaling pathways stimulated by KRASG12D in 
addition to MEK/ERK are required for the KRAS-induced proliferation increase in 
PDECs.  It is also possible that the signaling through MEK/ERK differs downstream of 
KRASG12D and BRAFV600E, and this signaling difference ultimately leads to the 
differential effect on proliferation that is observed.   
In addition, I find that expression of either KRASG12D or BRAFV600E in PDECs 
results in increased survival when cells are challenged with an apoptotic stimulus.  
Treatment of GFP expressing PDECs with either cycloheximide or UV irradiation results 
in increased cell death, and prior work within our lab has confirmed that this is due to 
apoptosis by demonstrating increased levels of cleaved caspase-3 in these cells (Morton, 
Mongeau et al. 2007).  Here, I find that both KRASG12D and BRAFV600E expressing 
PDECs have increased survival when treated with either cycloheximide or UV 
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irradiation.  As observed in cell proliferation studies, this increased survival is 
irrespective of tumor suppressor status, as the same results were observed in tumor 
suppressor wild type, Ink4a/Arf null, and Trp53, Ink4a/Arf null PDECs.   
Prior studies assessing the role of signaling downstream of activated KRAS have 
typically associated signaling through RAF/MEK/ERK with increased proliferation, and 
signaling through PI3K/AKT with increased survival.  Based upon this, I was surprised to 
find that the expression of activated BRAF was sufficient for increased survival in 
PDECs and next sought to determine if survival in these cells depended on signaling 
through either MEK or PI3K.  I found that treatment of KRASG12D and BRAFV600E 
expressing PDECs with either a MEK or a PI3K inhibitor resulted in decreased survival 
when challenged with an apoptotic stimuli.  These findings indicate that signaling 
through both MEK and PI3K are required for KRAS- and BRAF- mediated survival in 
PDECs.   
Having found that increased survival in KRASG12D and BRAFV600E expressing 
PDECs depends on signaling through both MEK and PI3K, I next investigated whether 
activated BRAF was stimulating the PI3K/AKT signaling cascade in these cells.  
Immunoblotting for phosphorylated ERK 1/2 and phosphorylated AKT at ser473 
confirmed that both the MEK/ERK and the PI3K/AKT signaling cascades were being 
activated downstream of KRASG12D and BRAFV600E expression in PDECs.  In addition, I 
found that the inhibition of MEK in BRAFV600E expressing PDECs resulted in decreased 
levels of both pERK 1/2 as well as pAKT at ser473, indicating that the activation of AKT 
in these cells is downstream of MEK/ERK signaling.  While KRASG12D expressing 
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PDECs did not show the same decrease in the levels of pAKT at ser473 following 
inhibition of MEK, this was likely due to the ability of activated KRAS to also directly 
stimulate PI3K/AKT signaling.  
These data are significant as they support a connection between the signaling 
downstream of activated BRAF and the PI3K/AKT signaling cascade, as well as a 
dependence of mutant BRAF on signaling through PI3K for cell survival.  Previous 
studies have clearly demonstrated mutant BRAF’s ability to signal through the 
MEK/ERK signaling cascade, but there is little evidence thus far to indicate the activation 
of PI3K/AKT downstream of BRAF (Cantwell-Dorris, O'Leary et al. 2011).  In our 
studies, though, we see activation of both the RAF/MEK/ERK and PI3K/AKT signaling 
cascades downstream of KRASG12D and BRAFV600E in PDECs, and we find that the 
activation of AKT lies downstream of the MEK/ERK signaling pathway in BRAFV600E 
expressing PDECs.   
Having found the activation of AKT downstream of MEK/ERK signaling in 
BRAFV600E expressing PDECs, I next sought to determine the mechanism of AKT 
activation in these cells.  I hypothesized that signaling through MEK/ERK resulted in the 
increased production of an autocrine growth factor, which would result in activation of 
growth factor receptor signaling, and subsequent activation of AKT.  Since I observed 
increased levels of IGF2 at both the message and protein levels in KRASG12D and 
BRAFV600E expressing PDECs, I hypothesized that signaling through the MEK/ERK 
pathway leads to increased IGF2 expression and results in activation of the IGF1R and 
subsequent activation of the PI3K/AKT signaling cascade.    
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Consistent with this hypothesis, there is increasing evidence for tumor cell 
dependence on growth factor receptor activation, even in the presence of activated KRAS 
mutations.  One such study found that cells expressing activated RAS had increased 
expression of heparin-binding epidermal growth factor (HB-EGF), a ligand for the 
epidermal growth factor receptor (EGFR), and that these cells were sensitive to inhibiting 
HB-EGF with diphtheria toxin in spite of their mutant RAS expression (McCarthy, 
Samuels et al. 1995).  Another recent study in immortalized human pancreatic ductal 
cells showed that the activation of KRAS and the loss of SMAD4 cooperated to induce 
the expression of EGFR, and that inhibition of EGFR in these cells resulted in decreased 
invasion even though the mutational status of KRAS was maintained (Zhao, Wang et al. 
2010). An additional study demonstrated that melanoma cells had decreased survival 
following inhibition of the IGF1R, regardless of whether these cells expressed activated 
NRAS or BRAF (Yeh, Bohula et al. 2006). Lastly, a study recently published by 
Engelman and colleagues demonstrated that the IGF1R is the dominant activator of 
PI3K/AKT signaling in colorectal tumors, even in the context of KRAS mutations (Ebi, 
Corcoran et al. 2011).   
In support of this hypothesis, I observe that inhibiton of MEK in KRASG12D 
expressing PDECs results in decreased levels of Igf2, indicating that increased expression 
of IGF2 is downstream of MEK/ERK signaling in these cells.  In addition, I found 
increased expression of phosphorylated IGF1R in both KRASG12D and BRAFV600E 
expressing PDECs when compared with GFP expressing cells, supporting activation of 
the IGF1R in these cells.  I also show that the activation of AKT at ser473 depends on 
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signaling through the IGF1R, since knockdown of the IGF1R results in loss of AKT 
phosphorylation at serine 473 in both KRASG12D and BRAFV600E expressing PDECs. 
Together, these data indicate that signaling through MEK/ERK downstream of activated 
KRAS- and BRAF- expression in PDECs results in increased levels of IGF2 and 
activation of the IGF1R, and this signaling through the IGF1R is required for activation 
of PI3K/AKT signaling.   
I next confirmed the role of the signaling through IGF2 and the IGF1R in KRAS- 
and BRAF-mediated cell survival by showing that the ectopic expression of IGF2 was 
sufficient to rescue survival in the presence of a MEK inhibitor, but not a PI3K inhibitor.  
These results indicate that the requirement for signaling through the MEK/ERK signaling 
cascade downstream of activated KRAS or BRAF for cell survival is due to a 
requirement for increased expression of IGF2 downstream of this signaling cascade.  In 
addition, I found that the inhibition of the IGF1R resulted in loss of survival in both 
KRASG12D and BRAFV600E expressing PDECs, indicating that signaling through the 
IGF1R is necessary for the activated KRAS and mutant BRAF induced survival 
phenotype.   
Prior work within our lab has shown that the expression of KRASG12D in 
Ink4a/Arf, Trp53 null PDECs is sufficient for tumor formation following orthotopic 
transplant of these cells (Morton, Mongeau et al. 2007).  Here, I show that the expression 
of BRAFV600E in double null PDECs is also sufficient for tumor formation using an 
orthotopic model.  I further show that shRNA-mediated knockdown of the IGF1R in 
either KRASG12D or BRAFV600E expressing Ink4a/Arf, Trp53 null PDECs results in 
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decreased tumor formation, indicating that signaling through the IGF1R is needed for 
KRAS- and BRAF-mediated pancreatic tumor formation.  These results are further 
supported by our findings that tumors formed from the pancreas specific expression of 
KRASG12D stain positive for phosphorylated IGF1R by immunostaining, underscoring a 
role for signaling through the IGF1R in KRAS-mediated pancreatic tumorigenesis.   
An extension of these studies assessing the role of IGF1R signaling in KRAS-
mediated pancreatic tumor formation could be conducted in the future using mouse 
modeling.  If, as my research indicates, pancreatic tumor initiation following the 
activation of KRAS requires signaling through the IGF1R, then mouse models combining 
pancreas specific expression of KRASG12D in conjunction with pancreas specific ablation 
of the IGF1R should result in decreased tumor formation and increased tumor free 
survival when compared with littermate controls that are wild type for the IGF1R and 
expressing pancreas specific KRASG12D.  These studies would not only confirm the role 
of the IGF1R in KRAS-mediated pancreatic tumor formation, but could provide new 
insight into the role of the IGF1R in tumor initiation through analysis of any precursor 
lesions (PanINs) or tumors that do form in the absence of IGF1R expression.   
A potential signaling loop that remains to be characterized within our system is 
the ability of activated KRAS or BRAF to increase activation of mTORC1 via inhibiton 
of the TSC1/TSC2 complex, which negatively regulates mTORC1 activity.  Recent work 
has demonstrated that phosphorylation of TSC2 by pERK 1/2 results in inhibition of the 
ability of the TSC1/TSC2 protein complex to convert Rheb-GTP to Rheb-GDP (Ma, 
Chen et al. 2005).  As Rheb-GTP is an activator of mTORC1, this results in increased 
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activation of mTORC1 (Shaw and Cantley 2006).  mTORC1, which can additionally be 
activated downstream of AKT as well as through many other mechanisms, is involved in 
cell growth through its phosphorylation of S6K, stimulation of HIF-1α and inhibition of 
4E-BP1 (Hara, Maruki et al. 2002; Hudson, Liu et al. 2002; Kim, Sarbassov et al. 2002).   
As our studies demonstrate that survival in both KRASG12D and BRAFV600E expressing 
PDECs is sensitive to inhibition of mTORC1 by rapamycin, this complex is clearly 
important in signaling downstream of activated KRAS and BRAF.  An intriguing 
question, therefore, is whether activation of mTORC1 downstream of KRASG12D and 
BRAFV600E occurs only following the activation of AKT, or whether ERK is also 
contributing to this through the phosphorylation of TSC2.   
To address this question, an investigation into the activation of mTORC1 
downstream of KRAS and BRAF induced MEK/ERK signaling could be conducted by 
first determining if activation of mTORC1 occurs in PDECs in the absence of signaling 
through AKT. In addition, the impact of ERK 1/2 inhibition on the activation of 
mTORC1 and its downstream targets, such as S6K could be evaluated to assess how 
much ERK 1/2 contributes to the activation of mTORC1 downstream of KRASG12D and 
BRAFV600E in PDECs.   
BRAF expressing PDECs may also be increasing the activation of mTORC1 
through the inhibition of LKB1.  LKB1 has been shown to inhibit mTORC1 signaling by 
phosphorylating AMPKα, thereby activating AMPK (Hardie 2007).  When activated, 
AMPK is able to phosphorylate TSC2 at Thr1227 and Ser1345 (Inoki, Zhu et al. 2003).  
Phosphorylation of TSC2 at this site results in the activation of the TSC1/TSC2 complex, 
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and increased conversion of Rheb-GTP to Rheb-GDP.  This results in decreased 
activation of mTORC1.  A recent study has identified that in melanoma cells, BRAFV600E 
is able to negatively regulate LKB1 by phosphorylating it at ser428 and ser325 and 
preventing its binding to AMPK (Zheng, Jeong et al. 2009).  Through inhibition of 
LKB1, the expression of activated BRAF could therefore reduce the levels of activated 
AMPK, and therefore impact the levels of activated TSC1/TSC2 in cells.  These studies 
identify a novel mechanism by which activated BRAF may increase mTORC1 activation 
in tumor cells.   
The potential for a similar signaling paradigm in activated BRAF expressing 
PDECs is particularly interesting, since a role for LKB1 inhibition in pancreatic tumors 
has already been established in several studies.  Studies have demonstrated that patients 
with Peutz-Jeghers syndrome, an autosomal dominantly inherited syndrome caused by 
inactivating mutations in LKB1, have an increased risk of developing pancreatic cancer 
(Hemminki, Avizienyte et al. 1998; Jenne, Reimann et al. 1998; Hearle, Schumacher et 
al. 2006).  Prior studies have also identified LKB1 gene inactivation in IPMNs, and that 
loss of Lkb1 leads to benign cystadenomas (Sato, Rosty et al. 2001; Hezel, Gurumurthy et 
al. 2008).  Moreover, a recent study demonstrated that loss of Lkb1 accelerated KRAS 
induced pancreatic tumor formation in mice (Morton, Jamieson et al. 2010).  In addition, 
one study investigating genetic alterations in acinar cell carcinoma demonstrated that 
while these tumors rarely have activating mutations in KRAS or loss of LKB1, there is at 
least one case of acinar cell carcinoma in a patient with LKB1 loss due to Peutz-Jeghers 
syndrome, and this tumor responded to treatment with rapamycin (Hoorens, Lemoine et 
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al. 1993; Klumpen, Queiroz et al. 2011). These findings point to a potential role for loss 
of LKB1 in the formation of pancreatic tumors, and highlight the possibility of effectively 
treating pancreatic tumors associated with LKB1 loss or inhibition with inhibitors of 
mTOR signaling.  Therefore, it is important to better understand whether activated BRAF 
expression in PDECs and tumor cell lines is increasing mTOR signaling via inhibition of 
LKB1, as this could point to increased efficacy of mTOR inhibition in BRAFV600E 
expressing tumors.   
Further support for the role of LKB1 and AMPK inhibition in pancreatic tumor 
initiation is found in studies investigating the impact of metformin on pancreatic tumors 
and tumor cell lines.  Metformin is an anti-diabetes drug that has been shown to stimulate 
activation of AMPK in an LKB1 dependent manner (Shaw, Lamia et al. 2005).  Recent 
studies have demonstrated that the use of metformin during the treatment of diabetes 
results in a decreased risk of cancer (Evans, Donnelly et al. 2005).  More specifically, the 
use of metformin was shown to decrease the risk of pancreatic cancer in patients with 
Type II diabetes by 62% (Li, Yeung et al. 2009).  A recent paper went on to demonstrate 
that treatment with metformin resulted in the inhibition of tumor growth in mice with 
sub-cutaneous injection of pancreatic cancer cell lines (Kisfalvi, Eibl et al. 2009).  
Collectively, these findings demonstrate a role for LKB1 and AMPK signaling in the 
inhibition of pancreatic tumors, and reveal an emerging role for metformin in the 
treatment of pancreatic tumors.  However, because metformin functions through LKB1 
dependent stimulation of AMPK, it is critical to understand if activated BRAF is 
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inhibiting LKB1 in pancreatic tumorigenesis, as this inhibition could prevent the efficacy 
of metformin in patients with BRAF mutations.   
To investigate the potential role of LKB1 inhibition and mTORC1 activation in 
KRAS and BRAF expressing PDECs, the expression and localization of phosphorylated 
LKB1, as well as total LKB1, could be assessed within these cells.  As LKB1 is 
phosphorylated both in its activated state as well as when inhibited, it is be important to 
determine which sites on LKB1 are phosphorylated downstream of activated KRAS and 
BRAF in PDECs.  In addition, the level of phosphorylated AMPK expression could be 
ascertained downstream of KRASG12D and BRAFV600E as further indication of whether 
this signaling pathway is being inhibited in these cells.  Lastly, inhibition of ERK 1/2 
could be used to determine if inhibiton of LKB1 downstream of activated KRAS or 
BRAF in PDECs occurs due to phosphorylation of LKB1 by ERK as was seen in 
melanoma cells (Zheng, Jeong et al. 2009).  
In these studies, I also identified a potential positive feedback loop between the 
RAF/MEK/ERK and PI3K/AKT signaling cascades, as inhibition of PI3K led to the 
decreased expression of phosphorylated ERK (1/2) in both KRASG12D and BRAFV600E 
expressing PDECs.  Cross talk between these two signaling cascades has been identified 
previously in many studies of cancer cells, and so it is not surprising to see such an 
interaction, although the mechanisms of this interaction downstream of KRAS are still 
not clearly understood (Duckworth and Cantley 1997; Rubio and Wetzker 2000).  
 One potential mechanism for the decreased levels of phosphorylated ERK 1/2 is 
through a change in expression of the Sprouty genes.  These proteins have been shown to 
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be inhibitors of MEK/ERK signaling downstream of receptor tyrosine kinases (Gross, 
Bassit et al. 2001; Yusoff, Lao et al. 2002).  Although their mechanism of function 
remains largely to be determined, the Sprouty genes have been shown to function in 
multiple cell types as part of higher order complexes that inhibit ERK activation 
downstream of multiple RTKs, such as FGFR and EGFR (Mason, Morrison et al. 2006).  
Previous studies have demonstrated that melanomas expressing activated BRAF are able 
to maintain hyperactivated ERK 1/2 through resistance to regulation by one of the 
Sprouty genes, Spry2 (Tsavachidou, Coleman et al. 2004).  Based upon these findings, 
one could speculate that it is possible that activated KRAS and BRAF expressing PDECs 
have developed a mechanism of avoiding regulation by the Sprouty genes in order to 
sustain hyperactivated ERK 1/2 levels.  Following this logic, its possible to extend that 
speculation and hypothesize that these mechanisms potentially rely on signaling through 
PI3K or the IGF1R, and therefore the inhibition of either of these proteins results in an 
inability to avoid Sprouty regulation, and decreased levels of phosphorylated ERK 1/2 in 
these cells.  Investigation into the expression of the Sprouty genes in KRASG12D and 
BRAFV600E expressing PDECs treated with MEK, PI3K, and IGF1R inhibitors could 
begin to shed light on whether the Sprouty genes are involved in the feedback loop 
observed in these cells.   
 While I identified many similarities in KRAS and BRAF induced MEK/ERK 
signaling, it is possible that the ultimate downstream signaling, as well as the 
mechanisms of feedback, are not that same downstream of activated KRAS and activated 
BRAF.   Indeed, the large disparity in KRAS mutations versus BRAF mutations in 
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pancreatic tumors would imply that these oncogenes are not fully redundant.  A better 
understanding of how KRAS promotes pancreatic tumorigenesis and the signaling that is 
critical to KRAS mediated tumorigenesis therefore requires further exploration into how 
these signaling pathways may differ.  One such difference lies potentially in the 
differential activation of MEK/ERK signaling and its downstream effects.  Previous work 
within our lab has demonstrated that signaling through MEK/ERK can have different 
consequences depending upon how that signaling is initiated upstream.  In these studies, 
we have shown that while both activated KRAS and SHH expression induces increased 
levels of pERK 1/2, only KRASG12D expressing PDECs require signaling through MEK 
for survival when challenged with an apoptotic stimulus (Morton, Mongeau et al. 2007).  
An additional study has demonstrated that in melanoma cells, MEK inhibitors inhibit 
proliferation in those with BRAF mutations, while proliferation in those with RAS 
mutations are not effected by MEK inhibition (Solit, Garraway et al. 2006).  In both of 
these cases, the MEK/ERK signaling cascade is being activated, but the impact of that 
activation is not the same.  These findings indicate that the ultimate effect of MEK/ERK 
activation on tumorigenic phenotypes depends on the upstream stimulus, and it is 
possible that some of these differences in signaling lie in the downstream changes that 
occur after phosphorylation of ERK 1/2.       
 To further explore the downstream effects of increased pERK 1/2 in KRASG12D 
and BRAFV600E expressing PDECs, and therefore potentially determine how signaling 
downstream of these two oncogenes may differ, gene expression analysis via microarray 
could be conducted.  In addition, phosphoproteome analysis could be used to determine 
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which proteins are being phosphorylated downstream of activated KRAS and BRAF.  
These analyses could compare not only the signaling downstream of activated KRAS and 
BRAF in PDECs, but could also look at the effects of expressing a KRASG12D binding 
mutant that preferentially signals through RAF/MEK/ERK in order to better focus on the 
effect of MEK/ERK signaling downstream of KRASG12D.  Through assessing the 
differences in gene expression and protein phosphorylation downstream of MEK/ERK 
activation in KRASG12D and BRAFV600E expressing cells, one would potentially gain a 
better understanding of how activated KRAS and BRAF differ, and how these differences 
may impact pancreatic tumor treatment options.   
It is also possible that the differential effects seen in ERK activation downstream 
of KRAS and BRAF may not be due entirely to the differential expression or activation 
of downstream targets.  Many factors have been shown to regulate the effects of ERK 
activation, including the magnitude of ERK activation, the localization of ERK, and the 
expression of scaffold proteins that interact with ERK (Harding, Tian et al. 2005; Casar, 
Arozarena et al. 2009). These differences open up numerous avenues of study for further 
evaluating how MEK/ERK signaling may differ downstream of activated KRAS and 
BRAF, and as a result may provide insight into how to best treat pancreatic tumors.   
 One key difference that I already identified between KRASG12D and BRAFV600E 
expressing PDECs lies in the increased expression of the AKT family of proteins.  Both 
KRASG12D and BRAFV600E expressing PDECs showed increased levels of total AKT 
when compared with GFP expressing PDECs.  However, the KRASG12D expressing 
PDECs had increased expression of AKT1, while the BRAFV600E expressing PDECs were 
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found to have a large increase in AKT3, with only a slight increase in the levels of 
AKT1.  In addition, KRASG12D expressing PDECs had increased levels of Akt3 mRNA, 
whereas BRAFV600E expressing PDECs had increased in mRNA levels of Akt1, Akt2, 
and Akt3.  These data indicate that KRASG12D and BRAFV600E expression in PDECs 
results in changes in both AKT family member gene expression as well as protein levels, 
and implicate a role for signaling downstream of activated KRAS and BRAF in the 
regulation of the translation or post-translational modification of AKT.   
The data regarding different AKT isoform expression downstream of activated 
KRAS and activated BRAF are particularly interesting considering recent findings 
regarding the roles of different AKT isoforms in tumorigenesis.  In one recent study of 
lung tumorigenesis, it was shown that the loss of AKT1 inhibited tumor formation in 
cells expressing activated KRAS, indicating that the increased levels of AKT1 
downstream of KRASG12D observed in PDECs may be important to Kras mediated 
tumorigenesis (Hollander, Maier et al. 2011).  AKT1 has also been shown to increase 
IGF1R expression in human pancreatic cancer cell lines, further demonstrating its 
potential role in pancreatic tumorigenesis (Tanno, Tanno et al. 2001).  In additional 
studies involving melanoma cells, it has been shown that increased expression of AKT3 
can rescue survival loss following the knockdown of BRAF, while the inhibition of 
AKT3 results in apoptosis, indicating that the increased expression of AKT3 that we 
observe downstream of BRAFV600E expression in PDECs may be aiding in the survival of 
those cells (Madhunapantula and Robertson 2009; Shao and Aplin 2010).  Expression 
levels of AKT family members has also been linked to migration and invasion ability 
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within a tumor (Toker and Yoeli-Lerner 2006).   In one study, it was demonstrated that in 
ovarian tumor cells, IGF1 induced increases in migration are mediated by mTORC2 
activation of AKT1, not AKT2 (Kim, Yun et al. 2011).  It is therefore possible that these 
differences in expression observed between the activated KRAS and the mutant BRAF 
expressing PDECs would result in different migration and invasion abilities, which were 
not addressed in PDECs in the present study.   
To further investigate the role of AKT isoforms in pancreatic tumor initiation and 
progression, shRNA mediated knockdown of the individual isoforms could be conducted 
in both KRASG12D and BRAFV600E expressing PDECs.  The impact of this knockdown on 
KRAS- and BRAF- induced tumor phenotypes such as proliferation, survival when 
challenged with an apoptotic stimulus, and the ability to form tumors following 
orthotopic transplant could then be assessed.  If the differential expression of AKT 
isoforms seen within activated KRAS and activated BRAF expressing PDECs is 
important to KRAS- and BRAF-mediated tumorigenesis, as recent studies would 
indicate, then the knockdown of a single isoform of AKT should have different effects on 
KRASG12D expressing PDECs versus BRAFV600E expressing PDECs.  More specifically, I 
would expect that only the knockdown of AKT1 would decrease KRAS-mediated 
proliferation, survival, and tumor formation following orthotopic transplant, while only 
the knockdown of AKT3 would decrease these phenotypes in BRAFV600E expressing 
PDECs.  These studies would not only further characterize signaling downstream of 
activated KRAS and activated BRAF, but would also highlight a difference between 
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these two oncogenes and provide potential insight into how to better and more 
specifically target tumors expressing KRASG12D or BRAFV600E.   
Likewise, similar studies using shRNA mediated knockdown of the AKT 
isoforms could be conducted to examine if the role of an individual isoform of AKT is 
important to activated KRAS or activated BRAF expressing tumor cell lines, thereby 
indicating if the expression of, and reliance on, the various isoforms is different between 
pancreatic tumor initiation and progression.  Due to the increased ease of working with 
the tumor cell lines, these studies could include an assessment of not only proliferation 
and survival, but also address the role of the individual isoforms in KRAS and BRAF 
induced migration, invasion, and anchorage independent growth of pancreatic tumor cell 
lines.   
If studies within PDECs and tumor cell lines indicate a role for specific AKT 
isoforms in KRAS- mediated pancreatic tumor formation, it is possible to then study this 
further through the use of mouse models with pancreas specific expression of KRASG12D 
in conjunction with ablation of individual AKT family members in the pancreas.  If a 
specific AKT family member is required for KRAS- mediated tumor formation, then I 
would expect increased survival and decreased tumor formation in mice lacking 
expression of that AKT family member in the pancreas when compared with littermate 
controls.  As with the tumor cell line and PDEC studies, these experiments would not 
only provide further insight into the role of the various AKT isoforms downstream of 
KRASG12D, but could potentially result in more targeted therapies for pancreatic tumors 
  135 
through identifying the specific AKT isoforms required for KRAS- mediated pancreatic 
tumorigenesis.   
An additional important question that remains to be addressed is how the IGF1R 
is signaling to the PI3K/AKT signaling cascade downstream of activated KRAS and 
BRAF.  Upon activation, the IGF1R recruits IRS1 and IRS2 to the membrane, and this 
results in the activation of several downstream targets, including PI3K and RAS 
(Baserga, Hongo et al. 1997; Pollak, Schernhammer et al. 2004).    A role for both IRS1 
and IRS2 has been previously established in pancreatic cancer studies.  One of these 
studies demonstrated that human pancreatic cancer cell lines have increased expression of 
both IRS1 and IRS1 expression (Bergmann, Funatomi et al. 1996).  Other studies have 
demonstrated, though, that IRS2 is also overexpressed in pancreatic cancer cell lines, and 
that IRS2 but not IRS1 is involved in the regulation of the IGF1R in these cells 
(Kornmann, Maruyama et al. 1998; Kwon, Stephan et al. 2009).  Determining which of 
the IRS proteins is needed for the signaling downstream of KRASG12D and BRAFV600E to 
PI3K/AKT through knockdown studies of IRS1 and IRS2 in PDECs could prove useful 
in further elucidating exactly how MEK/ERK is signaling through the IGF1R to activate 
AKT.  
Further studies could then explore the role of IRS1 and IRS2 in KRAS- mediated 
pancreatic tumor initiation through the use of mouse modeling.  As described above for 
AKT family members and the IGF1R, pancreas specific ablation of IRS1 or IRS2 in 
conjunction with pancreas specific expression of KRASG12D could be used to determine if 
IRS1 or IRS2 are required for KRAS- mediated pancreatic tumor formation. Together, 
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these in vitro and in vivo studies would help to further characterize signaling downstream 
of activated KRAS in pancreatic tumor initiation and progression.   
In addition to elucidating how the IGF1R is signaling through PI3K/AKT in 
KRASG12D and BRAFV600E expressing cells, it is prudent to also investigate what role, if 
any, the insulin receptor is playing in KRAS-mediated tumor formation.  IGF2 has been 
shown to have a comparable affinity for binding to the IR as for its binding to the IGF1R 
(De Meyts, Urso et al. 1995).  As the insulin receptor has also been shown to stimulate 
signaling through PI3K/AKT, it is possible that IGF2 stimulated IR signaling is involved 
in KRAS and BRAF induced tumor formation (Buck, Gokhale et al. 2010).  To 
investigate this, levels of phosphorylated IR in KRASG12D and BRAFV600E expressing 
PDECs should first be assessed.  If there is increased phosphorylated IR in these cells 
compared with GFP expressing PDECs, then the impact of IR inhibition on KRAS- and 
BRAF- induced PDEC survival could be investigated to determine if signaling through 
the IR is required for this phenotype.  Finally, knockdown of the IR in KRASG12D and 
BRAFV600E expressing PDECs followed by orthotopic transplant, or alternatively ablation 
of the IR in mice expressing pancreas specific KRASG12D, could be used to determine if 
signaling through the IR is required for KRAS- and BRAF- mediated tumor formation.   
Finally, in these studies I found that although KRASG12D and BRAFV600E 
expressing tumor cell lines also display survival when challenged with cycloheximide, 
the signaling requirements for tumor cell line survival differ from what was observed in 
the PDECs.  In KRASG12D and BRAFV600E expressing tumor cell lines, neither MEK 
inhibition nor IGF1R inhibition alone resulted in decreased survival when cells were 
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treated with cycloheximide.  Instead, the survival phenotype in these cells decreases only 
when either PI3K is inhibited, or MEK and the IGF1R are inhibited simultaneously.  The 
use of both the MEK and the IGF1R inhibitors simultaneously, however, was effective in 
not only decreasing tumor cell survival in response to cycloheximide, but also caused 
increased cell death when KRASG12D expressing tumor cell lines were treated with 
gemcitabine.  These findings demonstrate that the use of MEK and IGF1R inhibitors 
simultaneously in combination with current gemcitabine therapies may be more effective 
in treating pancreatic tumors than the use of gemcitabine alone.    
In addition to the differences observed in cell survival, I find that the signaling 
through ERK 1/2 and AKT differs between the KRASG12D expressing PDECs and tumor 
cell lines, as the inhibition of MEK or the IGF1R in these cells does not impact pAKT at 
ser473, and there does not appear to be any cross talk between the MEK and PI3K 
signaling cascades as was observed in the PDECs.  I further show that although the 
simultaneous inhibition of MEK and the IGF1R results in decreased survival in 
KRASG12D expressing tumor cells, immunoblotting of these cells still does not detect 
decreased levels of pAKT at ser473. These findings show a stark contrast between the 
signaling requirements in primary epithelial cells compared with transformed cells, and 
illustrate the need to study signaling downstream of activated KRAS in the proper 
context to fully understand the roles of specific signaling pathways in tumor initiation, 
progression, and maintenance.   
Despite these differences observed between PDECs and tumor cell lines, there is 
still a clear role for both the IGF1R and MEK in tumor progression, as inhibition of either 
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results in decreased proliferation in KRASG12D expressing tumor cell lines.  These data, in 
combination with the survival data in pancreatic tumor cell lines, argue that the combined 
inhibition of the IGF1R and MEK may prove to be an effective therapy for the treatment 
of pancreatic tumors, as studies have recently suggested for both colon carcinoma and 
melanoma (Villanueva, Vultur et al. 2010; Ebi, Corcoran et al. 2011).   
In support of this, other recent studies have identified signaling between the 
IGF1R and G protein-coupled receptors in pancreatic cancer (Rozengurt, Sinnett-Smith et 
al. 2010).   These studies propose that in the tumors studied, activation of the IGF1R lies 
downstream of PI3K/AKT activation, though, and not downstream of MEK/ERK 
signaling (Rozengurt, Sinnett-Smith et al. 2010).  In combination with our own data, 
these studies raise the possibility that signaling through the IGF1R occurs downstream of 
the RAF/MEK/ERK signaling cascades during tumor initiation, but that during tumor 
progression, IGF1R is being activated instead by PI3K/AKT signaling.  These studies add 
support to the idea that the IGF1R plays a critical role in pancreatic tumor progression 
and that the inhibition of the IGF1R could be an effective pancreatic tumor therapeutic.  
In fact, several clinical trials are currently underway to investigate the impact of IGF1R 
inhibition on pancreatic tumors and may soon shed light on if this is the case (Rozengurt, 
Sinnett-Smith et al. 2010). 
A potential mechanism for the change in signaling between KRASG12D and 
BRAFV600E expressing PDECs compared with tumor cell lines may involve the ability of 
FAK to compensate for the IGF1R.  When phosphorylated, FAK has been shown to 
increase cell survival through PI3K/AKT signaling (Yamamoto, Sonoda et al. 2003).  A 
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study in pancreatic cancer cell lines has recently demonstrated that FAK and the IGF1R 
physically interact in those cells, and that this interaction contributes to cell survival (Liu, 
Bloom et al. 2008).  Moreover, Hochwald and colleagues go on to show that the 
inhibition of both FAK and the IGF1R is effective in decreasing pancreatic cancer cell 
survival, indicating that the combined inhibition of these two pathways may prove an 
effective chemotherapy option (Zheng, Golubovskaya et al. 2010).  Understanding 
whether FAK is activated and able to interact with or compensate for IGF1R signaling 
downstream of activated KRAS or BRAF in PDECs or tumor cell lines could prove 
important in developing the most targeted therapeutics possible for pancreatic tumors.   
An additional line of investigation that has not yet been pursued in this system 
involves the interaction between the IGF1R and the RON receptor.  RON is a receptor 
tyrosine kinase that has been shown to be overexpressed in human pancreatic cancer, and 
to potentially contribute to resistance to treatment in pancreatic tumors (Thomas, Toney 
et al. 2007).  A recent study has identified that the RON receptor is able to interact with 
the IGF1R in pancreatic tumor cell lines, and that this interaction is required for IGF1 
induced migration of those cells (Jaquish, Yu et al. 2011).  Based upon these findings, it 
could be interesting to assess what role, if any, the RON receptor is playing in KRASG12D 
and BRAFV600E expressing PDECs and tumor cell lines.  These experiments would be 
two fold and include the assessment of RON receptor activation in activated KRAS and 
BRAF expressing cells, as well an assessment of the impact of RON knockdown on 
proliferation and survival of these cells.  It is possible that signaling from the IGF1R to 
the RON receptor may occur in the tumor cell lines and not the PDECs, and therefore at 
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least partially explain the differences seen between these two cell contexts.  These 
findings could support an additional therapeutic option in which both the IGF1R and the 
RON receptor are inhibited.   
Collectively, these studies support the importance of both the RAF/MEK/ERK 
and PI3K/AKT signaling cascades in KRAS-mediated tumor formation, and provide new 
evidence for the requirement of signaling through the IGF1R during KRAS-mediated 
pancreatic tumor initiation. These findings grant new understanding into the signaling 
downstream of activated KRAS in pancreatic tumor formation, and therefore provide new 
insight into effective therapeutic targets and options for combination drug therapies.  
These studies also indicate a requirement for signaling through receptor tyrosine kinases 
even in the context of activated KRAS and activated BRAF, uncovering a novel role for 
signaling through RTKs in KRAS mediated tumorigenesis and identifying RTK 
inhibitors as a viable option for pancreatic tumor therapeutics.  In addition, these studies 
underscore the need to ensure that the system in which you are studying signaling 
downstream of Kras is as relevant as possible, as we demonstrate different signaling 
requirements for survival downstream of activated Kras in PDECs and transformed cells. 
This research indicates differences exist in the signaling cascades necessary for tumor 
formation versus those needed for tumor maintenance and further understanding of these 
differences in signaling requirements may prove key to effective tumor treatment when 
utilizing inhibitors targeting pathways downstream of activated KRAS.  
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APPENDIX A: 
Investigation into the role of miRNAs in KRAS induced pancreatic tumor formation 
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Figure Contribution 
 
Victoria Appleman conducted the work described in Appendix A and shown in Figure 
A.1  
 
Brian Quattrochi is conducting all continuing and future experiments for this project.    
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Introduction 
 miRNAs are short, non-coding, single stranded segments of RNA that negatively 
regulate gene expression.  miRNAs are initially transcribed in the nucleus as long 
precursors referred to as a pri-miRNAs.  Following their transcription, pri-miRNAs are 
processed by Drosha and DGCR8 into pre-miRNAs, and are exported from the nucleus 
by Exportin 5.  Following this, pre-miRNAs are processed by Dicer, which cleaves the 
hairpin structure and unwinds the miRNA duplex.  The mature miRNA strand is then 
incorporated into the RISC complex, which binds to mRNA based upon sequence 
homology and results in either degradation of the mRNA or inhibition of mRNA 
translation (Garzon, Fabbri et al. 2006). 
 Many different human tumor samples, including those from pancreatic cancer, 
have abnormal expression of miRNAs when compared to normal tissue (Lee, Gusev et al. 
2007).  Based upon this, as well as their role in the regulation of gene expression, 
miRNAs have been implicated as having a role in tumorigenesis, and in fact, studies have 
shown that miRNAs can function as either tumor suppressors or oncogenes depending 
upon their target genes.  Some of the most notable examples of miRNA involvement in 
cancer include the miR 17-92 cluster, which has been shown to accelerate tumor 
development in a B-cell lymphoma model, and the let-7 family of miRNAs, which have 
been found to regulate RAS proteins (He, Thomson et al. 2005; Johnson, Grosshans et al. 
2005).  In addition, a key study demonstrating the regulation of the miR 17-92 cluster by 
c-Myc showed that miRNA expression could be regulated by oncogenes, underscoring 
their role in cancer (O'Donnell, Wentzel et al. 2005).   
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While many prior studies have looked at the expression of miRNAs in human 
pancreatic tumors and pancreatic tumor cell lines, none to date have assessed the role of 
miRNAs following KRAS activation in the early stages of pancreatic tumor formation.  
Many of the studies profiling miRNA expressing in pancreatic tumors have resulted in 
conflicting reports of expression changes in miRNA levels between normal tissue and 
tumor tissue (Bloomston, Frankel et al. 2007; Lee, Gusev et al. 2007; Szafranska, 
Davison et al. 2007).  These differences could be due at least in part to the fact that the 
tumor samples being assessed are quite heterogeneous, and could include samples of 
stroma, acini, and inflammatory cells, in addition to ductal cells (Kent, Mullendore et al. 
2009).  Studies have also been conducted to determine the differences in miRNA 
expression within pancreatic tumor cell lines (Kent, Mullendore et al. 2009).  However, 
these cell lines are often cultured for long periods of time, and may acquire significant 
genetic changes during this time that were not present within the tumor sample, making 
them a non-ideal comparison of human tumors.  In addition, despite the emerging role of 
miRNAs in cancer and the findings of abnormal miRNA expression in pancreatic cancer, 
few studies have sought to address the cause or the effect of abnormal expression of 
miRNAs in pancreatic tumors. Therefore, I attempted to determine if activated KRAS 
was involved in the regulation of miRNAs during pancreatic tumor initiation through an 
investigation into the impact of activated KRAS on miRNA expression in PDECs, the 
putative cell of origin for PDAC (Hruban, Goggins et al. 2000).  By demonstrating some 
of the earliest changes in miRNA expression following the expression of activated KRAS 
in PDECs, these studies can provide beneficial insight into those miRNAs that are critical 
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to pancreatic tumorigenesis, and potentially elucidate new targets for pancreatic tumor 
treatments.  
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Results 
To investigate the role of miRNAs in KRAS mediated pancreatic tumorigenesis, 
PDECs null for Ink4a/Arf were isolated and infected with RCAS-GFP and RCAS-
KRASG12D, and the differential expression of miRNAs between KRASG12D expressing 
and control cells was assessed via a microarray conducted by LC Sciences.  Results of 
this microarray identified 49 miRNAs that had differential expression between the 
control cells and those expressing activated KRAS and a p value <0.01.  30 of these 
miRNAs were found to be overexpressed in KRASG12D expressing PDECs relative to 
GFP expressing PDECs, while the remaining 19 showed decreased expression.    Of 
these, the differential expression of 14 miRNAs was subsequently validated via qRT-
PCR, as shown in Figure A.1.  Notably, several of the miRNAs found to be up regulated 
in KRASG12D expressing PDECs by our study have been identified as increased in human 
pancreatic tumors (Lee, Gusev et al. 2007).   
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Discussion and Future Directions 
 This study identified 49 miRNAs with differential expression between KRASG12D 
and GFP expressing Ink4a/Arf null PDECs, thereby identifying miRNAs that are either 
potentially regulated by activated KRAS or are otherwise differentially expressed in the 
early stages of KRAS-mediated pancreatic tumorigenesis.  In support of the role of these 
miRNAs in PDAC, several miRNAs identified have already been shown to have a role in 
the progression of other cancers, including miRNAs from the miR 17-92 cluster as well 
as miR 29b and miR 148b.  In addition, several of these miRNAs have been identified as 
differentially expressed between human pancreatic tumors and normal pancreas, further 
implying a role for these miRNAs in pancreatic tumor formation and progression (Lee, 
Gusev et al. 2007).  Having demonstrated differential regulation of miRNAs following 
the expression of activated KRAS, it is important to fully investigate whether these 
miRNAs are in fact regulated by activated KRAS and if so, how KRAS regulates miRNA 
expression.  In addition, it is important to determine whether these miRNAs, either 
independently or collectively, are important to the formation or progression of pancreatic 
tumors.   
To address the former of those questions, further studies should be conducted to 
examine the relationship between expression of activated KRAS in PDECs and changes 
in miRNA expression.  A potential way in which to examine this would be to isolate 
PDECs from mice that express KRASG12D under the expression of a tetracycline 
inducible promoter.  Such a model would enable more precise control of when activated 
KRAS is being expressed in the cells, and would allow for the analysis of miRNA 
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expression changes at multiple time points after the expression of KRASG12D to 
determine how quickly miRNA expression changes, as well as if the expression of 
different miRNAs change at different time points.  In addition, such a system would 
allow for the loss of KRASG12D expression in PDECs, thus allowing for the assessment of 
whether changes in miRNA expression are permanent following the expression of 
KRASG12D or if they depend upon the continued expression of activated KRAS.   
Once it is confirmed that KRASG12D is in fact regulating the expression of 
miRNAs, further studies should be done to determine how this regulation occurs.  One 
possible way to address these questions would be to infect PDECs with RCAS constructs 
that express KRASG12D with an additional single site mutation that results in the 
preferential activation of a single KRAS stimulated pathway (S35T stimulates RAF-MEK 
ERK, C40Y stimulates PI3K-AKT, G37D stimulates RAL/GDS, and N38D stimulates 
PLC-ε).  miRNA expression levels could then be compared between these PDECs 
expressing the additional site mutations, those expressing KRASG12D, and those 
expressing GFP to determine if the stimulation of any single pathway results in similar 
changes in miRNA expression to the expression of KRASG12D.  If necessary, infection 
with multiple RCAS constructs could be used to determine if a combination of pathways 
downstream of activated KRAS are needed to alter the expression of miRNAs.  In 
addition, inhibitors to MEK or PI3K could be used to determine if inhibiting either of 
these signaling cascades results in an inhibition of miRNA expression changes following 
the expression of KRASG12D, further pinpointing the role of these signaling cascades in 
KRAS regulated miRNA expression.   
  149 
To address whether miRNAs are collectively required for the formation or 
progression of pancreatic tumors, a mouse model expressing pancreas specific KrasG12D, 
in conjunction with loss of Dicer could be used.  Previous studies have demonstrated that 
the pancreas specific expression of activated KRAS is sufficient for the formation of 
PDAC in mice (Aguirre, Bardeesy et al. 2003; Guerra, Mijimolle et al. 2003; Hingorani, 
Petricoin et al. 2003; Hingorani, Wang et al. 2005).  If this KRAS induced tumor 
formation requires miRNAs, then the loss of Dicer in this mouse model would prevent 
the formation of PDAC and I would expect increased survival and decreased tumor 
formation in the Dicer null animals relative to their Dicer wild type littermate controls.   
In addition, as the orthotopic transplant of PDECs null for Ink4a/Arf and 
expressing KRASG12D has been shown to be sufficient for tumor formation in nude mice, 
a similar experiment could be done in which the processing of miRNAs is inhibited via 
knockdown of Drosha, DGCR8, or Dicer in PDECs lacking Ink4a/Arf and expressing 
KRASG12D.  The cells could then be assessed for the impact of miRNA loss on KRASG12D 
induced phenotypes, including increased proliferation, increased survival when 
challenged with apoptotic stimuli, and the ability to form tumors following orthotopic 
transplant.  As in the above mouse model, if miRNAs are required for KRAS induced 
tumor formation, I would expect to see a decrease in tumor formation following the 
knockdown of miRNAs processing proteins.   
To address whether individual miRNAs are required for pancreatic tumorigenesis, 
the same strategies as above could be applied, but instead of inhibiting global miRNA 
processing, mouse models could be generated with pancreas specific expression of 
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KRASG12D and ablation of an individual miRNA.  Likewise, PDECs could be generated 
that are null for Ink4a/Arf and express KRASG12D in which the expression of a specific 
miRNA could then be inhibited or reduced.  As above, these cells could then be assessed 
for impact on the KRASG12D mediated phenotypes of increased proliferation, increased 
survival, and tumor formation following orthotopic transplant.  In both of these 
experiments, I would expect that decreased expression of any miRNAs that are necessary 
for tumor formation would cause decreases tumor formation and increased survival 
relative to controls.   
As mouse models and primary cells can be difficult and time consuming systems 
in which to address these questions, it is also possible to begin these investigations in 
tumor cell lines that express activated KRAS.  Within these cells, it is possible to inhibit 
or overexpress individual miRNAs, or combinations of several miRNAs, and assess the 
impact on cell proliferation, survival, migration, and anchorage independent growth.  In 
this manner, it is possible to first determine in the tumor cell lines which miRNAs, or 
combinations of miRNAs, may be most important to KRAS induced tumor phenotypes, 
and to then continue to study those particular miRNAs in primary cells and mouse 
models.   
Collectively, these studies would better address the role of activated KRAS in the 
regulation of miRNA expression as well as which miRNAs are most important to KRAS 
induced pancreatic tumor formation and progression, and thus provide more insight into 
which miRNAs might serve as good therapeutic targets for the treatment of pancreatic 
tumors.    
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Figure A.1 
 
KRASG12D expression in Ink4a/Arf null PDECs results in differential miRNA 
expression levels when compared to control cells.   
 
The expression of each individual miRNA as assessed by microarray and qRT-PCR 
showing differential miRNA expression between KRASG12D expressing Ink4a/Arf null 
PDECs relative and GFP expressing control cells. miRNA expression levels are 
normalized such that the expression level of each miRNA in GFP expressing cells is 1.    
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Methods 
 
Isolation, culture, and infection of mouse PDECs.  
Isolation, culture, and infection of mouse PDECs were performed as previously 
described (Lewis, Chinnasamy et al. 2001; Schreiber, Deramaudt et al. 2004; Morton, 
Mongeau et al. 2007). Details are provided in the protocols below.   
 
Isolation of PDECs:  The pancreas of a K19-TVA expressing mouse was 
harvested into ~30ml G solution {HBSS (Gibco, Invitrogen, Carlsbad CA) plus 0.9g/L D-
Glucose (Calbiochem, San Diego, CA) plus 1X Penicillin/Streptomycin (Gibco, 
Invitrogen, Carlsbad CA)} in a falcon tube on ice.  In a sterile tissue culture hood, 
aspirate G solution and transfer the pancreas into a 50ml beaker.  Add ~5ml G solution. 
Cut up the pancreas with dissection scissors about 100 times (resulting in pieces ~1mm in 
size).  Resuspend the cut tissue in ~50ml G solution and transfer to a fresh 50ml falcon 
tube.  Allow tissue to settle and aspirate or decant G solution and any floating fatty tissue.  
Repeat the wash with G solution until all floating tissue has been removed.  Resuspend 
tissue in 15ml of filter-sterilized collagenase V solution {1mg/ml of Collagenase V 
(Sigma, St Louis MO) in DMEM (Invitrogen, Carlsbad CA) plus 10% FCS (Atlanta 
Biologicals, Atlanta GA)} and transfer to 100ml bottle with stir bar.  Digest tissue, with 
constant stirring, at 37°C for 20 minutes.  Use a beaker set on a stirrer hot plate if you 
don’t have a submersible stirrer.  Tissue should be free from large chunks at the end of 
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digestion.  If necessary, tissue can be digested up to 45 minutes to remove large chunks.  
Add 20ml G solution to stop reaction.  Transfer the solution onto a 100µm nylon cell 
strainer over a waste container.  Rinse the bottle with G solution if necessary to collect all 
remaining tissue.  Invert the strainer over a fresh falcon tube and recover the undigested 
tissue by pipetting G solution onto the reverse side of the mesh and collecting washed off 
tissue/G solution in the falcon tube. If needed, top off the tissue solution to 50ml with G 
solution.  Allow tissue to settle and pour off G solution to remove floating cells.  (These 
are most likely acinar cells).  Repeat.  Add 50ml of G solution again and resuspend cells 
by inverting.  Centrifuge cells at 1000rpm at 4°C, but stop the spin as soon as the 
centrifuge reaches speed and allow the centrifuge to decelerate using the minimum 
deceleration speed.  Carefully decant or aspirate the supernatant.  Repeat this wash step 3 
times to remove all traces of collagenase.  Add 2ml trypsin-EDTA (Invitrogen, Carlsbad 
CA) and incubate at room temperature for 5 minutes.  Add 40mls DMEM plus 10% FCS  
and invert to resuspend the cells. Centrifuge cells at 1000rpm 4°C and stop as soon as 
speed is reached (as in step 13). Remove the supernatant by decanting or by aspiration.   
Repeat this wash step 3 times. Resuspend the cells in 5ml PDEC medium and centrifuge 
at 1000rpm for 5 minutes at 4°C.  (Reset the brake to the usual setting).  Resuspend the 
tissue pellet in 12ml of PDEC medium (see description of media below) and plate 2ml 
onto each well of a 6-well plate.  Culture in humidified incubator at 37°C, 5%CO2.  Note: 
Up to two pancreata can be isolated into one falcon tube at the start of the protocol.  If 
this is done, the only change needed is to plate the cells onto two 6-well plates in step 20. 
  154 
Two days after isolation aspirate off medium and floating tissue.  Wash gently with PBS.  
Replace PDEC medium and incubate until confluent (at least 5-7 days).   
 
Culturing of PDECs: PDECs were cultured on collagen coated plates at 37 
degrees Celsius with 5% CO2.   Cells were cultured in DMEM/F12 Medium (Gibco, 
Invitrogen, Carlsbad, CA) plus 5 mg/ml D-Glucose (Calbiochem, San Diego, CA), 
0.1mg/mL Soybean Trypsin Inhibitor (Sigma, ), 5ml/L ITS+ (BD Biosciences, Billerica 
MA), 25ug/ml Bovine Pituitary Extract (BD Biosciences, Billerica MA), 20ng/ml EGF 
(BD Biosciences, Billerica MA), 5nM 3, 3, 5 tri-iodo-L-thyronine (Sigma, St Louis MO),  
1uM dexamethasone (Sigma, St Louis MO), 1.22 mg/ml nicotinamide (Sigma, St Louis, 
MO), 5% Nu Serum (BD Biosciences, Billerica MA), and 1X Penicillin/Streptomycin 
(Gibco, Invitrogen, Carlsbad CA).  To passage PDECs when confluent, media was 
removed and the collagen layer was pipetted into a filter-sterilized 1mg/ml collagenase V 
solution (Sigma, St Louis MO) and then incubated for 15-20 minutes at 37°C.  Cells were 
then pelleted by centrifugation at 1000rpm at 4°C for 5 minutes, and the supernatant 
removed by decanting or aspiration. 2ml trypsin-EDTA (Invitrogen, Carlsbad CA) were 
added to the cells, and the cells were incubated at room temperature for 5 minutes.  Next, 
40mls DMEM plus 10% FCS were added to the cells, and the cells were centrifuged at 
1000rpm for 5 minutes at 4°C.  Cells were washed twice more with DMEM plus 10% 
FCS and then resuspended into PDEC media and plated on collagen gel coated dishes.  
Infection of PDECs with RCAS Viruses:  Prior to infection, RCAS constructs 
were transfected into DF1 Chicken Fibroblasts using the Superfect Transfection Reagents 
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(Qiagen, Valencia CA).  Briefly, 5µg of plasmid was mixed with DMEM (Gibco, 
Invitrogen, Carlsbad CA) to a total volume of 150µL.  To this mixture, 25µL of the 
Superfect reagent was added and the mixture was incubated at room temperature for 5 
minutes.  Following the incubation, 2mls of fresh DMEM plus 10% FCS plus 1% 
Penicillin/Streptomycin was added to the mixture, and the mixture was transferred onto 
DF1 cells.  The DF1 cells plus transfection mixture were incubated for 2-3 hours at 37°C, 
following which fresh DMEM plus 10% FCS plus 1% Penicillin/Streptomycin was added 
and the DF1 cells were cultured as usual.  At least one week after transfection of the 
RCAS constructs, the virus within the culture media from 3 confluent 10cm2 dishes of 
DF1 cells was concentrated by ultracentrifugation at 27,000 rpms for 90minutes at 4°C.  
Following centrifugation, concentrated virus was then pipetted onto a single 10cm2 dish 
of TVA expressing PDECs.  For each virus, the infection protocol was repeated so that 
the virus was added to PDECs a total of four times within 48 hours. 
RCAS Constructs  
The retroviral constructs RCAS-GFP and RCAS-KrasG12D-IRES-GFP have 
been previously described (Morton, Mongeau et al. 2007).  
 
Microarray.  
RNA was extracted from PDECs using Trizol (Invitrogen, Carlsbad CA) and 
purified with an RNeasy Mini Kit (Qiagen, Valencia CA).  Microarray analysis of the 
total RNA was performed by LC Sciences (Houston, TX).   
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Quantitative RT-PCR.  
RNA was extracted from PDECs using Trizol (Invitrogen, Carlsbad CA), and 
purified with an RNeasy Mini Kit (Qiagen, Valencia CA).  miRNA expression analysis 
was conducted using TaqMan miRNA Assays and standard protocol (Applied 
Biosystems, Carlsbad CA).  PCR amplification was conducted using an ABI 7300 Real 
Time PCR System.   
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APPENDIX B: 
KRASG12D induced proliferation and survival in PDECs requires the Gli 
transcription factors 
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Figure Contribution 
 
 The experiments for Figure B.1 were conducted by Victoria Appleman as part of 
a collaboration with the laboratory of Junhao Mao.  Wilfredo de Jesus-Monge conducted 
the experiment shown in Figure B.2.  These data appear in the following manuscript as 
Supplementary Figure One, and Figure Three, respectively:  
  
 Gli transcriptional activity is essential for Kras-induced pancreatic 
tumorigenesis and regulates IKBKE/NF-kB activity in the tumor epithelium 
Mihir Rajurkar, Wilfredo E de Jesus-Monge, David R. Driscoll, Victoria A. Appleman, 
He Huang, Jennifer L. Cotton, David S. Klimstra, Lihua J. Zhu, Karl Simin, Lan Xu, 
Andrew P. McMahon, Brian C. Lewis, and Junhao Mao.  PNAS (In Press) 
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Introduction 
  
 Hedgehog (Hh) signaling is not normally active in the adult pancreas, but is 
aberrantly activated in pancreatic tumors, indicating a role for Hh signaling in pancreatic 
tumorigenesis (Berman, Karhadkar et al. 2003; Thayer, di Magliano et al. 2003).   GLI1, 
GLI2, and GLI3 are effectors of the Hh signaling pathway, and as such have been 
implicated as having a role in pancreatic cancer.  Recent evidence has demonstrated that 
the expression of the Gli transcription factors is maintained in pancreatic tumor 
epithelium even when upstream Hh signaling is disrupted via Smo deletion, indicating 
that the Gli transcription factors may have a Hh independent role in pancreatic tumor 
formation and progression (Nolan-Stevaux, Lau et al. 2009).  Analysis of human 
pancreatic tumors has also shown mutations in GLI1 and GLI3, further supporting an Hh 
independent role for GLI transcription in PDAC (Jones, Zhang et al. 2008).  However, 
thus far the role of GLI transcription in KRAS mediated pancreatic tumorigenesis has 
remained unclear.  These studies therefore sought to determine if Gli transcription was 
necessary for KRAS-induced pancreatic tumors, and how the Gli transcription factors 
might be contributing to pancreatic tumor initiation and progression through the use of 
Gli3T, a dominant negative construct that inhibits expression of Gli1 and Gli2.   
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Results 
 
To investigate the role of Gli transcription factors in KRASG12D induced 
pancreatic tumors, I assessed the impact of the expression of GLI3T on KRASG12D 
induced proliferation and survival in PDECs.  Ink4a/Arf, Trp53 null PDECs expressing 
an LSL-GLI3T allele were isolated and infected with either RCAS-GFP or RCAS-
KRASG12D.  Both GFP and KRASG12D expressing PDECs were then subsequently 
infected with either RCAS-GFP or RCAS-CRE, which generated four populations of 
PDECS: GFP, GLI3T, KRASG12D, and KRASG12D GLI3T expressing cells.  The 
expression of GLI3T in combination with KRASG12D in PDECs resulted in loss of 
survival when treated with cycloheximide, with the survival of these cells nearing that of 
control PDECs (Figure B.1).  The expression of GLI3T in combination with KRASG12D 
also resulted in decreased proliferation to the same level as GFP expressing PDECs 
(Figure B.2).  Collectively, these findings indicate that the increased proliferation and 
survival of KRASG12D expressing PDECs relative to controls depends on the Gli 
transcription factors.   
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Discussion and Future Directions 
These results demonstrate that the proliferation and survival increases seen in 
KRASG12D expressing PDECs depend upon the expression of the Gli transcription 
factors, and indicate a role for the Gli transcription factors in the formation of pancreatic 
tumors.  Indeed, my collaborators went on to demonstrate that a mouse model with 
pancreas specific expression of GLI3T and activated KRAS resulted in decreased PanIN 
and tumor formation and increased tumor free survival when compared with pancreas 
specific expression of activated KRAS alone (Fig B.1). These findings further 
demonstrate the requirement of Gli transcription factors for activated KRAS induced 
formation and progression of pancreatic tumors.  
An important question resulting from these findings is which targets of Gli 
transcription are needed for KRASG12D induced tumor formation, and to address this, my 
collaborators have demonstrated that increased expression of Gli1 results in increased 
expression of Ikbke, a member of the NF-ΚB signaling cascade.  They further 
demonstrate that shRNA mediated knockdown of Ikbke results in decreased colony 
formation and proliferation in vitro, and decreased tumor formation in vivo, 
demonstrating that the requirement for the Gli transcription factors in pancreatic tumor 
formation is at least partially due to a requirement for increased expression of Ikbke.   
 However, these studies have yet to identify if the expression of KRASG12D is 
sufficient for the induction of Gli1 and Gli2 expression, and if so, the mechanism of that 
induction.  To investigate this further, gene expression analysis could be done to compare 
the expression levels of the Gli transcription factors in PDECs expressing GFP compared 
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with those expressing KRASG12D.  In addition, a tetracycline inducible construct of 
KRASG12D could be used so that any changes in the expression levels of the Gli 
transcription factors could be better correlated with expression of activated KRAS, and 
the effect of removing the expression of activated KRAS on the levels of the Gli 
transcription factors could be assessed.  If these studies indicate that the expression of 
KRASG12D results in increased expression of the Gli transcription factors, indicating that 
activated KRAS stimulates the expression of Gli, further studies could be conducted to 
determine which of the KRAS stimulated signaling pathways are responsible for this 
induction of Gli and following this, continue to pinpoint a mechanism by which activated 
KRAS induces Gli expression.  Together, these studies would provide further insight into 
the non-canonical regulation of Gli expression by activated KRAS.   
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Figure B.1 
 
Inhibition of GLI results in decreased proliferation and survival of KRASG12D 
expressing Ink4a/Arf null PDECs.   
 
(A) Viability (as measured by trypan blue exclusion) of Ink4a/Arf, Trp53 null PDECs 
showing decreased survival in KRASG12D plus GLI3T expressing PDECs relative to 
KRASG12D expressing cells following treatment with 100 µM cycloheximide.  Values are 
normalized such that the viability of untreated cells is 1.  
 
(B) Cell numbers of Ink4a/Arf, Trp53 null PDECs showing decreased proliferation at 15 
days of KRASG12D plus GLI3T expressing PDECs relative to KRASG12D expressing cells.  
 
A 
 
B 
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Figure B.2 
Inhibition of the Gli transcription factors increases tumor free survival in mice 
expressing pancreas specific LSL-KRASG12D.   
Kaplan-Meier plot of tumor free survival of Ptf1a-Cre;LSL-KrasG12D;Trp53flox/wt mice, 
with or without R26-Gli3T expression.  Control mice were LSL-KrasG12D negative 
littermates.   
p < 0.001 for comparison between R26-Gli3T-positive and –negative animals. 
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Methods 
Transgenic Mice and Animal Care  
 As described in Rajurkar et al, offspring from the cross of LSL- KrasG12D;R26-
Gli3T to Ptf1a-cre;Trp53flox/flox mice were followed longitudinally for tumor 
development for 270 days. (Rajurkar et al, In Press).  All mice were housed in a specific 
pathogen-free facility with abundant food and water under guidelines approved by the 
University of Massachusetts Medical School Institutional Animal Care and Use 
Committee. 
 
Isolation, culture, and infection of mouse PDECs.  
Isolation, culture, and infection of mouse PDECs were performed as previously 
described (Lewis, Chinnasamy et al. 2001; Schreiber, Deramaudt et al. 2004; Morton, 
Mongeau et al. 2007). Details are provided in the protocols below.   
 
Isolation of PDECs:  The pancreas of a K19-TVA expressing mouse was 
harvested into ~30ml G solution {HBSS (Gibco, Invitrogen, Carlsbad CA) plus 0.9g/L D-
Glucose (Calbiochem, San Diego, CA) plus 1X Penicillin/Streptomycin (Gibco, 
Invitrogen, Carlsbad CA)} in a falcon tube on ice.  In a sterile tissue culture hood, 
aspirate G solution and transfer the pancreas into a 50ml beaker.  Add ~5ml G solution. 
Cut up the pancreas with dissection scissors about 100 times (resulting in pieces ~1mm in 
size).  Resuspend the cut tissue in ~50ml G solution and transfer to a fresh 50ml falcon 
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tube.  Allow tissue to settle and aspirate or decant G solution and any floating fatty tissue.  
Repeat the wash with G solution until all floating tissue has been removed.  Resuspend 
tissue in 15ml of filter-sterilized collagenase V solution {1mg/ml of Collagenase V 
(Sigma, St Louis MO) in DMEM (Invitrogen, Carlsbad CA) plus 10% FCS (Atlanta 
Biologicals, Atlanta GA)} and transfer to 100ml bottle with stir bar.  Digest tissue, with 
constant stirring, at 37°C for 20 minutes.  Use a beaker set on a stirrer hot plate if you 
don’t have a submersible stirrer.  Tissue should be free from large chunks at the end of 
digestion.  If necessary, tissue can be digested up to 45 minutes to remove large chunks.  
Add 20ml G solution to stop reaction.  Transfer the solution onto a 100µm nylon cell 
strainer over a waste container.  Rinse the bottle with G solution if necessary to collect all 
remaining tissue.  Invert the strainer over a fresh falcon tube and recover the undigested 
tissue by pipetting G solution onto the reverse side of the mesh and collecting washed off 
tissue/G solution in the falcon tube. If needed, top off the tissue solution to 50ml with G 
solution.  Allow tissue to settle and pour off G solution to remove floating cells.  (These 
are most likely acinar cells).  Repeat.  Add 50ml of G solution again and resuspend cells 
by inverting.  Centrifuge cells at 1000rpm at 4°C, but stop the spin as soon as the 
centrifuge reaches speed and allow the centrifuge to decelerate using the minimum 
deceleration speed.  Carefully decant or aspirate the supernatant.  Repeat this wash step 3 
times to remove all traces of collagenase.  Add 2ml trypsin-EDTA (Invitrogen, Carlsbad 
CA) and incubate at room temperature for 5 minutes.  Add 40mls DMEM plus 10% FCS  
and invert to resuspend the cells. Centrifuge cells at 1000rpm 4°C and stop as soon as 
speed is reached (as in step 13). Remove the supernatant by decanting or by aspiration.   
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Repeat this wash step 3 times. Resuspend the cells in 5ml PDEC medium and centrifuge 
at 1000rpm for 5 minutes at 4°C.  (Reset the brake to the usual setting).  Resuspend the 
tissue pellet in 12ml of PDEC medium (see description of media below) and plate 2ml 
onto each well of a 6-well plate.  Culture in humidified incubator at 37°C, 5%CO2.  Note: 
Up to two pancreata can be isolated into one falcon tube at the start of the protocol.  If 
this is done, the only change needed is to plate the cells onto two 6-well plates in step 20. 
Two days after isolation aspirate off medium and floating tissue.  Wash gently with PBS.  
Replace PDEC medium and incubate until confluent (at least 5-7 days).   
 
Culturing of PDECs: PDECs were cultured on collagen coated plates at 37 
degrees Celsius with 5% CO2.   Cells were cultured in DMEM/F12 Medium (Gibco, 
Invitrogen, Carlsbad, CA) plus 5 mg/ml D-Glucose (Calbiochem, San Diego, CA), 
0.1mg/mL Soybean Trypsin Inhibitor (Sigma, ), 5ml/L ITS+ (BD Biosciences, Billerica 
MA), 25ug/ml Bovine Pituitary Extract (BD Biosciences, Billerica MA), 20ng/ml EGF 
(BD Biosciences, Billerica MA), 5nM 3, 3, 5 tri-iodo-L-thyronine (Sigma, St Louis MO),  
1uM dexamethasone (Sigma, St Louis MO), 1.22 mg/ml nicotinamide (Sigma, St Louis, 
MO), 5% Nu Serum (BD Biosciences, Billerica MA), and 1X Penicillin/Streptomycin 
(Gibco, Invitrogen, Carlsbad CA).  To passage PDECs when confluent, media was 
removed and the collagen layer was pipetted into a filter-sterilized 1mg/ml collagenase V 
solution (Sigma, St Louis MO) and then incubated for 15-20 minutes at 37°C.  Cells were 
then pelleted by centrifugation at 1000rpm at 4°C for 5 minutes, and the supernatant 
removed by decanting or aspiration. 2ml trypsin-EDTA (Invitrogen, Carlsbad CA) were 
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added to the cells, and the cells were incubated at room temperature for 5 minutes.  Next, 
40mls DMEM plus 10% FCS were added to the cells, and the cells were centrifuged at 
1000rpm for 5 minutes at 4°C.  Cells were washed twice more with DMEM plus 10% 
FCS and then resuspended into PDEC media and plated on collagen gel coated dishes.  
Infection of PDECs with RCAS Viruses:  Prior to infection, RCAS constructs 
were transfected into DF1 Chicken Fibroblasts using the Superfect Transfection Reagents 
(Qiagen, Valencia CA).  Briefly, 5µg of plasmid was mixed with DMEM (Gibco, 
Invitrogen, Carlsbad CA) to a total volume of 150µL.  To this mixture, 25µL of the 
Superfect reagent was added and the mixture was incubated at room temperature for 5 
minutes.  Following the incubation, 2mls of fresh DMEM plus 10% FCS plus 1% 
Penicillin/Streptomycin was added to the mixture, and the mixture was transferred onto 
DF1 cells.  The DF1 cells plus transfection mixture were incubated for 2-3 hours at 37°C, 
following which fresh DMEM plus 10% FCS plus 1% Penicillin/Streptomycin was added 
and the DF1 cells were cultured as usual.  At least one week after transfection of the 
RCAS constructs, the virus within the culture media from 3 confluent 10cm2 dishes of 
DF1 cells was concentrated by ultracentrifugation at 27,000 rpms for 90minutes at 4°C.  
Following centrifugation, concentrated virus was then pipetted onto a single 10cm2 dish 
of TVA expressing PDECs.  For each virus, the infection protocol was repeated so that 
the virus was added to PDECs a total of four times within 48 hours. 
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RCAS Constructs   
The retroviral constructs RCAS-GFP and RCAS-KrasG12D-IRES-GFP have 
been previously described (Morton, Mongeau et al. 2007). RCAS-CRE was a gift from 
Eric Holland (Memorial Sloan-Kettering Cancer Center, New York, NY). Isolated 
PDECs were infected with either RCAS-KrasG12D-IRES-GFP or RCASGFP, and 
subsequently infected with RCAS-CRE to induce Gli3T expression, or with RCAS-GFP 
as a control.  
 
PDEC Proliferation and Survival Assays  
All proliferation and survival assays were conducted as previously described 
(Morton, Mongeau et al. 2007). For proliferation assays, 1x105 PDECs were plated per 
well in a 6 well plate on day zero.  Fresh media was added to the cells every 5 days, and 
total cell numbers were counted on days 5, 10, and 15. For survival assays, 1x106 PDECs 
were plated per well in a 6 well plate and incubated at 37°C overnight.  The following 
day, the media was removed and fresh media was added.  For cells treated with 
cycloheximide, the fresh media contained 100µM cycloheximide. 24 hours after 
treatment with cycloheximide, live and dead cells were counted by trypan blue exclusion 
and percent survival was calculated.  
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APPENDIX C: 
Investigation into the genetic changes required for KRAS induced tumor formation 
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Figure Contribution 
 
For the experiments described in Appendix C, Victoria Appleman generated the 
GFP, KRASG12D, and SHH expressing PDECs and isolated the RNA for the microarray 
studies.  David Driscoll confirmed the data in Table C.1 and is conducting all ongoing 
and future studies for this project.   
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Introduction 
Aberrant expression of SHH has been demonstrated in both PanIN lesions as well 
as in PDAC and is thought to be involved in the early stages of pancreatic tumor 
formation (Berman, Karhadkar et al. 2003; Thayer, di Magliano et al. 2003).  However, 
prior work in our lab demonstrated that while expression of both SHH and KRASG12D in 
PDECs resulted in increased proliferation and survival, as well as activation of the MEK-
ERK and PI3K-AKT signaling pathways, only the expression of KRASG12D in Ink4a/Arf 
null PDECs was sufficient for gross tumor formation following orthotopic transplant 
(Morton, Mongeau et al. 2007).  Based upon these data, we hypothesized that although 
KRASG12D and SHH can stimulate the same signaling cascades, and both are involved in 
pancreatic tumorigenesis, activated KRAS is enacting changes in the cell that SHH is not, 
and these changes are necessary for pancreatic tumor initiation.  This study therefore 
sought to identify which changes in gene expression might be necessary for KRAS 
induced tumor formation by assessing gene expression differences following the 
expression of activated KRAS versus the expression of SHH in PDECs.    
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Results 
To investigate the gene expression changes following the expression of activated 
KRAS or SHH, PDECs null for Ink4a/Arf and Trp53 were isolated and infected with 
RCAS-GFP, RCAS-KRASG12D, and RCAS-SHH.  Gene expression was then analyzed 
via microarray.  Results of this microarray identified 693 genes that had greater than 1.5 
fold increased expression in PDECs expressing KRASG12D relative to control cells, but 
not in PDECs expressing SHH relative to control cells (p value < 0.01).  Of these, the 
increased expression of 27 genes specifically in KRASG12D and not SHH expressing 
PDECs relative to control has been confirmed via qRT-PCR, and is shown in Table C.1.   
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Discussion and Future Directions 
 The results of this study have identified many genes with increased expression 
following the expression of KRASG12D, but not following expression of SHH, in PDECs.  
The differential expression of 27 of these genes has been verified by qRT-PCR, and a 
subset of those genes has been selected for future study.  The next step to pursue those 
genes will be to determine which ones are potentially important for KRAS induced 
tumorigenesis by first looking at which genes are important for KRASG12D induced 
phenotypes in pancreatic tumor cell lines.  This can be achieved through shRNA-
mediated knockdown of an individual gene in KRASG12D expressing tumor cell lines, and 
an assessment of the impact of knockdown on proliferation, survival, migration, and 
anchorage independent growth of those cells.  If a gene is important for KRAS mediated 
tumorigenesis, knockdown of that gene will likely result in decreases in some or all of 
those phenotypes.   
Following this, those genes that are found to be needed for KRAS induced 
phenotypes in the tumor cell lines could be subsequently knocked down in KRASG12D 
expressing PDECs to assess impact in those cells.  Again, any genes needed for KRAS 
mediated tumorigenesis will likely impact proliferation, survival, and tumor formation 
following orthotopic transplant of the PDECs.  Ultimately, any genes found to impact 
KRASG12D induced phenotypes in the PDECs could be studied using a mouse model with 
pancreas specific expression of activated KRAS and ablation of the selected gene.  In this 
model, if the gene is needed for KRAS induced tumor formation, those animals with 
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ablation of that gene will have decreased tumor formation and increased survival over 
their littermates that are not deficient in that gene’s expression.   
 Once a gene, or set of genes, has been confirmed in this manner to be important 
for KRAS mediated pancreatic tumor formation, further studies can examine how the 
expression of activated KRAS results in increased expression of those genes, and 
potentially which of the signaling pathways downstream of KRAS are required for the 
increased gene expression.   Ultimately, these studies will identify novel genes that are 
critical to KRAS- mediated pancreatic tumor formation, as well as potentially 
demonstrate how activated KRAS is regulating the expression of those genes, thereby 
providing much needed further insight into the role of activated KRAS in the formation 
of pancreatic tumors and identifying potential new therapeutic targets for the treatment of 
pancreatic cancer.     
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Table C.1 
 
Genes with greater than 1.5 fold increased expression in KRASG12D expressing 
Ink4a/Arf, Trp53 null PDECs relative to GFP expressing control cells, but not in 
SHH expressing Ink4a/Arf, Trp53 null PDECs relative to GFP expressing control 
cells, as confirmed by qRT-PCR.     
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Methods 
 
Isolation, culture, and infection of mouse PDECs.  
Isolation, culture, and infection of mouse PDECs were performed as previously 
described (Lewis, Chinnasamy et al. 2001; Schreiber, Deramaudt et al. 2004; Morton, 
Mongeau et al. 2007). Details are provided in the protocols below.   
 
Isolation of PDECs:  The pancreas of a K19-TVA expressing mouse was 
harvested into ~30ml G solution {HBSS (Gibco, Invitrogen, Carlsbad CA) plus 0.9g/L D-
Glucose (Calbiochem, San Diego, CA) plus 1X Penicillin/Streptomycin (Gibco, 
Invitrogen, Carlsbad CA)} in a falcon tube on ice.  In a sterile tissue culture hood, 
aspirate G solution and transfer the pancreas into a 50ml beaker.  Add ~5ml G solution. 
Cut up the pancreas with dissection scissors about 100 times (resulting in pieces ~1mm in 
size).  Resuspend the cut tissue in ~50ml G solution and transfer to a fresh 50ml falcon 
tube.  Allow tissue to settle and aspirate or decant G solution and any floating fatty tissue.  
Repeat the wash with G solution until all floating tissue has been removed.  Resuspend 
tissue in 15ml of filter-sterilized collagenase V solution {1mg/ml of Collagenase V 
(Sigma, St Louis MO) in DMEM (Invitrogen, Carlsbad CA) plus 10% FCS (Atlanta 
Biologicals, Atlanta GA)} and transfer to 100ml bottle with stir bar.  Digest tissue, with 
constant stirring, at 37°C for 20 minutes.  Use a beaker set on a stirrer hot plate if you 
don’t have a submersible stirrer.  Tissue should be free from large chunks at the end of 
digestion.  If necessary, tissue can be digested up to 45 minutes to remove large chunks.  
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Add 20ml G solution to stop reaction.  Transfer the solution onto a 100µm nylon cell 
strainer over a waste container.  Rinse the bottle with G solution if necessary to collect all 
remaining tissue.  Invert the strainer over a fresh falcon tube and recover the undigested 
tissue by pipetting G solution onto the reverse side of the mesh and collecting washed off 
tissue/G solution in the falcon tube. If needed, top off the tissue solution to 50ml with G 
solution.  Allow tissue to settle and pour off G solution to remove floating cells.  (These 
are most likely acinar cells).  Repeat.  Add 50ml of G solution again and resuspend cells 
by inverting.  Centrifuge cells at 1000rpm at 4°C, but stop the spin as soon as the 
centrifuge reaches speed and allow the centrifuge to decelerate using the minimum 
deceleration speed.  Carefully decant or aspirate the supernatant.  Repeat this wash step 3 
times to remove all traces of collagenase.  Add 2ml trypsin-EDTA (Invitrogen, Carlsbad 
CA) and incubate at room temperature for 5 minutes.  Add 40mls DMEM plus 10% FCS  
and invert to resuspend the cells. Centrifuge cells at 1000rpm 4°C and stop as soon as 
speed is reached (as in step 13). Remove the supernatant by decanting or by aspiration.   
Repeat this wash step 3 times. Resuspend the cells in 5ml PDEC medium and centrifuge 
at 1000rpm for 5 minutes at 4°C.  (Reset the brake to the usual setting).  Resuspend the 
tissue pellet in 12ml of PDEC medium (see description of media below) and plate 2ml 
onto each well of a 6-well plate.  Culture in humidified incubator at 37°C, 5%CO2.  Note: 
Up to two pancreata can be isolated into one falcon tube at the start of the protocol.  If 
this is done, the only change needed is to plate the cells onto two 6-well plates in step 20. 
Two days after isolation aspirate off medium and floating tissue.  Wash gently with PBS.  
Replace PDEC medium and incubate until confluent (at least 5-7 days).   
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Culturing of PDECs: PDECs were cultured on collagen coated plates at 37 
degrees Celsius with 5% CO2.   Cells were cultured in DMEM/F12 Medium (Gibco, 
Invitrogen, Carlsbad, CA) plus 5 mg/ml D-Glucose (Calbiochem, San Diego, CA), 
0.1mg/mL Soybean Trypsin Inhibitor (Sigma, ), 5ml/L ITS+ (BD Biosciences, Billerica 
MA), 25ug/ml Bovine Pituitary Extract (BD Biosciences, Billerica MA), 20ng/ml EGF 
(BD Biosciences, Billerica MA), 5nM 3, 3, 5 tri-iodo-L-thyronine (Sigma, St Louis MO),  
1uM dexamethasone (Sigma, St Louis MO), 1.22 mg/ml nicotinamide (Sigma, St Louis, 
MO), 5% Nu Serum (BD Biosciences, Billerica MA), and 1X Penicillin/Streptomycin 
(Gibco, Invitrogen, Carlsbad CA).  To passage PDECs when confluent, media was 
removed and the collagen layer was pipetted into a filter-sterilized 1mg/ml collagenase V 
solution (Sigma, St Louis MO) and then incubated for 15-20 minutes at 37°C.  Cells were 
then pelleted by centrifugation at 1000rpm at 4°C for 5 minutes, and the supernatant 
removed by decanting or aspiration. 2ml trypsin-EDTA (Invitrogen, Carlsbad CA) was 
added to the cells, and the cells were incubated at room temperature for 5 minutes.  Next, 
40mls DMEM plus 10% FCS were added to the cells, and the cells were centrifuged at 
1000rpm for 5 minutes at 4°C.  Cells were washed twice more with DMEM plus 10% 
FCS and then resuspended into PDEC media and plated on collagen gel coated dishes.  
Infection of PDECs with RCAS Viruses:  Prior to infection, RCAS constructs 
were transfected into DF1 Chicken Fibroblasts using the Superfect Transfection Reagents 
(Qiagen, Valencia CA).  Briefly, 5µg of plasmid was mixed with DMEM (Gibco, 
Invitrogen, Carlsbad CA) to a total volume of 150µL.  To this mixture, 25µL of the 
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Superfect reagent was added and the mixture was incubated at room temperature for 5 
minutes.  Following the incubation, 2mls of fresh DMEM plus 10% FCS plus 1% 
Penicillin/Streptomycin was added to the mixture, and the mixture was transferred onto 
DF1 cells.  The DF1 cells plus transfection mixture were incubated for 2-3 hours at 37°C, 
following which fresh DMEM plus 10% FCS plus 1% Penicillin/Streptomycin was added 
and the DF1 cells were cultured as usual.  At least one week after transfection of the 
RCAS constructs, the virus within the culture media from 3 confluent 10cm2 dishes of 
DF1 cells was concentrated by ultracentrifugation at 27,000 rpms for 90minutes at 4°C.  
Following centrifugation, concentrated virus was then pipetted onto a single 10cm2 dish 
of TVA expressing PDECs.  For each virus, the infection protocol was repeated so that 
the virus was added to PDECs a total of four times within 48 hours. 
 
RCAS Constructs  
The retroviral constructs RCAS-GFP and RCAS-KrasG12D-IRES-GFP have 
been previously described (Morton, Mongeau et al. 2007).  
 
Microarray.  
RNA was extracted from PDECs using Trizol (Invitrogen, Carlsbad CA) and 
purified with an RNeasy Mini Kit (Qiagen, Valencia CA).  Microarray analysis of the 
total RNA was performed by MSKCC Genomics Core Laboratory (New York, NY).   
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Quantitative RT-PCR.  
RNA was extracted from serum starved PDECs using Trizol (Invitrogen, Carlsbad 
CA), purified with an RNeasy Mini Kit (Qiagen, Valencia CA), and treated with Turbo 
DNase (Ambion, Austin TX).  cDNA was then generated using the Superscript III First 
Strand Synthesis System (Invitrogen, Carlsbad CA). 50ng of cDNA was combined with 
SYBR Green Reaction Mix (Quanta Biosciences, Gaithersburg, MD), and 500nm of the 
appropriate primer pairs (IDT, Coralville, Iowa). PCR amplification was conducted using 
an ABI 7300 Real Time PCR system using Applied Biosystems standard conditions. 
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